BioMedLib Search Engine
[ goto HOMEPAGE ]
Find more relevant answers, faster!
Skip to content
Advanced Search
Search History
MeSH Query
Page Format
Query is expanded
Login
Skip to content
Export Citations
Search Results
RSS
Email
Articles' Details
Start new query
Reset All
Refine your query
(more in Advanced-Search):
Search all of MEDLINE
Focus on the recent 5 years
Focus on the current year
Focus on the last 30 days
More choices ...
Focus on articles with free fulltexts
More choices ...
Do simple 'keyword' search (no query expansion)
[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click
here to
RESET
all values
Click
here to
GO BACK
without resetting any value
Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.
+
Publication-Date
Published in the last:
30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years
Or published in the following date range: From (yyyy/mm/dd - month and day are optional)
to ('to' is optional)
+
Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+
Sort-Order
Sort the retrieved articles by:
relevance
publication date
+
Language
And with languages:
English
French
German
Italian
Japanese
Russian
Spanish
More languages:
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Bengali
Bosnian
Bulgarian
Catalan
Chinese
Czech
Danish
Dutch
Esperanto
Estonian
Finnish
Georgian
Scottish Gaelic
Greek, Modern
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Kinyarwanda
Korean
Latin
Latvian
Lithuanian
Macedonian
Malayalam
Maori
Malay
Multiple languages
Norwegian
Persian
Polish
Portuguese
Pushto
Romanian
Sanskrit
Serbian
Croatian
Slovak
Slovenian
Swedish
Thai
Turkish
Ukrainian
Undetermined
Urdu
Vietnamese
Welsh
+
Publication-Type
And with publication types:
Clinical Trial
Editorial
Letter
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
More publication types:
Addresses
Bibliography
Biography
Case Reports
Classical Article
Clinical Conference
Clinical Trial, Phase I
Clinical Trial, Phase II
Clinical Trial, Phase III
Clinical Trial, Phase IV
Comment
Comparative Study
Congresses
Consensus Development Conference
Consensus Development Conference, NIH
Controlled Clinical Trial
Corrected and Republished Article
Dictionary
Directory
Duplicate Publication
English Abstract
Evaluation Studies
Festschrift
Government Publications
Guideline
Historical Article
Interactive Tutorial
Interview
Introductory Journal Article
In Vitro
Journal Article
Lectures
Legal Cases
Legislation
Multicenter Study
News
Newspaper Article
Overall
Patient Education Handout
Periodical Index
Portraits
Published Erratum
Retracted Publication
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Retraction of Publication
Scientific Integrity Review
Technical Report
Twin Study
Validation Studies
+
Species
And for:
Humans
Animals
+
Gender
And for:
Male
Female
+
Age
And for these age groups:
Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years
+
Title
And for this query matching the titles:
+
Transliterated-Title
And for this query matching the title in original language:
+
Abstract
And for this query matching the abstratcs:
+
Major-Mesh
And for this query matching the MeSH-Major terms:
+
Mesh
And for this query matching any MeSH terms:
+
Journal
And for one or more of these journal abbreviated names:
OR
OR
(see
title abbreviations
)
+
Volume
And with journal volume number:
+
Issue
And with journal issue number:
+
Page
And with page number:
+
ISSN
And with ISSN:
+
Publication-Place
And with journal's country of publication:
+
Author
And for...
all these author names:
AND
AND
(see
help
)
one or more of these author names:
OR
OR
but not having any of these unwanted author names:
NOT
NOT
+
Affiliation
And with affiliation to:
+
Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior)
+
PMID
Show me only articles for these PMIDs (PubMed IDs):
+
Semantic-Type
And with semantic types:
A. Entity
A1. Physical Object
A1.1. Organism
A1.1.1. Archaeon
A1.1.2. Bacterium
A1.1.3. Eukaryote
A1.1.3.1. Animal
A1.1.3.1.1. Vertebrate
A1.1.3.1.1.1. Amphibian
A1.1.3.1.1.2. Bird
A1.1.3.1.1.3. Fish
A1.1.3.1.1.4. Mammal
A1.1.3.1.1.4.1. Human
A1.1.3.1.1.5. Reptile
A1.1.3.2. Fungus
A1.1.3.3. Plant
A1.1.4. Virus
A1.2. Anatomical Structure
A1.2.1. Embryonic Structure
A1.2.2. Anatomical Abnormality
A1.2.2.1. Congenital Abnormality
A1.2.2.2. Acquired Abnormality
A1.2.3. Fully Formed Anatomical Structure
A1.2.3.1. Body Part, Organ, or Organ Component
A1.2.3.2. Tissue
A1.2.3.3. Cell
A1.2.3.4. Cell Component
A1.2.3.5. Gene or Genome
A1.3. Manufactured Object
A1.3.1. Medical Device
A1.3.1.1. Drug Delivery Device
A1.3.2. Research Device
A1.3.3. Clinical Drug
A1.4. Substance
A1.4.1. Chemical
A1.4.1.1. Chemical Viewed Functionally
A1.4.1.1.1. Pharmacologic Substance
A1.4.1.1.1.1. Antibiotic
A1.4.1.1.2. Biomedical or Dental Material
A1.4.1.1.3. Biologically Active Substance
A1.4.1.1.3.1. Neuroreactive Substance or Biogenic Amine
A1.4.1.1.3.2. Hormone
A1.4.1.1.3.3. Enzyme
A1.4.1.1.3.4. Vitamin
A1.4.1.1.3.5. Immunologic Factor
A1.4.1.1.3.6. Receptor
A1.4.1.1.4. Indicator, Reagent, or Diagnostic Aid
A1.4.1.1.5. Hazardous or Poisonous Substance
A1.4.1.2. Chemical Viewed Structurally
A1.4.1.2.1. Organic Chemical
A1.4.1.2.1.5. Nucleic Acid, Nucleoside, or Nucleotide
A1.4.1.2.1.6. Organophosphorus Compound
A1.4.1.2.1.7. Amino Acid, Peptide, or Protein
A1.4.1.2.1.8. Carbohydrate
A1.4.1.2.1.9. Lipid
A1.4.1.2.1.9.1. Steroid
A1.4.1.2.1.9.2. Eicosanoid
A1.4.1.2.2. Inorganic Chemical
A1.4.1.2.3. Element, Ion, or Isotope
A1.4.2. Body Substance
A1.4.3. Food
A2. Conceptual Entity
A2.1. Idea or Concept
A2.1.1. Temporal Concept
A2.1.2. Qualitative Concept
A2.1.3. Quantitative Concept
A2.1.4. Functional Concept
A2.1.4.1. Body System
A2.1.5. Spatial Concept
A2.1.5.1. Body Space or Junction
A2.1.5.2. Body Location or Region
A2.1.5.3. Molecular Sequence
A2.1.5.3.1. Nucleotide Sequence
A2.1.5.3.2. Amino Acid Sequence
A2.1.5.3.3. Carbohydrate Sequence
A2.1.5.4. Geographic Area
A2.2. Finding
A2.2.1. Laboratory or Test Result
A2.2.2. Sign or Symptom
A2.3. Organism Attribute
A2.3.1. Clinical Attribute
A2.4. Intellectual Product
A2.4.1. Classification
A2.4.2. Regulation or Law
A2.5. Language
A2.6. Occupation or Discipline
A2.6.1. Biomedical Occupation or Discipline
A2.7. Organization
A2.7.1. Health Care Related Organization
A2.7.2. Professional Society
A2.7.3. Self-help or Relief Organization
A2.8. Group Attribute
A2.9. Group
A2.9.1. Professional or Occupational Group
A2.9.2. Population Group
A2.9.3. Family Group
A2.9.4. Age Group
A2.9.5. Patient or Disabled Group
B. Event
B1. Activity
B1.1. Behavior
B1.1.1. Social Behavior
B1.1.2. Individual Behavior
B1.2. Daily or Recreational Activity
B1.3. Occupational Activity
B1.3.1. Health Care Activity
B1.3.1.1. Laboratory Procedure
B1.3.1.2. Diagnostic Procedure
B1.3.1.3. Therapeutic or Preventive Procedure
B1.3.2. Research Activity
B1.3.2.1. Molecular Biology Research Technique
B1.3.3. Governmental or Regulatory Activity
B1.3.4. Educational Activity
B1.4. Machine Activity
B2. Phenomenon or Process
B2.1. Human-caused Phenomenon or Process
B2.1.1. Environmental Effect of Humans
B2.2. Natural Phenomenon or Process
B2.2.1. Biologic Function
B2.2.1.1. Physiologic Function
B2.2.1.1.1. Organism Function
B2.2.1.1.1.1. Mental Process
B2.2.1.1.2. Organ or Tissue Function
B2.2.1.1.3. Cell Function
B2.2.1.1.4. Molecular Function
B2.2.1.1.4.1. Genetic Function
B2.2.1.2. Pathologic Function
B2.2.1.2.1. Disease or Syndrome
B2.2.1.2.1.1. Mental or Behavioral Dysfunction
B2.2.1.2.1.2. Neoplastic Process
B2.2.1.2.2. Cell or Molecular Dysfunction
B2.2.1.2.3. Experimental Model of Disease
B2.3. Injury or Poisoning
Page Format
Any submit button will submit all of the items you have changed.
[theme]
Use this page design theme:
original
twenty ten
[shown]
Results per page:
5
10
20
50
100
200
500
[expand/collapse]
show these sections expanded by default:
Advanced search
MeSH query
Search history
Page format
Query expansion
Articles details
Export citations
Email
[text size]
use this font size for text:
25%
50%
75%
100%
125%
150%
200%
or enter your choice of font size:
[page width]
use this page width (relative to the default initial value):
25%
50%
75%
100%
125%
150%
200%
or enter your choice of page width:
[highlight color]
use this color to highlight query words in the articles:
red
green
blue
black
purple
yellow
orange
navy
olive
maroon
none
[query history]
maximum number of queries shown in the history section:
[annotate]
Annotate these parts of each article:
title
abstract
both
none
Reset all values
Find best MeSH terms for
Search History
1
acute nonlymphoblastic leukemia secondary 2005:2010[pubdate] *count=100
168 results
Searchbox
Export
PDF
RSS
Email
Delete
Email this search result to the following email address:
[X] Close
Expand the query
'
acute nonlymphoblastic leukemia secondary
' expanded to all its synonyms;
details
Email the results to the following email address:
Export the checked citations in RIS format (RIS format is used by RefWorks, Endnote, among others).
Items 1 to 100 of about 168
1.
Büchner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Kienast J, Schnittger S, Kern W, Tchinda J, Reichle A, Lengfelder E, Staib P, Ludwig WD, Aul C, Eimermacher H, Balleisen L, Sauerland MC, Heinecke A, Wörmann B, Hiddemann W:
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.
J Clin Oncol
; 2006 Jun 1;24(16):2480-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for
acute
myeloid
leukemia
.
PURPOSE: Intensification by high-dose cytarabine in postremission or induction therapy and prolonged maintenance are established strategies to improve the outcome in patients with
acute
myeloid
leukemia
(
AML
).
PATIENTS AND METHODS: A total of 1,770 patients (age 16 to 85 years) with de novo or
secondary
AML
or high-risk myelodysplastic syndrome (MDS) were randomly assigned upfront for induction therapy containing one course with standard dose and one course with high-dose cytarabine, or two courses with high-dose cytarabine, and in the same step received postremission prolonged maintenance or busulfan/cyclophosphamide chemotherapy with autologous stem-cell transplantation.
There was no significant difference in any prognostic subgroup according to
secondary
AML
/MDS, cytogenetics, WBC, lactate dehydrogenase, and early blast clearance.
CONCLUSION: The regimen of one course with standard-dose cytarabine and one course with high-dose cytarabine for induction, and prolonged maintenance for postremission chemotherapy in patients with
AML
is not improved by additional escalation in cytotoxic treatment.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation.
Leukemia
,
Myeloid
/ drug therapy.
Leukemia
,
Myeloid
/ surgery. Myelodysplastic Syndromes / drug therapy. Myelodysplastic Syndromes / surgery
[MeSH-minor]
Acute
Disease. Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Cytarabine / administration & dosage. Drug Administration Schedule. Female. Humans. L-Lactate Dehydrogenase / blood. Leukocyte Count. Male. Middle Aged. Mitoxantrone / administration & dosage. Multivariate Analysis. Prognosis. Prospective Studies. Remission Induction. Risk Factors. Transplantation, Autologous. Treatment Outcome
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
Hazardous Substances Data Bank.
CYTARABINE
.
Hazardous Substances Data Bank.
NOVANTRONE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
J Clin Oncol. 2006 Dec 1;24(34):5471-2; author reply 5472-3
[
17135654.001
]
[ErratumIn]
J Clin Oncol. 2011 Jul 1;29(19):2739
(PMID = 16735702.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Publication-type]
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
04079A1RDZ / Cytarabine; BZ114NVM5P / Mitoxantrone; EC 1.1.1.27 / L-Lactate Dehydrogenase
2.
Barresi V, Palumbo GA, Musso N, Consoli C, Capizzi C, Meli CR, Romano A, Di Raimondo F, Condorelli DF:
Clonal selection of 11q CN-LOH and CBL gene mutation in a serially studied patient during MDS progression to AML.
Leuk Res
; 2010 Nov;34(11):1539-42
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Clonal selection of 11q CN-LOH and CBL gene mutation in a serially studied patient during MDS progression to
AML
.
By conventional metaphase and SNP array cytogenetics we serially studied a patient affected by high-risk myelodysplastic syndrome (MDS), documenting the conversion from partial trisomy 8q to trisomy 8 and partial tetrasomy 8q during progression to
acute
myeloid
leukemia
(
AML
).
Moreover, the serial application of high resolution genomic array analysis at different disease stages allowed the description of cryptic abnormalities and the demonstration of their enrichment in the
AML
phase.
In particular the detection and quantification of a copy-neutral loss of heterozygosity region located in chromosome 11q guided the search for point mutations in the CBL gene, thus allowing the escription of the novel missense mutation K382E and the demonstration of its selection during progression to
secondary
AML
.
[MeSH-major]
Chromosomes, Human, Pair 11.
Leukemia
,
Myeloid
,
Acute
/ genetics. Loss of Heterozygosity. Myelodysplastic Syndromes / genetics. Proto-Oncogene Proteins c-cbl / genetics
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright © 2010 Elsevier Ltd. All rights reserved.
(PMID = 20674974.001).
[ISSN]
1873-5835
[Journal-full-title]
Leukemia research
[ISO-abbreviation]
Leuk. Res.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
EC 6.3.2.- / CBL protein, human; EC 6.3.2.- / Proto-Oncogene Proteins c-cbl
3.
Szotkowski T, Rohon P, Zapletalova L, Sicova K, Hubacek J, Indrak K:
Secondary acute myeloid leukemia - a single center experience.
Neoplasma
; 2010;57(2):170-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Secondary acute
myeloid
leukemia
- a single center experience.
Secondary acute
myeloid
leukemia
(sAML) may arise from the previous clonal disorder of hematopoiesis, usually from myelodysplastic syndrome (MDS) or from chronic myeloproliferative neoplasia (cMPN) or after exposure to a leukemogenic agent (previous chemotherapy or radiotherapy, some immunosuppressive drugs or environmental leukemogenic agents).
Secondary
origin of
AML
is associated with unfavorable prognosis and it is not considered to be conventionally curable (with the exception of
secondary acute
promyelocytic
leukemia
).
Over that period of time, a total 574 patients with
AML
were diagnosed.
Of those, 430 patients were diagnosed as having primary
AML
; in 86 patients, sAML transformed from myelodysplastic syndrome and 58 patients were followed or treated for various malignancies or were treated with potentially leukemogenic agents because of
non
-malignant disorders.
Patients with
secondary
AML
are older and less commonly treated with curative intention than those with primary
AML
.
With the exception of
secondary acute
promyelocytic
leukemia
, the prognosis of which does not differ from very good prognosis of the primary forms,
secondary
AML
is not considered a conventionally curable disease.
[MeSH-major]
Leukemia
,
Myeloid
,
Acute
/ etiology. Myelodysplastic Syndromes / complications. Myeloproliferative Disorders / complications. Neoplasm Recurrence, Local / etiology. Neoplasms, Second Primary / etiology
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20099982.001).
[ISSN]
0028-2685
[Journal-full-title]
Neoplasma
[ISO-abbreviation]
Neoplasma
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Slovakia
Advertisement
4.
Perl AE, Kasner MT, Tsai DE, Vogl DT, Loren AW, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Frey NV, Nasta SD, Hexner EO, Dierov JK, Swider CR, Bagg A, Gewirtz AM, Carroll M, Luger SM:
A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.
Clin Cancer Res
; 2009 Nov 1;15(21):6732-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory
acute
myelogenous
leukemia
.
PURPOSE: Inhibiting mammalian target of rapamycin (mTOR) signaling in
acute
myelogenous
leukemia
(
AML
) blasts and leukemic stem cells may enhance their sensitivity to cytotoxic agents.
We sought to determine the safety and describe the toxicity of this approach by adding the mTOR inhibitor, sirolimus (rapamycin), to intensive
AML
induction chemotherapy.
EXPERIMENTAL DESIGN: We performed a phase I dose escalation study of sirolimus with the chemotherapy regimen MEC (mitoxantrone, etoposide, and cytarabine) in patients with relapsed, refractory, or untreated
secondary
AML
.
Future studies are planned with different schedules to clarify the clinical and biochemical effects of sirolimus in
AML
and to determine whether target inhibition predicts chemotherapy response.
[MeSH-major]
Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Leukemia
,
Myeloid
,
Acute
/ drug therapy. Sirolimus / administration & dosage
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
MELPHALAN
.
Hazardous Substances Data Bank.
ETOPOSIDE
.
Hazardous Substances Data Bank.
CARBOPLATIN
.
Hazardous Substances Data Bank.
SIROLIMUS
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19843663.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
eng
[Publication-type]
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibiotics, Antineoplastic; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; Q41OR9510P / Melphalan; W36ZG6FT64 / Sirolimus; MEC regimen
5.
Makishima H, Cazzolli H, Szpurka H, Dunbar A, Tiu R, Huh J, Muramatsu H, O'Keefe C, Hsi E, Paquette RL, Kojima S, List AF, Sekeres MA, McDevitt MA, Maciejewski JP:
Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.
J Clin Oncol
; 2009 Dec 20;27(36):6109-16
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in
myeloid
malignancies.
PURPOSE: Acquired somatic uniparental disomy (UPD) is commonly observed in myelodysplastic syndromes (MDS), myelodysplastic/myeloproliferative neoplasms (MDS/MPN), or
secondary acute
myelogenous
leukemia
(sAML) and may point toward genes harboring mutations.
METHODS: We applied high-density SNP-A karyotyping to identify loss of heterozygosity of 11q in 442 patients with MDS, MDS/MPN, MPN, sAML evolved from these conditions, and primary
AML
.
RESULTS: We identified c-Cbl mutations in 5% and 9% of patients with chronic myelomonocytic
leukemia
(CMML) and sAML, and also in CML blast crisis and juvenile myelomonocytic
leukemia
(JMML).
CONCLUSION: Mutations in the Cbl family RING finger domain or linker sequence constitute important pathogenic lesions associated with not only preleukemic CMML, JMML, and other MPN, but also progression to
AML
, suggesting that impairment of degradation of activated tyrosine kinases constitutes an important cancer mechanism.
COS Scholar Universe.
author profiles
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Leukemia. 2009 Mar;23(3):610-4
[
18818701.001
]
[Cites]
Haematologica. 2008 Oct;93(10):1595-7
[
18698078.001
]
[Cites]
Nat Genet. 2004 Sep;36(9):949-51
[
15286789.001
]
[Cites]
Oncogene. 1991 Apr;6(4):653-7
[
2030914.001
]
[Cites]
Mol Cell Biol. 1998 Aug;18(8):4872-82
[
9671496.001
]
[Cites]
Lancet. 2005 Mar 19-25;365(9464):1054-61
[
15781101.001
]
[Cites]
Cancer Cell. 2005 Apr;7(4):387-97
[
15837627.001
]
[Cites]
N Engl J Med. 2005 Apr 28;352(17):1779-90
[
15858187.001
]
[Cites]
Nat Rev Mol Cell Biol. 2005 Dec;6(12):907-18
[
16227975.001
]
[Cites]
Blood. 2006 Feb 1;107(3):1242-3
[
16434499.001
]
[Cites]
PLoS Genet. 2005 Dec;1(6):e49
[
16444292.001
]
[Cites]
Blood. 2006 Mar 1;107(5):1791-9
[
16254134.001
]
[Cites]
J Cell Physiol. 2006 Oct;209(1):21-43
[
16741904.001
]
[Cites]
Blood. 2006 Oct 1;108(7):2173-81
[
16741247.001
]
[Cites]
PLoS Med. 2006 Jul;3(7):e270
[
16834459.001
]
[Cites]
Am J Surg Pathol. 2007 Feb;31(2):233-9
[
17255768.001
]
[Cites]
Blood. 2007 Aug 1;110(3):1004-12
[
17446348.001
]
[Cites]
Blood. 2007 Aug 1;110(3):1022-4
[
17475912.001
]
[Cites]
Leukemia. 2007 Sep;21(9):2058-61
[
17525728.001
]
[Cites]
Blood. 2007 Nov 1;110(9):3365-73
[
17634407.001
]
[Cites]
PLoS One. 2007;2(11):e1225
[
18030353.001
]
[Cites]
Blood. 2008 Feb 1;111(3):1534-42
[
17954704.001
]
[Cites]
N Engl J Med. 2008 May 1;358(18):1909-18
[
18450602.001
]
[Cites]
Blood. 2008 Aug 15;112(4):965-74
[
18505780.001
]
[Cites]
Semin Oncol. 2008 Aug;35(4):365-77
[
18692687.001
]
[Cites]
Leukemia. 2008 Aug;22(8):1539-41
[
18528419.001
]
[Cites]
Cancer Res. 2008 Dec 15;68(24):10349-57
[
19074904.001
]
[Cites]
Blood. 2008 Sep 1;112(5):2017-9
[
18566322.001
]
[Cites]
Curr Opin Hematol. 2001 Jul;8(4):189-91
[
11561153.001
]
(PMID = 19901108.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
ENG
[Grant]
United States / NHLBI NIH HHS / HL / K24 HL077522; United States / NHLBI NIH HHS / HL / R01 HL082983; United States / NCRR NIH HHS / RR / U54 RR019391; United States / NHLBI NIH HHS / HL / K24 HL-077522; United States / NHLBI NIH HHS / HL / R01HL-082983; United States / NCRR NIH HHS / RR / S10 RR019391
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
EC 6.3.2.- / Proto-Oncogene Proteins c-cbl
[Other-IDs]
NLM/ PMC3040009
6.
Kröger N, Shimoni A, Zabelina T, Schieder H, Panse J, Ayuk F, Wolschke C, Renges H, Dahlke J, Atanackovic D, Nagler A, Zander A:
Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
Bone Marrow Transplant
; 2006 Feb;37(4):339-44
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with
secondary acute
myeloid
leukemia
(sAML) or myelodysplastic syndrome (MDS).
We investigated a dose-reduced conditioning regimen consisting of treosulfan and fludarabine followed by allogeneic stem cell transplantation (SCT) in 26 patients with
secondary
AML
or MDS.
Acute
graft-versus-host disease (GvHD) grade II-IV was seen in 23% and severe grade III GvHD in 12% of the patients.
No patients experienced grade IV
acute
GvHD.
[MeSH-major]
Antilymphocyte Serum / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Busulfan / analogs & derivatives. Hematopoietic Stem Cell Transplantation.
Leukemia
,
Myeloid
/ therapy. Myelodysplastic Syndromes / therapy. Transplantation Conditioning / methods. Vidarabine / analogs & derivatives
[MeSH-minor]
Acute
Disease. Adult. Aged. Disease-Free Survival. Female. Graft vs Host Disease / drug therapy. Graft vs Host Disease / prevention & control. HLA Antigens / analysis. Humans. Male. Middle Aged. Prospective Studies. Recurrence. Siblings. Survival Rate. Transplantation, Homologous. Treatment Outcome
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
Genetic Alliance.
consumer health - Myelodysplastic syndromes
.
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
FLUDARABINE
.
Hazardous Substances Data Bank.
TREOSULFAN
.
Hazardous Substances Data Bank.
BUSULFAN
.
Hazardous Substances Data Bank.
VIDARABINE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16415898.001).
[ISSN]
0268-3369
[Journal-full-title]
Bone marrow transplantation
[ISO-abbreviation]
Bone Marrow Transplant.
[Language]
eng
[Publication-type]
Clinical Trial; Comparative Study; Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Antilymphocyte Serum; 0 / HLA Antigens; CO61ER3EPI / treosulfan; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine
7.
Szotkowski T, Muzik J, Voglova J, Koza V, Maaloufova J, Kozak T, Jarosova M, Michalova K, Zak P, Steinerova K, Vydra J, Lanska M, Katrincsakova B, Sicova K, Pavlik T, Dusek L, Indrak K:
Prognostic factors and treatment outcome in 1,516 adult patients with de novo and secondary acute myeloid leukemia in 1999-2009 in 5 hematology intensive care centers in the Czech Republic.
Neoplasma
; 2010;57(6):578-89
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prognostic factors and treatment outcome in 1,516 adult patients with de novo and
secondary acute
myeloid
leukemia
in 1999-2009 in 5 hematology intensive care centers in the Czech Republic.
Acute
myeloid
leukemia
(
AML
) is a severe condition with a high mortality.
The study represents a detailed analysis of the role of these factors and treatment outcomes based on a long-term follow-up of patients treated in 5 hematology intensive care centers in the Czech Republic.The studied group comprised 1,188 patients with de novo
AML
and 328 patients with
secondary
AML
.
Curatively treated patients achieved fewer complete remissions and relapsed more often than those with de novo
AML
.
Patients with
secondary
AML
had lower rates of allogeneic transplantation as part of consolidation therapy and a significantly shorter median overall survival.
However, the treatment outcome of de novo
AML
patients is not satisfactory, the only exception being those with
acute
promyelocytic
leukemia
.
[MeSH-major]
Leukemia
,
Myeloid
,
Acute
/ mortality. Neoplasms, Second Primary / mortality
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20845997.001).
[ISSN]
0028-2685
[Journal-full-title]
Neoplasma
[ISO-abbreviation]
Neoplasma
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Slovakia
8.
Nevill TJ, Shepherd JD, Sutherland HJ, Abou Mourad YR, Lavoie JC, Barnett MJ, Nantel SH, Toze CL, Hogge DE, Forrest DL, Song KW, Power MM, Nitta JY, Dai Y, Smith CA:
IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
Biol Blood Marrow Transplant
; 2009 Feb;15(2):205-13
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
A retrospective review was performed of 156 patients who underwent SCT (114 BM, 42 BSC) for MDS or
secondary acute
myelogenous
leukemia
(sAML) at our institution.
Multivariate analysis showed IPSS poor-risk cytogenetics (P< .001), time from diagnosis to SCT (P< .001), FAB subgroup (P= .001), recipients not in complete remission (CR1) at SCT (P= .005), and the development of
acute
graft-versus-host disease (aGVHD) (P= .04) were all predictive of an inferior EFS.
The FAB subgroup (P= .002), poor-risk karyotype (P= .004), and
non
-CR1 status also correlated with ROR in multivariate analysis.
Genetic Alliance.
consumer health - Myelodysplastic syndromes
.
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19167680.001).
[ISSN]
1523-6536
[Journal-full-title]
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
[ISO-abbreviation]
Biol. Blood Marrow Transplant.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
9.
Chau M, Christensen JL, Ajami AM, Capizzi RL:
Amonafide, a topoisomerase II inhibitor, is unaffected by P-glycoprotein-mediated efflux.
Leuk Res
; 2008 Mar;32(3):465-73
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Over-expression of P-glycoprotein (Pgp+) has been related to resistance to classical Topo II inhibitors used in the treatment of
AML
and is common in patients with poor-prognosis, such as those with
secondary
AML
(sAML).
Since clinical trials with amonafide, a unique ATP-independent Topo II inhibitor, in combination with cytarabine, have shown significant efficacy for remission induction in patients with sAML, we compared the cytotoxic effect of amonafide (amonafide l-malate, Xanafide) to the classical Topo II inhibitors (daunorubicin, doxorubicin, idarubicin, etoposide, and mitoxantrone) in K562
leukemia
cells and in the MDR subline, K562/DOX.
Pgp expression was found to be approximately 6.5-fold greater in K562/DOX and causes the rapid efflux of these drugs from the
leukemia
cell.
A similar result was also observed in murine P388 and P388/ADR
leukemia
cells.
These observations suggest that amonafide is a promising therapeutic candidate directed toward bypassing this common mechanism of drug resistance encountered in the treatment of patients with
AML
, and possibly in other resistant hematological malignancies as well.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17826829.001).
[ISSN]
0145-2126
[Journal-full-title]
Leukemia research
[ISO-abbreviation]
Leuk. Res.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Enzyme Inhibitors; 0 / Imides; 0 / Isoquinolines; 0 / Naphthalimides; 0 / P-Glycoprotein; 0 / Topoisomerase II Inhibitors; 1Q8D39N37L / amonafide
10.
Tavil B, Cetin M, Tuncer M:
CD34/CD117 positivity in assessment of prognosis in children with myelodysplastic syndrome.
Leuk Res
; 2006 Feb;30(2):222-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal stem cell disorders that are characterized by morphology identifying dysplastic changes in one or more cell lineages, peripheral blood cytopenias and a propensity to evolve into
secondary acute
myeloid
leukemia
(
AML
).
CD34 is commonly expressed in all types of childhood leukemias, whereas CD117 is a reliable and specific marker to detect
leukemia
cells committed to
myeloid
lineage.
Co-expression of CD34/CD117 may strongly suggest the diagnosis of
AML
(Rytting ME.
May; Uçkan D, Hiçsönmez G, Yetgin S, Gürgey A, Cetin M, Karaağaoğlu E, et al. CD34/CD117 co-expression in childhood
acute leukemia
.
Leukemia
Res 2000;24:201-6.).
We describe the case of a 22 month-old-girl with MDS and Down syndrome who was presented with severe anemia and thrombocytosis at diagnosis, transformed into
AML
-M7.
As the disease progressed, CD34/117 co-existence was increased and MDS transformed into
AML
.
[MeSH-minor]
Bone Marrow Examination. Female. Humans. Infant.
Leukemia
,
Myeloid
,
Acute
/ etiology. Prognosis
Genetic Alliance.
consumer health - Myelodysplastic syndromes
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16098587.001).
[ISSN]
0145-2126
[Journal-full-title]
Leukemia research
[ISO-abbreviation]
Leuk. Res.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Antigens, CD34; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
11.
Verma D, O'Brien S, Thomas D, Faderl S, Koller C, Pierce S, Kebriaei P, Garcia-Manero G, Cortes J, Kantarjian H, Ravandi F:
Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.
Cancer
; 2009 Jan 1;115(1):101-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Therapy-related
acute
myelogenous
leukemia
and myelodysplastic syndrome in patients with
acute
lymphoblastic
leukemia
treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.
BACKGROUND:
Secondary
malignancies including
myeloid
neoplasms occur infrequently in
acute
lymphoblastic
leukemia
(ALL) and to the authors' knowledge have not been as well documented in adults as in children.
RESULTS: Sixteen patients (2.49%) developed
secondary acute
myelogenous
leukemia
(
AML
) (6 patients) or myelodysplastic syndrome (MDS) (10 patients).
Karyotype at time of
AML
/MDS diagnosis was -5, -7 in 9 patients, normal in 1 patient, complex in 1 patient, inv(11) in 1 patient, t(4;11) in 1 patient, del(20) in 1 patient, and unavailable in 2 patients.
Secondary
AML
/MDS developed at a median of 32 months after ALL diagnosis.
Cytarabine plus anthracycline-based treatment was given to 12 patients with
AML
and high-risk MDS.
Eight patients (1 with
AML
and 7 with MDS) underwent allogeneic stem cell transplantation, and all but 2 died at a median of 3 months (range, 0.5-11 months) after transplantation.
The median overall survival after a diagnosis of
secondary
AML
and MDS was 9.25 months (range, 1+ to 26+ months).
CONCLUSIONS:
Secondary
AML
and MDS occur infrequently in adult patients with de novo ALL treated with the hyper-CVAD regimens, and response to therapy is poor.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Leukemia
,
Myeloid
,
Acute
/ chemically induced. Myelodysplastic Syndromes / chemically induced. Precursor Cell
Lymphoblastic
Leukemia
-Lymphoma / drug therapy
Genetic Alliance.
consumer health - Acute Lymphoblastic Leukemia
.
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
Genetic Alliance.
consumer health - Myelodysplastic syndromes
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
DEXAMETHASONE
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright (c) 2008 American Cancer Society.
(PMID = 19090005.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / P30 CA016672
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
[Other-IDs]
NLM/ NIHMS629435; NLM/ PMC4180242
12.
Giles F, Rizzieri D, Karp J, Vey N, Ravandi F, Faderl S, Khan KD, Verhoef G, Wijermans P, Advani A, Roboz G, Kantarjian H, Bilgrami SF, Ferrant A, Daenen SM, Karsten V, Cahill A, Albitar M, Mufti G, O'Brien S:
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.
J Clin Oncol
; 2007 Jan 1;25(1):25-31
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated
acute
myeloid
leukemia
.
A multicenter phase II study of cloretazine was conducted in patients 60 years of age or older with previously untreated
acute
myeloid
leukemia
(
AML
) or high-risk myelodysplastic syndrome (MDS).
Patients were stratified by age, performance score, cytogenetic risk category, type of
AML
, and comorbidity.
Response rates in 44 de novo
AML
patients, 45
secondary
AML
patients, and 15 high-risk MDS patients were 50%, 11%, and 40%, respectively.
CONCLUSION: Cloretazine has significant activity and modest extramedullary toxicity in elderly patients with
AML
or high-risk MDS.
[MeSH-major]
Antineoplastic Agents, Alkylating / therapeutic use. Hydrazines / therapeutic use.
Leukemia
,
Myeloid
,
Acute
/ drug therapy. Sulfonamides / therapeutic use
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
SciCrunch.
DrugBank: Data: Chemical
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
J Clin Oncol. 2007 Jan 1;25(1):1-2
[
17146103.001
]
(PMID = 17146105.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Publication-type]
Clinical Trial, Phase II; Journal Article; Multicenter Study
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents, Alkylating; 0 / Hydrazines; 0 / Sulfonamides; 14J2G0U3NQ / laromustine
13.
Stifter G, Heiss S, Gastl G, Tzankov A, Stauder R:
Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
Eur J Haematol
; 2005 Dec;75(6):485-91
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Enhanced bone marrow (BM) angiogenesis is regarded as an essential cofactor in the progression of MDS to
acute
myelogenous
leukemia
(
AML
) and microvessel formation may be induced by TNF-alpha as well.
METHODS: TNF-alpha expression and BM vessels were immunohistochemically analyzed on 89 paraffin-embedded BM biopsies from patients with MDS and
secondary
AML
, including 12 control samples.
MVD was increased in MDS and
secondary
AML
and correlated with marrow cellularity and expression of TNF-alpha, but was not of prognostic significance.
CONCLUSIONS: TNF-alpha expression and MVD are elevated in MDS and
secondary
AML
.
[MeSH-major]
Biomarkers, Tumor / biosynthesis. Erythroid Precursor Cells / metabolism. Gene Expression Regulation, Leukemic.
Leukemia
,
Myeloid
,
Acute
/ metabolism. Myelodysplastic Syndromes / metabolism. Tumor Necrosis Factor-alpha / biosynthesis
Genetic Alliance.
consumer health - Anemia
.
Genetic Alliance.
consumer health - Myelodysplastic syndromes
.
Genetic Alliance.
consumer health - Bone marrow necrosis
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16313260.001).
[ISSN]
0902-4441
[Journal-full-title]
European journal of haematology
[ISO-abbreviation]
Eur. J. Haematol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Denmark
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Tumor Necrosis Factor-alpha
14.
Récher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas VM, Benzaquen D, Laurent G, Huguet F, Payrastre B:
Antileukemic activity of rapamycin in acute myeloid leukemia.
Blood
; 2005 Mar 15;105(6):2527-34
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Antileukemic activity of rapamycin in
acute
myeloid
leukemia
.
In this study, we show that mTOR inhibition by rapamycin strongly inhibits the growth of the most immature
acute
myeloid
leukemia
(
AML
) cell lines through blockade in G0/G1 phase of the cell cycle.
Accordingly, 2 downstream effectors of mTOR, 4E-BP1 and p70S6K, are phosphorylated in a rapamycin-sensitive manner in a series of 23
AML
cases.
Interestingly, the mTOR inhibitor markedly impairs the clonogenic properties of fresh
AML
cells while sparing normal hematopoietic progenitors.
Moreover, rapamycin induces significant clinical responses in 4 of 9 patients with either refractory/relapsed de novo
AML
or
secondary
AML
.
Overall, our data strongly suggest that mTOR is aberrantly regulated in most
AML
cells and that rapamycin and analogs, by targeting the clonogenic compartment of the leukemic clone, may be used as new compounds in
AML
therapy.
[MeSH-major]
Antibiotics, Antineoplastic / pharmacology. G0 Phase / drug effects. G1 Phase / drug effects.
Leukemia
,
Myeloid
,
Acute
/ metabolism. Protein Kinases / metabolism. Sirolimus / pharmacology
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
SIROLIMUS
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15550488.001).
[ISSN]
0006-4971
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Adaptor Proteins, Signal Transducing; 0 / Antibiotics, Antineoplastic; 0 / EIF4EBP1 protein, human; 0 / Phosphoproteins; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa; W36ZG6FT64 / Sirolimus
15.
Boehm A, Sperr WR, Leitner G, Worel N, Oehler L, Jaeger E, Mitterbauer M, Haas OA, Valent P, Kalhs P, Rabitsch W:
Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation.
Eur J Clin Invest
; 2008 Dec;38(12):945-52
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Comorbidity predicts survival in myelodysplastic syndromes or
secondary acute
myeloid
leukaemia after allogeneic stem cell transplantation.
PATIENTS AND METHODS: We examined the overall survival (OS) and underlying risk factors in 45 adult patients with MDS (n = 38), chronic myelomonocytic leukaemia (n = 1), or
secondary acute
myeloid
leukaemia (
AML
) arising from MDS (n = 6), who underwent allogeneic SCT at our Institution.
CONCLUSIONS: Based on these data and similar published data we recommend selecting patients with MDS or
secondary
AML
for SCT according to the presence of comorbidities.
[MeSH-major]
Disease-Free Survival. Hematopoietic Stem Cell Transplantation.
Leukemia
,
Myeloid
,
Acute
/ mortality.
Leukemia
, Myelomonocytic, Chronic / mortality. Neoplasms, Second Primary / mortality
Genetic Alliance.
consumer health - Myelodysplastic syndromes
.
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19021720.001).
[ISSN]
1365-2362
[Journal-full-title]
European journal of clinical investigation
[ISO-abbreviation]
Eur. J. Clin. Invest.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
16.
Schmid C, Schleuning M, Hentrich M, Markl GE, Gerbitz A, Tischer J, Ledderose G, Oruzio D, Hiddemann W, Kolb HJ:
High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission.
Bone Marrow Transplant
; 2008 Apr;41(8):721-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk
acute
myeloid
leukemia
in first complete remission.
The goal of this analysis was to define the role of the moderate-intensity fludarabin Ara-C amsacrin (FLAMSA)-reduced intensity conditioning (RIC) regimen for patients with high-risk
AML
undergoing allogeneic SCT (alloSCT) in first CR1.
High-risk was defined by (1)
AML
secondary
to MDS or radio/chemotherapy, (2) unfavorable cytogenetics or (3) delayed response to induction chemotherapy.
A total of 23 of 44
AML
patients referred to the University of Munich for alloSCT in CR1 between 1999 and 2006 fulfilled these criteria and received FLAMSA chemotherapy, followed by RIC (4 Gy TBI/cyclophosphamide/ATG) for alloSCT.
Four-year overall and
leukemia
-free survival was 72.7% (median follow-up among survivors: 35 months).
The results of this high-risk cohort were compared to the outcome of 21 consecutive standard-risk patients <55 years, who had received standard, myeloablative sibling SCT in CR1
AML
within the same center and time period.
In conclusion, the FLAMSA-RIC regimen produces long-term remission in a high proportion of patients with high-risk
AML
transplanted in CR1.
[MeSH-major]
Hematopoietic Stem Cell Transplantation / methods.
Leukemia
,
Myeloid
,
Acute
/ therapy. Transplantation Conditioning / methods
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18176613.001).
[ISSN]
0268-3369
[Journal-full-title]
Bone marrow transplantation
[ISO-abbreviation]
Bone Marrow Transplant.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
17.
Ferrara F, D'Arco AM, De Simone M, Mele G, Califano C, Pocali B, Danise P, Palmieri S:
Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia.
Haematologica
; 2005 Jun;90(6):776-84
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Fludarabine and cytarabine as continuous sequential infusion for elderly patients with
acute
myeloid
leukemia
.
BACKGROUND AND OBJECTIVES: A phase II study was conducted to investigate the effects of a therapeutic program based on the combination of fludarabine and cytarabine (ARA-C) administered as a sequential continuous infusion in untreated elderly patients with
acute
myeloid
leukemia
(
AML
).
DESIGN AND METHODS: Sixty-three patients with
non
-M3
AML
, median age 69 years (range 61-81), were accrued.
Twenty-four patients (38%) had
AML
secondary
to myelodysplastic syndrome.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / administration & dosage.
Leukemia
,
Myeloid
,
Acute
/ drug therapy. Vidarabine / analogs & derivatives
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
Hazardous Substances Data Bank.
CYTARABINE
.
Hazardous Substances Data Bank.
FLUDARABINE
.
Hazardous Substances Data Bank.
VIDARABINE
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15951290.001).
[ISSN]
1592-8721
[Journal-full-title]
Haematologica
[ISO-abbreviation]
Haematologica
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Italy
[Chemical-registry-number]
0 / Antigens, CD34; 04079A1RDZ / Cytarabine; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
18.
Manvelyan M, Kempf P, Weise A, Mrasek K, Heller A, Lier A, Höffken K, Fricke HJ, Sayer HG, Liehr T, Mkrtchyan H:
Preferred co-localization of chromosome 8 and 21 in myeloid bone marrow cells detected by three dimensional molecular cytogenetics.
Int J Mol Med
; 2009 Sep;24(3):335-41
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Preferred co-localization of chromosome 8 and 21 in
myeloid
bone marrow cells detected by three dimensional molecular cytogenetics.
In this study, BM of three
secondary acute
myelogenous
leukemia
(
AML
) cases with trisomy 8 and otherwise normal karyotype were evaluated.
Bone marrow cells of one
AML
and one ALL (
acute
lymphoblastic
leukemia
) case, peripheral blood lymphocytes and human sperm, all of them with normal karyotype, served as controls.
Interestingly, in
myeloid
bone marrow cells chromosomes 8 (di- and trisomic) and 21 tended to co-localize with their homologue chromosome(s), rather than to be separated.
Thus, the co-localization of chromosomes 8 and 21 might promote a translocation providing a selective advantage of t(8;21) cells in
AML
-M2.
[MeSH-major]
Bone Marrow Cells / metabolism. Chromosomes, Human, Pair 21 / metabolism. Chromosomes, Human, Pair 8 / metabolism. Cytogenetic Analysis / methods.
Myeloid
Cells / metabolism
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19639225.001).
[ISSN]
1107-3756
[Journal-full-title]
International journal of molecular medicine
[ISO-abbreviation]
Int. J. Mol. Med.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Greece
19.
Rizzieri DA, O'Brien JA, Broadwater G, Decastro CM, Dev P, Diehl L, Beaven A, Lagoo A, Gockerman JP, Chao NJ, Moore JO:
Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia.
Cancer
; 2009 Jul 1;115(13):2922-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Outcomes of patients who undergo aggressive induction therapy for
secondary acute
myeloid
leukemia
.
BACKGROUND: Response and survival in 96 patients with
secondary acute
myeloid
leukemia
(sAML) who received aggressive induction chemotherapy was reviewed.
Patients with
AML
after previous chemotherapy or radiation therapy had a higher morphologic remission rate compared with those arising from myelodysplastic syndrome or myeloproliferative disease (82% vs 62%; P = .027).
In this population of patients who received aggressive chemotherapy, Charlson comorbidity index or a higher number of factors recognized as high risk in
leukemia
patients did not affect the chance of OS, DFS, and EFS, although having more recognized
leukemia
risk factors was related to a lower chance of surviving 1 year.
[MeSH-major]
Leukemia
,
Myeloid
,
Acute
/ drug therapy. Neoplasms, Second Primary / drug therapy
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19452542.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
20.
Fianchi L, Pagano L, Leoni F, Storti S, Voso MT, Valentini CG, Rutella S, Scardocci A, Caira M, Gianfaldoni G, Leone G:
Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia.
Ann Oncol
; 2008 Jan;19(1):128-34
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis
acute
myeloid
leukemia
.
BACKGROUND: Gemtuzumab ozogamicin (GO) is effective as single agent in the treatment of
acute
myeloid
leukemia
(
AML
).
We evaluated efficacy and safety of a chemotherapy including growth factors, cytarabine, and GO (G-AraMy) in the treatment of poor-prognosis
AML
in elderly patients.
PATIENTS AND METHODS: In three Italian hematology departments from September 2003 to September 2006, 53 elderly patients [median age 69 years (range 65-77)] with untreated or primary refractory/relapsed
AML
were enrolled on the combination G-AraMy administered according to two consecutive schedules (G-AraMy1 and G-AraMy2), with intensified consolidation in the second.
Twenty-three of 53 patients had a
secondary acute
myeloid
leukemia
(sAML).
No differences for response rate and toxicity profile were observed between untreated and primary resistant/relapsed patients, de novo
AML
and sAML, and in the two treatment trials.
CONCLUSIONS: G-AraMy therapy may be considered an useful treatment approach for poor-risk elderly
AML
patients, with a complete remission rate comparable to literature data with reduced side-effects, also in a poor-prognosis population.
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
Hazardous Substances Data Bank.
CYTARABINE
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17906298.001).
[ISSN]
1569-8041
[Journal-full-title]
Annals of oncology : official journal of the European Society for Medical Oncology
[ISO-abbreviation]
Ann. Oncol.
[Language]
ENG
[Publication-type]
Clinical Trial; Comparative Study; Journal Article; Multicenter Study
[Publication-country]
England
[Chemical-registry-number]
0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / gemtuzumab; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor
21.
Varet B, Ifrah N:
[Criteria for suspecting a myelodysplastic syndrome].
Rev Prat
; 2010 Dec 20;60(10):1404-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The myelodysplastic syndromes are a group of heterogeneous acquired and clonal disorders that are characterized by the intramedullar, abnormal death of
myeloid
progenitors leading to peripheral variable cytopenias.
It is predictive for the risk of transformation in
secondary acute
myeloid
leukemia
.
Genetic Alliance.
consumer health - Myelodysplastic syndromes
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21425539.001).
[ISSN]
0035-2640
[Journal-full-title]
La Revue du praticien
[ISO-abbreviation]
Rev Prat
[Language]
fre
[Publication-type]
English Abstract; Journal Article
[Publication-country]
France
22.
Anwar Iqbal M, Al-Omar HM, Owaidah T, Al-Humaidan H, Bhuiyan ZA, Sahovic E:
del(6)(p23) in two cases of de novo AML--a new recurrent primary chromosome abnormality.
Eur J Haematol
; 2006 Sep;77(3):245-50
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
del(6)(p23) in two cases of de novo
AML
--a new recurrent primary chromosome abnormality.
OBJECTIVE: Previously, deletion 6p23 was generally reported in therapy-related
secondary acute
myeloid
leukemia
(
AML
) as part of complex karyotypes.
In this report, we present two young adult patients with de novo
AML
-M2 and a terminal deletion 6p23 as a sole primary abnormality, confirmed by chromosome 6 specific subtelomeric probes.
RESULTS: A diagnosis of
AML
-M2 was confirmed in both patients by morphological and immunophenotyping studies.
The common morphological, immunophenotypic, and cytogenetic features in our two patients strongly support a separate new entity of de novo
AML
with deletion 6p23.
[MeSH-major]
Chromosome Deletion. Chromosomes, Human, Pair 6 / genetics.
Leukemia
,
Myeloid
,
Acute
/ genetics
[MeSH-minor]
Adult. Chromosomal Proteins,
Non
-Histone / genetics. Cytogenetics. Female. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Karyotyping. Oncogene Proteins / genetics. Oncogenes. Recurrence
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16856925.001).
[ISSN]
0902-4441
[Journal-full-title]
European journal of haematology
[ISO-abbreviation]
Eur. J. Haematol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Denmark
[Chemical-registry-number]
0 / Chromosomal Proteins, Non-Histone; 0 / Dek protein, human; 0 / Oncogene Proteins
23.
Tam CS, Seymour JF, Prince HM, Kenealy M, Wolf M, Januszewicz EH, Westerman D:
Treatment-related myelodysplasia following fludarabine combination chemotherapy.
Haematologica
; 2006 Nov;91(11):1546-50
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Although myelodysplasia (MDS) and
secondary acute
myeloid
leukemia
(sAML) are rare following fludarabine monotherapy, the risk of these diseases may potentially be increased when fludarabine is combined with cyclophosphamide or mitoxantrone due to synergistic effects on the inhibition of DNA repair.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
FLUDARABINE
.
Hazardous Substances Data Bank.
VIDARABINE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17082012.001).
[ISSN]
1592-8721
[Journal-full-title]
Haematologica
[ISO-abbreviation]
Haematologica
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Italy
[Chemical-registry-number]
FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
24.
Römermann D, Hasemeier B, Metzig K, Schlegelberger B, Länger F, Kreipe H, Lehmann U:
[Methylation status of LINE-1 sequences in patients with MDS or secondary AML].
Verh Dtsch Ges Pathol
; 2007;91:338-42
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Methylation status of LINE-1 sequences in patients with MDS or
secondary
AML
].
[Transliterated title]
Methylierungszustand von LINE-1-Sequenzen bei Patienten mit MDS oder sekundärer
AML
.
[MeSH-minor]
Humans.
Leukemia
,
Myeloid
,
Acute
/ genetics
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18314632.001).
[ISSN]
0070-4113
[Journal-full-title]
Verhandlungen der Deutschen Gesellschaft für Pathologie
[ISO-abbreviation]
Verh Dtsch Ges Pathol
[Language]
ger
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Germany
25.
Schwarz J, Pytlík R, Doubek M, Brychtová Y, Dulícek P, Campr V, Kren L, Penka M:
Analysis of risk factors: the rationale of the guidelines of the Czech Hematological Society for diagnosis and treatment of chronic myeloproliferative disorders with thrombocythemia.
Semin Thromb Hemost
; 2006 Apr;32(3):231-45
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The histopathology-based nosological distinction provided by these classifications yields valuable information on prognosis (including the risks of transition into
secondary acute
myeloid
leukemia
and myelofibrosis).
Genetic Alliance.
consumer health - Chronic Myeloproliferative Disorders
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16673277.001).
[ISSN]
0094-6176
[Journal-full-title]
Seminars in thrombosis and hemostasis
[ISO-abbreviation]
Semin. Thromb. Hemost.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
26.
Creutzig U, Diekamp S, Zimmermann M, Reinhardt D:
Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML.
Pediatr Blood Cancer
; 2007 Jun 15;48(7):651-62
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with
AML
.
BACKGROUND: Anthracyclines are effective antineoplastic drugs in
acute
myelogenous
leukemia
(
AML
).
PROCEDURE: To evaluate anthracycline-associated cardiomyopathy in pediatric
AML
-patients, the incidence of early and late (>1 year after intensive
AML
chemotherapy) clinical and subclinical cardiotoxicity was analyzed out of a total of 1,207 patients <18 years treated between 1993 and 2003 in trials
AML
-BFM93/98: 1,010 protocol patients with de novo
AML
, 121 with Down syndrome (DS)-
AML
, and 76 with
secondary
AML
.
RESULTS: Thirty-eight patients (4.3%), including 3 DS-
AML
and 1
secondary
AML
, suffered from early cardiomyopathy.
After 5 years, four patients showed temporarily or persistently a reduced shortening fraction, which led to death in one DS-
AML
patient.
Late clinical cardiomyopathy mainly affected patients with a second anthracycline therapy (
secondary
malignancy) and those with early cardiotoxicity.
CONCLUSION: In spite of a highly intensive and effective treatment, the frequency of anthracycline-associated cardiomyopathy was low in the
AML
-BFM studies.
[MeSH-major]
Anthracyclines / adverse effects. Heart / drug effects. Heart Diseases / chemically induced.
Leukemia
,
Myeloid
/ drug therapy
[MeSH-minor]
Acute
Disease. Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Dose-Response Relationship, Drug. Drug-Related Side Effects and Adverse Reactions. Echocardiography / methods. Female. Follow-Up Studies. Humans. Infant. Longitudinal Studies. Male. Pilot Projects. Risk Factors. Survivors. Time. Treatment Outcome
MedlinePlus Health Information.
consumer health - Heart Disease in Women
.
MedlinePlus Health Information.
consumer health - Heart Diseases
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2006 Wiley-Liss, Inc.
[CommentIn]
Pediatr Blood Cancer. 2007 Jun 15;48(7):649-50
[
17318875.001
]
(PMID = 17183582.001).
[ISSN]
1545-5009
[Journal-full-title]
Pediatric blood & cancer
[ISO-abbreviation]
Pediatr Blood Cancer
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Anthracyclines
27.
Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B, Berger U, Telford N, Aruliah S, Yin JA, Vanstraelen D, Barker HF, Taylor PC, O'Driscoll A, Benedetti F, Rudolph C, Kolb HJ, Hochhaus A, Hehlmann R, Chase A, Cross NC:
The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2.
Cancer Res
; 2005 Apr 1;65(7):2662-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The t(8;9)(p22;p24) is a recurrent abnormality in chronic and
acute leukemia
that fuses PCM1 to JAK2.
We have identified a t(8;9)(p21-23;p23-24) in seven male patients (mean age 50, range 32-74) with diverse hematologic malignancies and clinical outcomes: atypical chronic
myeloid
leukemia
/chronic eosinophilic
leukemia
(n = 5),
secondary acute
myeloid
leukemia
(n = 1), and pre-B-cell
acute
lymphoblastic
leukemia
(n = 1).
[MeSH-major]
Cell Cycle Proteins / genetics. Chromosomes, Human, Pair 8 / genetics. Chromosomes, Human, Pair 9 / genetics.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / genetics.
Leukemia
,
Myeloid
/ genetics. Oncogene Proteins, Fusion / genetics. Protein-Tyrosine Kinases / genetics. Proto-Oncogene Proteins / genetics. Translocation, Genetic
[MeSH-minor]
Acute
Disease. Adult. Aged. Amino Acid Sequence. Autoantigens. Base Sequence. Humans. Janus Kinase 2. Male. Middle Aged. Molecular Sequence Data. Reverse Transcriptase Polymerase Chain Reaction
MedlinePlus Health Information.
consumer health - Chronic Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15805263.001).
[ISSN]
0008-5472
[Journal-full-title]
Cancer research
[ISO-abbreviation]
Cancer Res.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Autoantigens; 0 / Cell Cycle Proteins; 0 / Oncogene Proteins, Fusion; 0 / PCM1 protein, human; 0 / PCM1-JAK2 fusion protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
28.
Then Bergh F, Niklas A, Strauss A, von Ahsen N, Niederwieser D, Schwarz J, Wagner A, Al-Ali HK:
Rapid progression of Myelodysplastic syndrome to acute myeloid leukemia on sequential azathioprine, IFN-beta and copolymer-1 in a patient with multiple sclerosis.
Acta Haematol
; 2006;116(3):207-10
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Rapid progression of Myelodysplastic syndrome to
acute
myeloid
leukemia
on sequential azathioprine, IFN-beta and copolymer-1 in a patient with multiple sclerosis.
Within several months, unusually rapid for this subtype, MDS progressed to
secondary acute
myeloid
leukemia
.
[MeSH-major]
Azathioprine / adverse effects. Interferon-beta / adverse effects.
Leukemia
,
Myeloid
/ chemically induced. Multiple Sclerosis / complications. Multiple Sclerosis / drug therapy. Myelodysplastic Syndromes / complications. Peptides / adverse effects
[MeSH-minor]
Acute
Disease. Disease Progression. Fatal Outcome. Female. Glatiramer Acetate. Humans. Middle Aged
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
Genetic Alliance.
consumer health - Multiple Sclerosis
.
Genetic Alliance.
consumer health - Myelodysplastic syndromes
.
MedlinePlus Health Information.
consumer health - Multiple Sclerosis
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
Hazardous Substances Data Bank.
AZATHIOPRINE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2006 S. Karger AG, Basel.
(PMID = 17016041.001).
[ISSN]
0001-5792
[Journal-full-title]
Acta haematologica
[ISO-abbreviation]
Acta Haematol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Switzerland
[Chemical-registry-number]
0 / Peptides; 5M691HL4BO / Glatiramer Acetate; 77238-31-4 / Interferon-beta; MRK240IY2L / Azathioprine
29.
Gondek LP, Tiu R, O'Keefe CL, Sekeres MA, Theil KS, Maciejewski JP:
Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML.
Blood
; 2008 Feb 1;111(3):1534-42
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived
AML
.
We have applied 250K single nucleotide polymorphisms (SNP) arrays (SNP-A) to study chromosomal lesions in samples from 174 patients (94 MDS, 33
secondary acute
myeloid
leukemia
[sAML], and 47 myelodysplastic/myeloproliferative disease [MDS/MPD]) and 76 controls.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Res. 2005 Oct 1;65(19):8597-603
[
16204023.001
]
[Cites]
Cancer Res. 2005 Oct 15;65(20):9152-4
[
16230371.001
]
[Cites]
Blood. 2005 Nov 15;106(10):3553-8
[
16030187.001
]
[Cites]
Clin Cancer Res. 2006 Jan 1;12(1):5-10
[
16397017.001
]
[Cites]
Cancer Res. 2006 Apr 1;66(7):3471-9
[
16585170.001
]
[Cites]
Leukemia. 2006 May;20(5):904-5
[
16511509.001
]
[Cites]
Blood. 2006 Sep 1;108(5):1733-43
[
16705090.001
]
[Cites]
Leukemia. 2006 Sep;20(9):1610-7
[
16826223.001
]
[Cites]
N Engl J Med. 2006 Oct 5;355(14):1456-65
[
17021321.001
]
[Cites]
Cancer Genet Cytogenet. 2006 Nov;171(1):9-16
[
17074585.001
]
[Cites]
Blood. 2006 Nov 15;108(10):3280-8
[
16840728.001
]
[Cites]
Nature. 2006 Nov 23;444(7118):444-54
[
17122850.001
]
[Cites]
J Clin Pathol. 2007 Jan;60(1):1-7
[
16790693.001
]
[Cites]
Blood. 2007 Feb 1;109(3):1202-10
[
17053054.001
]
[Cites]
Nature. 2007 Apr 12;446(7137):758-64
[
17344859.001
]
[Cites]
Leukemia. 2007 Sep;21(9):2058-61
[
17525728.001
]
[Cites]
Blood. 2007 Nov 1;110(9):3365-73
[
17634407.001
]
[Cites]
J Clin Oncol. 1999 Dec;17(12):3835-49
[
10577857.001
]
[Cites]
Br J Haematol. 2000 Feb;108(2):346-56
[
10691865.001
]
[Cites]
Am J Pathol. 2001 Apr;158(4):1253-62
[
11290543.001
]
[Cites]
J Med Genet. 2001 Aug;38(8):497-507
[
11483637.001
]
[Cites]
Int J Hematol. 2001 Jun;73(4):429-37
[
11503956.001
]
[Cites]
Exp Hematol. 2002 Mar;30(3):229-36
[
11882360.001
]
[Cites]
Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3586-90
[
11891338.001
]
[Cites]
Blood. 2004 Oct 15;104(8):2263-8
[
15238427.001
]
[Cites]
Leukemia. 1993 Sep;7(9):1315-23
[
8371581.001
]
[Cites]
Br J Haematol. 1996 Mar;92(3):574-81
[
8616020.001
]
[Cites]
Blood. 1997 Mar 15;89(6):2079-88
[
9058730.001
]
[Cites]
N Engl J Med. 1999 May 27;340(21):1649-60
[
10341278.001
]
[Cites]
Br J Haematol. 1999 Aug;106(2):455-63
[
10460606.001
]
[Cites]
N Engl J Med. 2005 Feb 10;352(6):549-57
[
15703420.001
]
[Cites]
Cancer Res. 2005 Apr 15;65(8):3053-8
[
15833833.001
]
[Cites]
N Engl J Med. 2005 Apr 28;352(17):1779-90
[
15858187.001
]
[Cites]
Cancer Res. 2005 Jul 15;65(14):6071-9
[
16024607.001
]
[Cites]
Genes Chromosomes Cancer. 2005 Nov;44(3):334-7
[
16015648.001
]
[Cites]
Haematologica. 2005 Sep;90(9):1168-78
[
16154839.001
]
(PMID = 17954704.001).
[ISSN]
0006-4971
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
ENG
[Grant]
United States / NHLBI NIH HHS / HL / K24 HL077522; United States / NHLBI NIH HHS / HL / R01 HL082983; United States / NCRR NIH HHS / RR / S10 RR019391; United States / NCRR NIH HHS / RR / U54 RR019391
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Other-IDs]
NLM/ PMC2214746
30.
Junghanss C, Waak M, Knopp A, Kleine HD, Kundt G, Leithäuser M, Hilgendorf I, Wolff D, Casper J, Freund M:
Multivariate analyses of prognostic factors in acute myeloid leukemia: relevance of cytogenetic abnormalities and CD34 expression.
Neoplasma
; 2005;52(5):402-10
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Multivariate analyses of prognostic factors in
acute
myeloid
leukemia
: relevance of cytogenetic abnormalities and CD34 expression.
Identification of additional prognostic factors besides karyotype is important for the improvement of the risk adapted treatment strategies in
acute
myeloid
leukemia
(
AML
).
The aim of this study was to investigate whether other factors besides karyotype could be used as a prognostic tool in newly diagnosed
AML
.
Biological and disease related established and potential prognostic factors were retrospectively analysed in 124 consecutive
AML
patients treated between 1993 and 2002 at the University hospital Rostock (Germany).
In patients that received potential curative therapies LDH >or=2000 U/l, WBC >50 GPT/l, CD34 surface expression on the
AML
blasts,
secondary
AML
, unfavorable karyotype and no allogeneic HSCT at some point of treatment course were associated with unfavorable prognosis.
However, in the multivariate risk factor analyses only unfavorable karyotype (p=0.012), CD34 positivity of
AML
blasts (p=0.046), no allogeneic HSCT (p=0.008) and first diagnosis after 1997 (p=0.025) were independent unfavourable prognostic factors.
In conclusion, karyotype and CD34 expression are independent prognostic markers in newly diagnosed
AML
.
Furthermore, receiving an allogeneic HSCT at some point of the treatment course seems to be of benefit for
AML
patients.
[MeSH-major]
Antigens, CD34 / metabolism. Biomarkers, Tumor / analysis. Chromosome Aberrations.
Leukemia
,
Myeloid
/ genetics.
Leukemia
,
Myeloid
/ mortality
[MeSH-minor]
Acute
Disease / therapy. Adult. Age Factors. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Flow Cytometry. Hematopoietic Stem Cell Transplantation. Humans. Karyotyping. Middle Aged. Multivariate Analysis. Palliative Care. Prognosis. Remission Induction. Retrospective Studies. Risk Factors. Survival Analysis. Treatment Outcome
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16151585.001).
[ISSN]
0028-2685
[Journal-full-title]
Neoplasma
[ISO-abbreviation]
Neoplasma
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Slovakia
[Chemical-registry-number]
0 / Antigens, CD34; 0 / Biomarkers, Tumor
31.
Dale DC:
Advances in the treatment of neutropenia.
Curr Opin Support Palliat Care
; 2009 Sep;3(3):207-12
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Current guidelines recommend the prophylactic use of the
myeloid
growth factors for the first cycle of chemotherapy for patients with more than a 20% risk of febrile neutropenia.
Meta analysis from randomized trials shows that granulocyte colony-stimulating factor prophylaxis is associated with patients receiving more intensive chemotherapy, having better survival, but also having a higher risk of
secondary acute
myeloid
leukemia
.
SUMMARY: The
myeloid
growth factor granulocyte colony-stimulating factor has radically changed our approach to the prevention of febrile neutropenia.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Crit Rev Oncol Hematol. 2008 Jun;66(3):237-47
[
18243010.001
]
[Cites]
Niger J Med. 2008 Jan-Mar;17(1):57-60
[
18390135.001
]
[Cites]
Ann Oncol. 2008 May;19 Suppl 2:ii116-8
[
18456747.001
]
[Cites]
J Support Oncol. 2008 May-Jun;6(5):199-208
[
18551855.001
]
[Cites]
Infection. 2008 Jun;36(3):250-5
[
18458815.001
]
[Cites]
Am J Med. 2008 Aug;121(8):709-14
[
18691485.001
]
[Cites]
Scand J Infect Dis. 2008;40(4):301-7
[
17918015.001
]
[Cites]
Drugs. 2008;68(14):1941-62
[
18778118.001
]
[Cites]
Clin Infect Dis. 2008 Nov 1;47(9):1176-84
[
18808352.001
]
[Cites]
J Clin Pharm Ther. 2008 Oct;33(5):459-64
[
18834359.001
]
[Cites]
Eur J Clin Microbiol Infect Dis. 2008 Oct;27(10):969-76
[
18449581.001
]
[Cites]
Cochrane Database Syst Rev. 2008;(4):CD003189
[
18843642.001
]
[Cites]
Am J Clin Oncol. 2008 Aug;31(4):369-74
[
18845996.001
]
[Cites]
Pediatr Blood Cancer. 2008 Dec;51(6):778-83
[
18726920.001
]
[Cites]
Br J Haematol. 2008 Oct;143(2):222-9
[
18713253.001
]
[Cites]
Int J Antimicrob Agents. 2008 Nov;32 Suppl 2:S119-23
[
19013335.001
]
[Cites]
Blood. 2008 Dec 1;112(12):4445-51
[
18799726.001
]
[Cites]
Bone Marrow Transplant. 2008 Nov;42(10):679-84
[
18695660.001
]
[Cites]
Lancet Oncol. 2008 Dec;9(12):1157-65
[
19038762.001
]
[Cites]
Curr Opin Hematol. 2009 Jan;16(1):1-2
[
19057197.001
]
[Cites]
N Engl J Med. 2009 Jan 1;360(1):3-5
[
19118300.001
]
[Cites]
J Natl Compr Canc Netw. 2009 Jan;7(1):92-8
[
19176209.001
]
[Cites]
J Natl Compr Canc Netw. 2009 Jan;7(1):99-108
[
19176210.001
]
[Cites]
Br J Haematol. 2009 Feb;144(4):459-67
[
19120359.001
]
[Cites]
Br J Haematol. 2009 Mar;144(5):677-85
[
19055662.001
]
[Cites]
Support Care Cancer. 2009 Jun;17(6):735-44
[
19096882.001
]
[Cites]
Am J Hematol. 2009 Jul;84(7):414-7
[
19415727.001
]
[Cites]
Value Health. 2009 Mar-Apr;12(2):217-25
[
18673353.001
]
[Cites]
Blood. 1996 Jul 1;88(1):335-40
[
8704192.001
]
[Cites]
Am J Hematol. 1998 Jan;57(1):7-15
[
9423810.001
]
[Cites]
J Clin Oncol. 2006 Jul 1;24(19):3187-205
[
16682719.001
]
[Cites]
J Natl Compr Canc Netw. 2007 Feb;5(2):188-202
[
17335688.001
]
[Cites]
Pharmacoeconomics. 2007;25(4):343-51
[
17402806.001
]
[Cites]
Ann Intern Med. 2007 May 1;146(9):657-65
[
17470834.001
]
[Cites]
Curr Opin Hematol. 2008 Jan;15(1):15-21
[
18043241.001
]
[Cites]
Support Care Cancer. 2008 Jan;16(1):47-56
[
17619911.001
]
[Cites]
Vox Sang. 2007 Nov;93(4):363-9
[
18070282.001
]
[Cites]
Ann Hematol. 2008 Feb;87(2):139-45
[
17938926.001
]
[Cites]
Br J Haematol. 2008 Jan;140(2):210-3
[
18028488.001
]
[Cites]
Eur J Cancer Care (Engl). 2008 Jan;17(1):19-25
[
18181887.001
]
[Cites]
J Clin Oncol. 2008 Jan 10;26(2):290-6
[
18182670.001
]
[Cites]
Support Care Cancer. 2008 Feb;16(2):181-91
[
17943327.001
]
[Cites]
J Natl Compr Canc Netw. 2008 Feb;6(2):109-18
[
18319047.001
]
[Cites]
Value Health. 2008 Mar-Apr;11(2):172-9
[
18380630.001
]
[Cites]
Eur J Oncol Nurs. 2008 Feb;12(1):14-25
[
18291720.001
]
(PMID = 19550332.001).
[ISSN]
1751-4266
[Journal-full-title]
Current opinion in supportive and palliative care
[ISO-abbreviation]
Curr Opin Support Palliat Care
[Language]
eng
[Grant]
United States / NIAID NIH HHS / AI / R24 AI049393; United States / NIAID NIH HHS / AI / R24 AI049393-09
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor
[Number-of-references]
48
[Other-IDs]
NLM/ NIHMS202938; NLM/ PMC3390973
32.
Willems L, Suarez F, Messas E, Baubion N, Decaudin D, Fourquet A, Ghez D, Delarue R, Hermine O, Buzyn A, Varet B, Rubio MT:
[High risk of cardiac dysfunction after treatment of secondary acute myeloid leukemia following chemotherapy and radiotherapy for breast cancer].
Bull Cancer
; 2010 Feb;97(2):245-54
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[High risk of cardiac dysfunction after treatment of
secondary acute
myeloid
leukemia
following chemotherapy and radiotherapy for breast cancer].
Secondary acute
myeloid
leukaemia (
AML
) occurring after breast cancer is a rare long-term complication of the chemo- and/or radiation therapy required to treat breast cancer.
The usually recognized curative option of these
secondary
AML
includes courses of anthracycline-based chemotherapy followed by haematopoietic stem cell transplantation (HSCT).
Cardiac dysfunction during
AML
treatment of these patients previously treated with anthracyclines for breast cancer has not been reported to date.
We evaluated the evolution of cardiac function in seven patients treated with anthracyclines and/or autologous or allogeneic bone marrow transplantation for
secondary
AML
occurring after breast cancer.
All of the patients who received a cumulative anthracycline dose above the cardiac toxicity threshold developed cardiac symptoms during
AML
chemotherapy courses.
Thus, the risk of severe cardiac dysfunction after treatment of
secondary
AML
following breast cancer must be taken in account as part of the therapeutic strategy of those patients.
As discussed here, an accurate evaluation of risk factors, the use of sensitive detection tests and of cardioprotective drugs as well as that of
non
-cardiotoxic chemotherapy might decrease the occurrence and severity of this life-threatening complication.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / adverse effects. Breast Neoplasms. Hematopoietic Stem Cell Transplantation / adverse effects.
Leukemia
,
Myeloid
/ therapy. Neoplasms, Second Primary / therapy
[MeSH-minor]
Acute
Disease. Adult. Chemotherapy, Adjuvant / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Daunorubicin / administration & dosage. Daunorubicin / adverse effects. Epirubicin / administration & dosage. Epirubicin / adverse effects. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Heart Diseases / chemically induced. Heart Diseases / drug therapy. Heart Diseases / physiopathology. Humans. Middle Aged. Remission Induction. Stroke Volume / drug effects. Stroke Volume / physiology
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
Hazardous Substances Data Bank.
DAUNORUBICIN
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
Hazardous Substances Data Bank.
EPIRUBICIN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19819776.001).
[ISSN]
1769-6917
[Journal-full-title]
Bulletin du cancer
[ISO-abbreviation]
Bull Cancer
[Language]
fre
[Publication-type]
English Abstract; Journal Article
[Publication-country]
France
[Chemical-registry-number]
3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; ZS7284E0ZP / Daunorubicin; FEC protocol
33.
Ferrara F, Mele G, Palmieri S, Pedata M, Copia C, Riccardi C, Izzo T, Criscuolo C, Musto P:
Continuous infusion idarubicin and intravenous busulphan as conditioning regimen to autologous stem cell transplantation for patients with acute myeloid leukaemia.
Hematol Oncol
; 2009 Dec;27(4):198-202
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Continuous infusion idarubicin and intravenous busulphan as conditioning regimen to autologous stem cell transplantation for patients with
acute
myeloid
leukaemia.
The current study aimed to evaluate the efficacy and toxicity of a combination of intravenous (iv) busulfan (Bu) and continuous infusion Idarubicin (IDA) as a conditioning regimen to autologous haematopoietic stem cell transplantation (ASCT) in patients with
acute
myeloid
leukaemia (
AML
).
In order to perform a comparison in terms of haematological and
non
haematological toxicity, a group of 30 patients, who were previously autografted after conditioning with IDA and oral Bu was considered.
Selection of factors for a matched pair analysis included median age, percentage of subjects aged over 60 years, median CD34+ cell received, cytogenetic and molecular findings and per cent of
secondary
AML
.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / administration & dosage.
Leukemia
,
Myeloid
,
Acute
/ therapy. Stem Cell Transplantation / methods. Transplantation Conditioning / methods
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
Hazardous Substances Data Bank.
BUSULFAN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright (c) 2009 John Wiley & Sons, Ltd.
(PMID = 19475701.001).
[ISSN]
1099-1069
[Journal-full-title]
Hematological oncology
[ISO-abbreviation]
Hematol Oncol
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article
[Publication-country]
England
[Chemical-registry-number]
G1LN9045DK / Busulfan; ZRP63D75JW / Idarubicin
34.
Bastianutto C, Mian A, Symes J, Mocanu J, Alajez N, Sleep G, Shi W, Keating A, Crump M, Gospodarowicz M, Medin J, Minden M, Liu FF:
Local radiotherapy induces homing of hematopoietic stem cells to the irradiated bone marrow.
Cancer Res
; 2007 Nov 1;67(21):10112-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Local breast radiation therapy (RT) is associated with a 3-fold increased risk of
secondary acute
myeloid
leukemia
.
Our data also suggest some opportunities for
leukemia
prevention in breast cancer patients undergoing RT.
[MeSH-major]
Bone Marrow Cells / radiation effects. Hematopoietic Stem Cells / radiation effects.
Leukemia
,
Myeloid
,
Acute
/ etiology.
Leukemia
, Radiation-Induced / etiology. Radiotherapy / adverse effects
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Radiation Therapy
.
MedlinePlus Health Information.
consumer health - Stem Cells
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17974951.001).
[ISSN]
1538-7445
[Journal-full-title]
Cancer research
[ISO-abbreviation]
Cancer Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Chemokine CXCL12; 0 / Cxcl12 protein, mouse; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
35.
Sakai R, Fujimaki K, Yamazaki E, Sakamoto H, Kanamori H, Miura I, Ishigatsubo Y:
Acute myelomonocytic leukemia with dysplastic bone marrow eosinophils showing t(5;17)(q13;q11) and a secondary chromosomal aberration, inv(16)(p13q22).
Int J Hematol
; 2006 Dec;84(5):417-20
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Acute
myelomonocytic
leukemia
with dysplastic bone marrow eosinophils showing t(5;17)(q13;q11) and a
secondary
chromosomal aberration, inv(16)(p13q22).
inv(16)(p13q22) is associated with de novo
acute
myelomonocytic
leukemia
with dysplastic bone marrow eosinophils (AMML Eo), which has a relatively favorable clinical course with a longer remission duration and better survival prospects.
On the other hand, t(5; 17)(q13;q11), although relatively rare, has been reported to be a component of complex chromosomal abnormalities in myelodysplastic syndromes and
secondary acute
myeloid
leukemia
(
AML
).
In general, certain
secondary
chromosomal abnormalities are associated with the phenotype of the disease, which retains its essential biologic characteristics established by the primary abnormality.
Accordingly, the primary nature of the leukemic cells in this case differs from the findings for core-binding factor
AML
with inv(16)(p13q22).
We believe this report is the first of de novo AMML Eo with t(5; 17)(q13;q11) showing as a
secondary
chromosomal aberration with inv(16)(p13q22).
[MeSH-major]
Bone Marrow Cells / pathology. Chromosome Inversion. Chromosomes, Human / genetics. Eosinophils / pathology.
Leukemia
, Myelomonocytic,
Acute
. Translocation, Genetic
Genetic Alliance.
consumer health - Acute Myelomonocytic Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Oncogene. 2005 Apr 14;24(16):2625-34
[
15782145.001
]
[Cites]
Oncogene. 1990 Oct;5(10):1557-63
[
1701231.001
]
[Cites]
Blood. 1993 Dec 1;82(11):3424-9
[
8241509.001
]
[Cites]
J Clin Oncol. 2005 Aug 20;23(24):5705-17
[
16110030.001
]
[Cites]
Cancer Genet Cytogenet. 1992 Mar;59(1):35-8
[
1555189.001
]
[Cites]
Leuk Res. 2007 Jan;31(1):39-47
[
16687173.001
]
[Cites]
Cancer Genet Cytogenet. 1992 Jul 15;61(2):197-200
[
1638503.001
]
[Cites]
N Engl J Med. 1983 Sep 15;309(11):630-6
[
6577285.001
]
[Cites]
Blood. 1998 Oct 1;92(7):2322-33
[
9746770.001
]
[Cites]
Leukemia. 1992 May;6(5):381-4
[
1593903.001
]
[Cites]
Blood. 1998 Feb 1;91(3):1008-15
[
9446663.001
]
[Cites]
Blood. 1986 Feb;67(2):270-4
[
3455826.001
]
[Cites]
Leukemia. 1994 Jun;8(6):953-62
[
8207990.001
]
[Cites]
Leuk Lymphoma. 1998 Sep;31(1-2):231-6
[
9720733.001
]
[Cites]
Cancer. 2005 Dec 15;104(12):2726-34
[
16284985.001
]
[Cites]
Cancer Genet Cytogenet. 1989 Oct 1;42(1):43-50
[
2790745.001
]
[Cites]
Blood. 2000 Mar 15;95(6):2138-43
[
10706886.001
]
(PMID = 17189222.001).
[ISSN]
0925-5710
[Journal-full-title]
International journal of hematology
[ISO-abbreviation]
Int. J. Hematol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Japan
36.
Borthakur G, Lin E, Jain N, Estey EE, Cortes JE, O'Brien S, Faderl S, Ravandi F, Pierce S, Kantarjian H:
Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia.
Cancer
; 2009 Jul 15;115(14):3217-21
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Survival is poorer in patients with
secondary
core-binding factor
acute
myelogenous
leukemia
compared with de novo core-binding factor
leukemia
.
BACKGROUND: Therapy related
secondary acute
myelogenous
leukemia
(
AML
) was commonly associated with prior exposure to alkylating agents or topoisomerase inhibitor.
The long-term outcome of such patients with
secondary
AML
was found to be worse than that of patients with de novo
AML
.
Earlier reports suggested similar outcomes for patients with de novo and
secondary
AML
associated with core-binding factor (CBF) abnormalities.
METHODS: A total of 188 patients with CBF
AML
were analyzed.
The frequency of
secondary
CBF
AML
was 9%.
RESULTS: Patients with
secondary
CBF
AML
were found to have significantly worse overall (OS) and event-free survival (EFS) compared with patients with de novo CBF
AML
.
Secondary
CBF
AML
status appeared to have only marginal significance in multivariate analysis.
CONCLUSIONS: Matched analysis (by age, Eastern Cooperative Oncology Group performance status, and additional cytogenetic abnormality) indicated worse OS and EFS in patients with
secondary
CBF
AML
.
[MeSH-major]
Core Binding Factors / metabolism.
Leukemia
,
Myeloid
,
Acute
/ mortality. Neoplasms, Second Primary / mortality
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
Hazardous Substances Data Bank.
CYTARABINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Leukemia. 1999 Nov;13(11):1735-40
[
10557046.001
]
[Cites]
Leuk Lymphoma. 2008 Mar;49(3):517-23
[
18297529.001
]
[Cites]
Genes Chromosomes Cancer. 2002 Apr;33(4):395-400
[
11921273.001
]
[Cites]
Br J Haematol. 2002 Aug;118(2):385-400
[
12139722.001
]
[Cites]
Eur J Haematol. 2003 Sep;71(3):143-54
[
12930314.001
]
[Cites]
J Clin Oncol. 2003 Dec 1;21(23):4413-22
[
14645432.001
]
[Cites]
J Clin Oncol. 2004 Mar 15;22(6):1087-94
[
15020610.001
]
[Cites]
J Clin Oncol. 2004 Sep 15;22(18):3741-50
[
15289486.001
]
[Cites]
Blood. 1992 Oct 1;80(7):1825-31
[
1391946.001
]
[Cites]
Science. 1993 Aug 20;261(5124):1041-4
[
8351518.001
]
[Cites]
J Clin Oncol. 1993 Dec;11(12):2370-9
[
8246025.001
]
[Cites]
J Clin Oncol. 1998 May;16(5):1890-6
[
9586906.001
]
[Cites]
Cancer Res. 1998 Sep 15;58(18):4173-9
[
9751631.001
]
[Cites]
Biochim Biophys Acta. 1998 Oct 1;1400(1-3):233-55
[
9748598.001
]
[Cites]
Br J Haematol. 2006 Oct;135(2):165-73
[
16939487.001
]
[Cites]
Leukemia. 2007 Apr;21(4):725-31
[
17287858.001
]
[Cites]
Genes Chromosomes Cancer. 2002 Apr;33(4):379-94
[
11921272.001
]
(PMID = 19441109.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / P30 CA016672
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Core Binding Factors; 04079A1RDZ / Cytarabine
[Other-IDs]
NLM/ NIHMS629439; NLM/ PMC4184418
37.
Ayash LJ, Ratanatharathorn V, Braun T, Silver SM, Reynolds CM, Uberti JP:
Unrelated donor bone marrow transplantation using a chemotherapy-only preparative regimen for adults with high-risk acute myelogenous leukemia.
Am J Hematol
; 2007 Jan;82(1):6-14
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Unrelated donor bone marrow transplantation using a chemotherapy-only preparative regimen for adults with high-risk
acute
myelogenous
leukemia
.
Limited data are available for adults undergoing unrelated donor (URD) BMT for
AML
using chemotherapy-only preparative regimens.
Previous studies incorporated irradiation, included adults and children, and excluded
secondary leukemia
.
Herein we report long-term outcomes for adults with poor-prognostic
AML
receiving a novel regimen of busulfan (16 mg/kg), cytarabine (8,000 mg/m(2)), and cyclophosphamide (120 mg/kg) (BAC), followed by URD BMT.
Adverse features included unfavorable cytogenetics (49%),
secondary
AML
(47%),
leukemia
at transplant (42%), and extramedullary disease (16%).
At time of BMT, 23 were in remission (12 CR1) while 22 had
leukemia
.
Acute
and chronic GVHD rates were 44 and 67%, respectively.
Seventeen (38%) were disease-free 52 months post-BMT; 13 were
leukemia
-free (eight CR1) at transplant.
Secondary leukemia
, cytogenetics, cell dose, and GVHD did not influence outcome.
In poor-risk
AML
, BAC provided cytoreduction comparable to reported TBI-containing regimens, when administered for URD BMT.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Marrow Transplantation.
Leukemia
,
Myeloid
,
Acute
/ therapy. Tissue Donors. Transplantation Conditioning
[MeSH-minor]
Acute
Disease. Adult. Chronic Disease. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Factor XIII / administration & dosage. Factor XIII / adverse effects. Female. Fibrinogen / administration & dosage. Fibrinogen / adverse effects. Follow-Up Studies. Graft vs Host Disease / etiology. Graft vs Host Disease / mortality. Humans. Male. Middle Aged. Recurrence. Remission Induction. Retrospective Studies. Thrombin / administration & dosage. Thrombin / adverse effects. Transplantation, Homologous
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Bone Marrow Transplantation
.
MedlinePlus Health Information.
consumer health - Organ Donation
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16986128.001).
[ISSN]
0361-8609
[Journal-full-title]
American journal of hematology
[ISO-abbreviation]
Am. J. Hematol.
[Language]
eng
[Publication-type]
Clinical Trial; Comparative Study; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
80168379AG / Doxorubicin; 9001-32-5 / Fibrinogen; 9013-56-3 / Factor XIII; EC 3.4.21.5 / Thrombin; bio-adhesio-chemo protocol
38.
Sovinz P, Urban C, Hausegger K:
Life-threatening hemangiomatosis of the liver in an infant: multimodal therapy including cyclophosphamide and secondary acute myeloid leukemia.
Pediatr Blood Cancer
; 2006 Dec;47(7):972-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Life-threatening hemangiomatosis of the liver in an infant: multimodal therapy including cyclophosphamide and
secondary acute
myeloid
leukemia
.
[MeSH-major]
Cyclophosphamide / adverse effects. Hemangioma / therapy.
Leukemia
,
Myeloid
,
Acute
/ etiology. Liver Neoplasms / therapy. Neoplasms, Second Primary / etiology
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Birthmarks
.
MedlinePlus Health Information.
consumer health - Liver Cancer
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentOn]
Pediatr Blood Cancer. 2006 Feb;46(2):239-42
[
16369922.001
]
(PMID = 16609951.001).
[ISSN]
1545-5009
[Journal-full-title]
Pediatric blood & cancer
[ISO-abbreviation]
Pediatr Blood Cancer
[Language]
eng
[Publication-type]
Case Reports; Comment; Letter
[Publication-country]
United States
[Chemical-registry-number]
8N3DW7272P / Cyclophosphamide
39.
Harousseau JL, Martinelli G, Jedrzejczak WW, Brandwein JM, Bordessoule D, Masszi T, Ossenkoppele GJ, Alexeeva JA, Beutel G, Maertens J, Vidriales MB, Dombret H, Thomas X, Burnett AK, Robak T, Khuageva NK, Golenkov AK, Tothova E, Mollgard L, Park YC, Bessems A, De Porre P, Howes AJ, FIGHT-AML-301 Investigators:
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.
Blood
; 2009 Aug 6;114(6):1166-73
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed
acute
myeloid
leukemia
in patients 70 years or older.
This phase 3, multicenter, open-label study evaluated the efficacy and safety of tipifarnib compared with best supportive care (BSC), including hydroxyurea, as first-line therapy in elderly patients (>or=70 years) with newly diagnosed, de novo, or
secondary acute
myeloid
leukemia
.
[MeSH-major]
Antineoplastic Agents / administration & dosage. Hydroxyurea / administration & dosage.
Leukemia
,
Myeloid
,
Acute
/ drug therapy.
Leukemia
,
Myeloid
,
Acute
/ mortality. Quinolones / administration & dosage
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
HYDROXYUREA
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19470696.001).
[ISSN]
1528-0020
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
eng
[Databank-accession-numbers]
ClinicalTrials.gov/ NCT00093990
[Publication-type]
Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Quinolones; 192185-72-1 / tipifarnib; X6Q56QN5QC / Hydroxyurea
[Investigator]
Bezares R; Calahonra R; Fernandez I; Bosly J; Bries G; Bron D; Demuynck H; Ferrant A; Maertens J; Noens L; Selleslag D; Zachee P; Del Giglio; Figueiras R; Hungria V; Brandwein J; Kassis J; Sheridan D; Van der Jagt R; Mayer J; Dufva I; Juul Nielsen O; Friis L; Scholer Kristensen J; Bordessoule D; Dombret H; Fenaux P; Harousseau JL; Huguet F; Ifrah N; Pigneaux A; Quesnel B; Randriamalala E; Rossi JF; Thomas X; Vey N; Ganser A; Germing U; Hänel M; Moritz T; Niederwieser; Noppeney R; Borbényi Z; Losonczy H; Masszi T; Radványi G; Udvardy M; Conneally E; O'Dwyer M; Alimena G; Baccarani M; De Fabritiis P; Fanin R; Martinelli G; Kim I; Lee KH; Min YH; Garcés O; Plasencia A; Sobrevilla P; Vela J; Dmoszynska A; Jedrzejczak W; Kloczko J; Kuliczkowski K; Robak T; Skotnicki A; Sulek K; Alexeeva JA; Abdulkadyrov KM; Domnikova N; Dunaev YA; Gaisarova G; Gavrilenko A; Golenkov AK; Khuageva NK; Khlevnaya N; Loginov AB; Patrin VF; Pristupa A; Rossiev VA; Samoilova OS; Shneider TV; Suvorov A; Yablokova VV; Demeckova E; Tothova E; Wild A; Brunet S; Esteve J; Garcia J; Laraña; San Miguel J; Björkholm M; Mollgard L; Tidefelt U; Chou WC; Hsiao LT; Kuo CY; Lin TL; Löwenberg B; Van Marwijk Kooy M; Muus P; Ossenkoppele GJ; Schipperus MR; Schouten HC; Wittebol S; Gülbas Z; Burnett AK; Carr R; El-Agnaf M; Mufti GJ; Rudin C; Kaplan PE; Kryachok IA; Lysa I; Masliak ZV; Pylypenko HV; Stulginskaya MA; Manges RF
40.
Sekeres MA, Elson P, Kalaycio ME, Advani AS, Copelan EA, Faderl S, Kantarjian HM, Estey E:
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients.
Blood
; 2009 Jan 1;113(1):28-36
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Time from diagnosis to treatment initiation predicts survival in younger, but not older,
acute
myeloid
leukemia
patients.
Acute
myeloid
leukemia
(
AML
) is considered an oncologic emergency.
We examined the effect of time from
AML
diagnosis to treatment (TDT) on complete remission (CR) and overall survival (OS), using patient characteristics available at diagnosis.
Regression models were applied to older (> or = 60 years) and younger (< 60 years) adults, controlling for age, baseline white blood cell count,
secondary
AML
(sAML), and performance status.
AML
therapy should be initiated immediately in younger patients.
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
Hazardous Substances Data Bank.
CYTARABINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Res. 1998 Sep 15;58(18):4173-9
[
9751631.001
]
[Cites]
Cancer. 2008 May 15;112(10):2233-40
[
18348307.001
]
[Cites]
Blood. 2000 Sep 1;96(5):1670-3
[
10961861.001
]
[Cites]
Blood. 2001 Aug 1;98(3):548-53
[
11468148.001
]
[Cites]
Blood. 2001 Sep 1;98(5):1302-11
[
11520775.001
]
[Cites]
Blood. 2001 Sep 1;98(5):1312-20
[
11520776.001
]
[Cites]
Blood. 2002 Aug 15;100(4):1224-32
[
12149202.001
]
[Cites]
Blood. 2002 Oct 1;100(7):2292-302
[
12239137.001
]
[Cites]
Blood. 2002 Dec 15;100(13):4325-36
[
12393746.001
]
[Cites]
N Engl J Med. 2003 Aug 21;349(8):743-52
[
12930926.001
]
[Cites]
J Clin Oncol. 2003 Dec 15;21(24):4642-9
[
14673054.001
]
[Cites]
Blood. 2004 Jan 15;103(2):479-85
[
14512295.001
]
[Cites]
J Clin Oncol. 2004 Mar 15;22(6):1087-94
[
15020610.001
]
[Cites]
Blood. 2004 May 15;103(10):3669-76
[
14726387.001
]
[Cites]
Cancer. 1981 May 15;47(10):2460-9
[
6944140.001
]
[Cites]
J Clin Oncol. 1989 Sep;7(9):1268-74
[
2475589.001
]
[Cites]
J Clin Oncol. 1990 Feb;8(2):272-9
[
2299370.001
]
[Cites]
N Engl J Med. 1995 Jun 22;332(25):1671-7
[
7760868.001
]
[Cites]
Blood. 1998 May 15;91(10):3607-15
[
9572995.001
]
[Cites]
Blood. 1998 Oct 1;92(7):2322-33
[
9746770.001
]
[Cites]
Blood. 1999 Apr 15;93(8):2478-84
[
10194425.001
]
[Cites]
Blood. 2005 Jan 1;105(1):54-60
[
15345597.001
]
[Cites]
Drugs Aging. 2005;22(11):943-55
[
16323971.001
]
[Cites]
Blood. 2006 May 1;107(9):3481-5
[
16455952.001
]
[Cites]
Blood. 2006 Jul 1;108(1):63-73
[
16522815.001
]
[Cites]
Cancer. 2007 Oct 15;110(8):1752-9
[
17724726.001
]
[Cites]
J Clin Oncol. 1999 Dec;17(12):3767-75
[
10577848.001
]
(PMID = 18827183.001).
[ISSN]
1528-0020
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
ENG
[Grant]
United States / NCRR NIH HHS / RR / U54 RR019397; United States / NCRR NIH HHS / RR / U54 RR 19397-03
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine
[Other-IDs]
NLM/ PMC2614639
41.
Rubio S, Martins C, Lacerda JF, Carmo JA, Lourenço F, Lacerda JM:
Allogeneic stem cell transplantation in patients with myelodysplastic syndrome: outcome analysis according to the International Prognostic Scoring System.
Acta Med Port
; 2006 Sep-Oct;19(5):343-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We determined the outcome of patients with myelodysplastic syndrome (MDS) and
secondary acute
myeloid
leukemia
(sAML) after allogeneic stem cell transplantation according to their international prognostic scoring system (IPSS) risk categories at diagnosis.
[MeSH-minor]
Acute
Disease. Adolescent. Adult. Female. Humans.
Leukemia
,
Myeloid
/ surgery. Male. Middle Aged. Prognosis. Recurrence. Risk Assessment. Treatment Outcome
Genetic Alliance.
consumer health - Myelodysplastic syndromes
.
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17376319.001).
[ISSN]
1646-0758
[Journal-full-title]
Acta médica portuguesa
[ISO-abbreviation]
Acta Med Port
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Portugal
42.
Tefferi A:
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
Leukemia
; 2010 Jun;24(6):1128-38
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Beginning in early 2005, a number of novel mutations involving Janus kinase 2 (JAK2), Myeloproliferative
Leukemia
Virus (MPL), TET oncogene family member 2 (TET2), Additional Sex Combs-Like 1 (ASXL1), Casitas B-lineage lymphoma proto-oncogene (CBL), Isocitrate dehydrogenase (IDH) and IKAROS family zinc finger 1 (IKZF1) have been described in BCR-ABL1-negative MPNs.
The incidence of TET2, ASXL1, CBL, IDH or IKZF1 mutations in these disorders ranges from 0 to 17%; these latter mutations are more common in chronic (TET2, ASXL1, CBL) or juvenile (CBL) myelomonocytic leukemias, mastocytosis (TET2), myelodysplastic syndromes (TET2, ASXL1) and
secondary acute
myeloid
leukemia
, including blast-phase MPN (IDH, ASXL1, IKZF1).
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Haematologica. 2007 Dec;92(12):1717-8
[
18056003.001
]
[Cites]
Haematologica. 2008 Jan;93(1):34-40
[
18166783.001
]
[Cites]
Leukemia. 2008 Jan;22(1):216
[
17851549.001
]
[Cites]
N Engl J Med. 1976 Oct 21;295(17):913-6
[
967201.001
]
[Cites]
Blood. 1981 Nov;58(5):916-9
[
7296002.001
]
[Cites]
Lancet. 2005 Mar 19-25;365(9464):1054-61
[
15781101.001
]
[Cites]
Nature. 2005 Apr 28;434(7037):1144-8
[
15793561.001
]
[Cites]
Leukemia. 2005 Aug;19(8):1411-5
[
15920487.001
]
[Cites]
Blood. 2005 Aug 15;106(4):1207-9
[
15860661.001
]
[Cites]
N Engl J Med. 2005 Sep 29;353(13):1416-7; author reply 1416-7
[
16192494.001
]
[Cites]
Br J Haematol. 2005 Oct;131(2):166-71
[
16197445.001
]
[Cites]
Br J Haematol. 2005 Nov;131(3):320-8
[
16225651.001
]
[Cites]
Blood. 2005 Nov 15;106(10):3377-9
[
16081687.001
]
[Cites]
Lancet. 2005 Dec 3;366(9501):1945-53
[
16325696.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):18962-7
[
16365288.001
]
[Cites]
Cancer. 2006 Feb 1;106(3):631-5
[
16369984.001
]
[Cites]
Blood. 2006 Mar 1;107(5):2098-100
[
16293597.001
]
[Cites]
Leukemia. 2006 Jan;20(1):157-8
[
16331280.001
]
[Cites]
Leukemia. 2006 Jun;20(6):971-8
[
16598306.001
]
[Cites]
Gastroenterology. 2006 Jun;130(7):2031-8
[
16762626.001
]
[Cites]
Blood. 2006 Aug 15;108(4):1377-80
[
16675710.001
]
[Cites]
J Cell Physiol. 2006 Oct;209(1):21-43
[
16741904.001
]
[Cites]
Leukemia. 2006 Nov;20(11):2067-70
[
16990759.001
]
[Cites]
Blood. 2006 Nov 15;108(10):3472-6
[
16868251.001
]
[Cites]
PLoS Med. 2006 Jul;3(7):e270
[
16834459.001
]
[Cites]
Br J Haematol. 2006 Dec;135(5):683-7
[
17107350.001
]
[Cites]
N Engl J Med. 2007 Feb 1;356(5):459-68
[
17267906.001
]
[Cites]
Br J Haematol. 2007 Feb;136(4):678-9
[
17223913.001
]
[Cites]
J Immunol. 2007 Mar 1;178(5):2623-9
[
17312100.001
]
[Cites]
Br J Haematol. 2007 May;137(3):244-7
[
17408465.001
]
[Cites]
Cancer. 2007 Jun 1;109(11):2279-84
[
17440984.001
]
[Cites]
Blood. 2007 Jul 1;110(1):375-9
[
17363731.001
]
[Cites]
Leukemia. 2007 Aug;21(8):1658-68
[
17541402.001
]
[Cites]
Blood. 2007 Aug 1;110(3):840-6
[
17379742.001
]
[Cites]
Blood. 2007 Aug 1;110(3):1004-12
[
17446348.001
]
[Cites]
Blood. 2007 Aug 15;110(4):1092-7
[
17488875.001
]
[Cites]
Leukemia. 2007 Sep;21(9):2074-5
[
17476276.001
]
[Cites]
Leukemia. 2007 Sep;21(9):1960-3
[
17597810.001
]
[Cites]
Leukemia. 2007 Sep;21(9):1952-9
[
17625606.001
]
[Cites]
Stem Cells. 2007 Sep;25(9):2358-62
[
17540852.001
]
[Cites]
Leukemia. 2007 Oct;21(10):2206-7
[
17507998.001
]
[Cites]
Blood. 2007 Nov 15;110(10):3735-43
[
17709604.001
]
[Cites]
Blood. 2007 Dec 1;110(12):4030-6
[
17712047.001
]
[Cites]
Leukemia. 2008 Jan;22(1):14-22
[
17882280.001
]
[Cites]
Leukemia. 2008 Jan;22(1):23-30
[
17882282.001
]
[Cites]
Leukemia. 2008 Jan;22(1):3-13
[
17882283.001
]
[Cites]
Leukemia. 2008 Jan;22(1):87-95
[
18033315.001
]
[Cites]
Blood. 2008 Feb 1;111(3):1686-9
[
17984312.001
]
[Cites]
Leukemia. 2008 Feb;22(2):450-1
[
17851561.001
]
[Cites]
Blood. 2008 Mar 1;111(5):2785-9
[
18006699.001
]
[Cites]
Blood. 2008 Apr 15;111(8):3931-40
[
18160670.001
]
[Cites]
Leukemia. 2008 Apr;22(4):870-3
[
17914411.001
]
[Cites]
Leukemia. 2008 Sep;22(9):1790-2
[
18354492.001
]
[Cites]
Science. 2008 Sep 26;321(5897):1807-12
[
18772396.001
]
[Cites]
Haematologica. 2008 Oct;93(10):1595-7
[
18698078.001
]
[Cites]
Leukemia. 2008 Oct;22(10):1813-7
[
18754026.001
]
[Cites]
Leukemia. 2008 Oct;22(10):1841-8
[
18754034.001
]
[Cites]
Leukemia. 2008 Oct;22(10):1828-40
[
18769448.001
]
[Cites]
Trends Cell Biol. 2008 Nov;18(11):545-51
[
18848449.001
]
[Cites]
Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17050-4
[
18957548.001
]
[Cites]
Acta Neuropathol. 2008 Dec;116(6):597-602
[
18985363.001
]
[Cites]
Leukemia. 2009 Jan;23(1):144-52
[
18843287.001
]
[Cites]
Hum Mutat. 2009 Jan;30(1):7-11
[
19117336.001
]
[Cites]
N Engl J Med. 2009 Feb 19;360(8):765-73
[
19228619.001
]
[Cites]
Leuk Lymphoma. 2009 Feb;50(2):247-53
[
19235016.001
]
[Cites]
Blood. 2009 Feb 26;113(9):2022-7
[
19047681.001
]
[Cites]
Br J Haematol. 2009 Mar;144(6):904-8
[
19170680.001
]
[Cites]
Leukemia. 2009 Mar;23(3):610-4
[
18818701.001
]
[Cites]
J Cell Mol Med. 2009 Feb;13(2):215-37
[
19175693.001
]
[Cites]
Immunol Rev. 2009 Mar;228(1):273-87
[
19290934.001
]
[Cites]
Blood. 2009 Mar 26;113(13):2895-901
[
18988864.001
]
[Cites]
Nat Genet. 2009 Apr;41(4):446-9
[
19287382.001
]
[Cites]
Nat Genet. 2009 Apr;41(4):450-4
[
19287385.001
]
[Cites]
Blood. 1978 Feb;51(2):189-94
[
620081.001
]
[Cites]
Clin Cancer Res. 2009 Apr 1;15(7):2238-47
[
19276253.001
]
[Cites]
Science. 2009 Apr 10;324(5924):261-5
[
19359588.001
]
[Cites]
Eur J Haematol. 2009 May;82(5):329-38
[
19141119.001
]
[Cites]
Leukemia. 2009 May;23(5):1008-9
[
19151782.001
]
[Cites]
Leukemia. 2009 May;23(5):852-5
[
19194467.001
]
[Cites]
Leukemia. 2009 May;23(5):900-4
[
19262599.001
]
[Cites]
Leukemia. 2009 May;23(5):905-11
[
19262601.001
]
[Cites]
Leukemia. 2009 May;23(5):834-44
[
19295544.001
]
[Cites]
Science. 2009 May 15;324(5929):930-5
[
19372391.001
]
[Cites]
N Engl J Med. 2009 May 28;360(22):2289-301
[
19474426.001
]
[Cites]
Int J Cancer. 2009 Jul 15;125(2):353-5
[
19378339.001
]
[Cites]
Blood. 2009 Jun 11;113(24):6182-92
[
19387008.001
]
[Cites]
Blood. 2009 Jun 18;113(25):6403-10
[
19372255.001
]
[Cites]
Nat Genet. 2009 Jul;41(7):838-42
[
19483684.001
]
[Cites]
Blood. 2009 Jul 2;114(1):144-7
[
19420352.001
]
[Cites]
Leukemia. 2009 Jul;23(7):1343-5
[
19295549.001
]
[Cites]
Br J Haematol. 2009 Jun;145(6):788-800
[
19388938.001
]
[Cites]
Blood. 2009 Jul 30;114(5):937-51
[
19357394.001
]
[Cites]
Leukemia. 2009 Aug;23(8):1441-5
[
19295546.001
]
[Cites]
Nature. 2009 Aug 13;460(7257):904-8
[
19620960.001
]
[Cites]
J Clin Oncol. 2009 Aug 20;27(24):4002-6
[
19528370.001
]
[Cites]
Blood. 2009 Aug 20;114(8):1477-83
[
19549988.001
]
[Cites]
Blood. 2009 Aug 27;114(9):1859-63
[
19571318.001
]
[Cites]
J Clin Oncol. 2009 Sep 1;27(25):4150-4
[
19636000.001
]
[Cites]
Acta Neuropathol. 2009 Oct;118(4):469-74
[
19554337.001
]
[Cites]
N Engl J Med. 2009 Sep 10;361(11):1058-66
[
19657110.001
]
[Cites]
N Engl J Med. 2009 Sep 10;361(11):1117; author reply 1117-8
[
19741235.001
]
[Cites]
Leukemia. 2003 Mar;17(3):637-41
[
12646957.001
]
[Cites]
Genes Chromosomes Cancer. 2003 Jun;37(2):214-9
[
12696071.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11444-7
[
15269348.001
]
[Cites]
Cancer Cell. 2005 Apr;7(4):387-97
[
15837627.001
]
[Cites]
N Engl J Med. 2005 Apr 28;352(17):1779-90
[
15858187.001
]
[Cites]
J Clin Oncol. 2009 Dec 20;27(36):6109-16
[
19901108.001
]
[Cites]
Am J Hematol. 2010 Jan;85(1):81-3
[
19957346.001
]
[Cites]
J Biol Chem. 2010 Jan 1;285(1):18-29
[
19880879.001
]
[Cites]
Blood. 2010 Jan 7;115(1):38-46
[
19861679.001
]
[Cites]
Haematologica. 2010 Jan;95(1):65-70
[
19713221.001
]
[Cites]
Leukemia. 2010 Jan;24(1):201-3
[
19710701.001
]
[Cites]
Leukemia. 2010 Jan;24(1):110-4
[
19847198.001
]
[Cites]
Leukemia. 2010 Jan;24(1):105-9
[
19847199.001
]
[Cites]
Cancer Res. 2010 Jan 15;70(2):447-52
[
20068184.001
]
[Cites]
N Engl J Med. 2010 Jan 28;362(4):369-70
[
20107228.001
]
[Cites]
Blood. 2010 Jan 28;115(4):778-82
[
19965680.001
]
[Cites]
Blood. 2010 Feb 4;115(5):1037-48
[
19996410.001
]
[Cites]
Leukemia. 2010 Feb;24(2):469-73
[
19865112.001
]
[Cites]
Blood. 2010 Feb 11;115(6):1254-63
[
19880496.001
]
[Cites]
J Biol Chem. 2010 Feb 19;285(8):5296-307
[
20028972.001
]
[Cites]
J Exp Med. 2010 Feb 15;207(2):339-44
[
20142433.001
]
[Cites]
Hum Mutat. 2010 Mar;31(3):E1186-99
[
20077503.001
]
[Cites]
J Clin Endocrinol Metab. 2010 Mar;95(3):1274-8
[
19915015.001
]
[Cites]
Haematologica. 2010 Mar;95(3):518-9
[
19903679.001
]
[Cites]
Blood. 2010 Mar 11;115(10):1969-75
[
20008299.001
]
[Cites]
Blood. 2010 Mar 11;115(10):2003-7
[
20061559.001
]
[Cites]
Cancer Cell. 2010 Mar 16;17(3):225-34
[
20171147.001
]
[Cites]
Acta Neuropathol. 2010 Apr;119(4):487-94
[
20127344.001
]
[Cites]
Hum Mol Genet. 2010 Apr 15;19(8):1507-14
[
20093295.001
]
[Cites]
Blood. 2010 Apr 8;115(14):2891-900
[
20008300.001
]
[Cites]
Leukemia. 2010 Apr;24(4):859-60
[
20111067.001
]
[Cites]
Blood. 2010 Apr 29;115(17):3589-97
[
20197548.001
]
[Cites]
Leukemia. 2010 May;24(5):1069-73
[
20182460.001
]
[Cites]
Leukemia. 2010 Jun;24(6):1146-51
[
20410924.001
]
[Cites]
Leukemia. 2008 Apr;22(4):740-7
[
18079739.001
]
[Cites]
Leukemia. 2008 Apr;22(4):756-61
[
18216871.001
]
[Cites]
Nature. 2008 May 1;453(7191):110-4
[
18408710.001
]
[Cites]
Leuk Lymphoma. 2008 May;49(5):847-9
[
18464105.001
]
[Cites]
Leukemia. 2008 May;22(5):1059-62
[
17972958.001
]
[Cites]
Leukemia. 2008 Jun;22(6):1295-8
[
18059483.001
]
[Cites]
Leukemia. 2008 Jun;22(6):1289
[
18079740.001
]
[Cites]
Blood. 2008 Jul 1;112(1):141-9
[
18451306.001
]
[Cites]
Leukemia. 2008 Jul;22(7):1472-4
[
18239619.001
]
[Cites]
Leukemia. 2008 Jul;22(7):1299-307
[
18496562.001
]
[Cites]
Blood. 2008 Aug 1;112(3):844-7
[
18519816.001
]
[Cites]
Blood. 2008 Aug 15;112(4):1402-12
[
18515659.001
]
[Cites]
Leukemia. 2008 Aug;22(8):1557-66
[
18528423.001
]
[Cites]
Blood. 2008 Sep 15;112(6):2199-204
[
18451307.001
]
[Cites]
Blood. 2008 Sep 15;112(6):2429-38
[
18612101.001
]
[Cites]
Int J Cancer. 2009 Nov 15;125(10):2485-6
[
19530255.001
]
[Cites]
Blood. 2009 Oct 1;114(14):3018-23
[
19541820.001
]
[Cites]
Clin Cancer Res. 2009 Oct 1;15(19):6002-7
[
19755387.001
]
[Cites]
Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16616-21
[
19805346.001
]
[Cites]
Nature. 2009 Oct 8;461(7265):819-22
[
19783980.001
]
[Cites]
Blood. 2009 Oct 8;114(15):3285-91
[
19666869.001
]
[Cites]
Leukemia. 2009 Oct;23(10):1924-6
[
19440215.001
]
[Cites]
Am J Physiol Heart Circ Physiol. 2009 Nov;297(5):H1545-56
[
19717737.001
]
[Cites]
N Engl J Med. 2009 Nov 5;361(19):1872-85
[
19890130.001
]
[Cites]
Blood. 2009 Nov 5;114(19):4197-208
[
19734451.001
]
[Cites]
Leukemia. 2009 Nov;23(11):2183-6
[
19609284.001
]
[Cites]
J Clin Oncol. 2009 Dec 1;27(34):5743-50
[
19805672.001
]
[Cites]
Haematologica. 2009 Dec;94(12):1676-81
[
19797729.001
]
[Cites]
J Clin Oncol. 2009 Dec 10;27(35):5874-80
[
19901110.001
]
[Cites]
Nature. 2009 Dec 10;462(7274):739-44
[
19935646.001
]
(PMID = 20428194.001).
[ISSN]
1476-5551
[Journal-full-title]
Leukemia
[ISO-abbreviation]
Leukemia
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Chemical-registry-number]
0 / ASXL1 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / IKZF1 protein, human; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins; 0 / Receptors, Thrombopoietin; 0 / Repressor Proteins; 0 / TET2 protein, human; 143641-95-6 / MPL protein, human; 148971-36-2 / Ikaros Transcription Factor; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.42. / IDH1 protein, human; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2; EC 6.3.2.- / CBL protein, human; EC 6.3.2.- / Proto-Oncogene Proteins c-cbl
[Number-of-references]
171
[Other-IDs]
NLM/ PMC3035972
43.
Winter SS, Holdsworth MT, Devidas M, Raisch DW, Chauvenet A, Ravindranath Y, Ducore JM, Amylon MD:
Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
Pediatr Blood Cancer
; 2006 Feb;46(2):179-86
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Antimetabolite-based therapy in childhood T-cell
acute
lymphoblastic
leukemia
: a report of POG study 9296.
PURPOSE: A previous Pediatric Oncology Group (POG) study showed high incidence of
secondary acute
myelogenous
leukemia
(
AML
) in children treated for T-cell
acute
lymphoblastic
leukemia
(T-ALL) or higher-stage
lymphoblastic
lymphoma.
To prevent
secondary
neoplasms, induce prolonged asparagine depletion, and maintain high event-free survival (EFS) in children with newly diagnosed T-ALL or higher-stage
non
-Hodgkins lymphoma (NHL), we designed this pilot study to determine feasibility and safety of substituting methotrexate/mercaptopurine for teniposide/cytarabine and PEG-asparaginase for native asparaginase.
No patients treated entirely on this study developed
secondary
neoplasms.
One patient taken off study for asparaginase toxicity was treated with multiagent therapy that contained teniposide, and died from
secondary
myelodysplasia (sMDS)/
AML
.
EFS was not compromised and
secondary
neoplasms were decreased.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Precursor Cell
Lymphoblastic
Leukemia
-Lymphoma / drug therapy
[MeSH-minor]
Adolescent. Anthracyclines / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Asparaginase / administration & dosage. Asparaginase / adverse effects. Child. Child, Preschool. Disease-Free Survival. Drug Hypersensitivity / etiology. Female. Follow-Up Studies. Humans. Lymphoma,
Non
-Hodgkin / drug therapy. Lymphoma,
Non
-Hodgkin / mortality. Male. Pilot Projects. Remission Induction. Sepsis / etiology. Sepsis / mortality
Genetic Alliance.
consumer health - Acute Lymphoblastic Leukemia
.
Genetic Alliance.
consumer health - Acute Lymphoblastic Leukemia, Childhood
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16007607.001).
[ISSN]
1545-5009
[Journal-full-title]
Pediatric blood & cancer
[ISO-abbreviation]
Pediatr Blood Cancer
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / 5 U10 CA5312; United States / NCI NIH HHS / CA / CA29139
[Publication-type]
Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Anthracyclines; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; EC 3.5.1.1 / Asparaginase
44.
Yesilipek MA, Karasu GT, Kupesiz A, Uygun V, Hazar V:
Better posttransplant outcome with fludarabine based conditioning in multitransfused fanconi anemia patients who underwent peripheral blood stem cell transplantation.
J Pediatr Hematol Oncol
; 2009 Jul;31(7):512-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We lost 3 patients in regimen A group and 1 of them from
secondary acute
myeloid
leukemia
.
Genetic Alliance.
consumer health - Fanconi Anemia
.
Genetic Alliance.
consumer health - Anemia
.
Genetic Alliance.
consumer health - Transplantation
.
Hazardous Substances Data Bank.
FLUDARABINE
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
VIDARABINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19564748.001).
[ISSN]
1536-3678
[Journal-full-title]
Journal of pediatric hematology/oncology
[ISO-abbreviation]
J. Pediatr. Hematol. Oncol.
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antilymphocyte Serum; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
45.
Tangen JM, Fløisand Y, Foss-Abrahamsen J, Haukås E, Naess IA, Skjelbakken T:
[Survival in adults with acute myelogenous leukemia].
Tidsskr Nor Laegeforen
; 2008 May 15;128(10):1164-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Survival in adults with
acute
myelogenous
leukemia
].
BACKGROUND:
Acute
myelogenous
leukemia
is the most common type of
acute leukemia
in adults.
MATERIAL AND METHODS: Survival data were retrieved from the Norwegian Registry for
Acute
Leukemias and
Lymphoblastic
Lymphomas for patients with
acute
myelogenous
leukemia
(aged from 16 to 60 years) who were registered in the period 1.1.2000-31.12.2005.
Patients with
secondary acute
myelogenous
leukemia
were classified as high-risk.
RESULTS AND INTERPRETATION: 4-year survival was 94.5% in
acute
promyelocytic
leukemia
, 77.7% in other low-risk
acute
myelogenous
leukemia
, 39.0% in standard risk patients and 29.1% in high-risk patients.
The increase is most probably due to an intensification of chemotherapy after remission and to the implementation of all-trans-retinoic acid in the treatment of promyelocytic
leukemia
.
[MeSH-major]
Leukemia
,
Myeloid
,
Acute
/ mortality
[MeSH-minor]
Adolescent. Adult. Age Factors. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Female. Humans.
Leukemia
, Promyelocytic,
Acute
/ drug therapy.
Leukemia
, Promyelocytic,
Acute
/ genetics.
Leukemia
, Promyelocytic,
Acute
/ mortality. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Norway / epidemiology. Risk Factors. Survival Rate
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Tidsskr Nor Laegeforen. 2008 Aug 14;128(15):1681-2; author reply 1682
[
18704137.001
]
(PMID = 18480864.001).
[ISSN]
0807-7096
[Journal-full-title]
Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
[ISO-abbreviation]
Tidsskr. Nor. Laegeforen.
[Language]
nor
[Publication-type]
Comparative Study; English Abstract; Journal Article
[Publication-country]
Norway
46.
Kuptsova-Clarkson N, Ambrosone CB, Weiss J, Baer MR, Sucheston LE, Zirpoli G, Kopecky KJ, Ford L, Blanco J, Wetzler M, Moysich KB:
XPD DNA nucleotide excision repair gene polymorphisms associated with DNA repair deficiency predict better treatment outcomes in secondary acute myeloid leukemia.
Int J Mol Epidemiol Genet
; 2010;1(4):278-94
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
XPD DNA nucleotide excision repair gene polymorphisms associated with DNA repair deficiency predict better treatment outcomes in
secondary acute
myeloid
leukemia
.
We evaluated these polymorphisms and XPD haplotypes in adult de novo (n=214) and
secondary
(n=79)
acute
myeloid
leukemia
(
AML
) patients treated with cytarabine and anthracycline chemotherapy.
Differential responses were observed in
secondary
, but not de novo,
AML
.
Among
secondary
AML
patients, the odds of achieving complete remission (CR) were higher for the XPD 312Asn/Asn (OR= 11.23; 95% CI, 2.23-56.63) and XPD 751Gln/Gln (OR= 7.07; 95% CI, 1.42-35.18) genotypes.
If validated, these findings could support stratification of chemotherapy in
secondary
AML
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21394217.001).
[ISSN]
1948-1756
[Journal-full-title]
International journal of molecular epidemiology and genetics
[ISO-abbreviation]
Int J Mol Epidemiol Genet
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA108353-02; United States / NCI NIH HHS / CA / R03 CA108353; United States / NCI NIH HHS / CA / CA108353-01; United States / NCI NIH HHS / CA / R03 CA108353-02; United States / NCI NIH HHS / CA / R03 CA108353-01
[Publication-type]
Journal Article
[Publication-country]
United States
[Other-IDs]
NLM/ NIHMS247623; NLM/ PMC3049908
[Keywords]
NOTNLM ; Acute Myeloid Leukemia (AML) / DNA repair gene polymorphisms / pharmacogenetics/pharmacogenomics / secondary AML
47.
Ferrara F, Palmieri S, Izzo T, Criscuolo C, Riccardi C:
Continuous sequential infusion of fludarabine and cytarabine for elderly patients with acute myeloid leukaemia secondary to a previously diagnosed myelodysplastic syndrome.
Hematol Oncol
; 2010 Dec;28(4):202-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Continuous sequential infusion of fludarabine and cytarabine for elderly patients with
acute
myeloid
leukaemia
secondary
to a previously diagnosed myelodysplastic syndrome.
Acute
myeloid
leukaemia (
AML
)
secondary
to myelodysplastic syndrome (MDS) is characterized by poor prognosis, namely in older patients.
The combination of fludarabine (F) with cytarabine (ARA-C) ± G-CSF was proven as effective in patients with poor risk
AML
.
The efficacy and toxicity of a regimen including F + ARA-C as sequential continuous infusion (CI-FLA) in 64 untreated patients aged >60 years, in which
AML
arose after a previous MDS, was investigated.
CI-FLA is effective in elderly patients with
AML
secondary
to previously diagnosed MDS.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods.
Leukemia
,
Myeloid
/ therapy. Myelodysplastic Syndromes / complications
[MeSH-minor]
Acute
Disease. Aged. Aged, 80 and over. Combined Modality Therapy. Cytarabine / administration & dosage. Cytarabine / adverse effects. Diarrhea / chemically induced. Disease-Free Survival. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Remission Induction. Transplantation, Autologous. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / adverse effects. Vidarabine / analogs & derivatives
Genetic Alliance.
consumer health - Myelodysplastic syndromes
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
Hazardous Substances Data Bank.
CYTARABINE
.
Hazardous Substances Data Bank.
FLUDARABINE
.
Hazardous Substances Data Bank.
VIDARABINE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright © 2010 John Wiley & Sons, Ltd.
(PMID = 21136583.001).
[ISSN]
1099-1069
[Journal-full-title]
Hematological oncology
[ISO-abbreviation]
Hematol Oncol
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article
[Publication-country]
England
[Chemical-registry-number]
04079A1RDZ / Cytarabine; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
48.
Allen SL, Kolitz JE, Lundberg AS, Bennett JM, Capizzi RL, Budman DR:
Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia.
Leuk Res
; 2010 Apr;34(4):487-91
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk
acute
myeloid
leukemia
.
Amonafide-l-malate (amonafide) is a unique DNA intercalator that maintains activity in the presence of MDR mechanisms, a frequent cause of treatment-failure in
secondary
AML
.
43 patients with relapsed/refractory or
secondary
AML
or CML blast crisis were enrolled into two phase I dose-escalation studies investigating amonafide as monotherapy or in combination with cytarabine.
Between both trials responses occurred in 9/20 patients with
secondary
AML
.
Both trials demonstrated an acceptable safety profile and significant antileukemic activity in patients with poor-risk
AML
, especially those with
secondary
AML
.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / administration & dosage.
Leukemia
,
Myeloid
,
Acute
/ drug therapy. Naphthalimides / administration & dosage
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
CYTARABINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright (c) 2009 Elsevier Ltd. All rights reserved.
(PMID = 19748672.001).
[ISSN]
1873-5835
[Journal-full-title]
Leukemia research
[ISO-abbreviation]
Leuk. Res.
[Language]
eng
[Publication-type]
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Naphthalimides; 04079A1RDZ / Cytarabine; 1Q8D39N37L / amonafide
49.
Mittal R, Ramaswamy NV, Pandita R, Al Bahar S, Khalifa N, Omar S:
Secondary acute myeloid leukemia after successful treatment for osteosarcoma.
Indian J Med Paediatr Oncol
; 2010 Jan;31(1):33-5
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Secondary acute
myeloid
leukemia
after successful treatment for osteosarcoma.
Secondary acute
myeloid
leukemia
(sAML) is a rare complication following chemotherapy for osteogenic sarcoma.
Eight months after completion of therapy, while on follow-up, he presented with leukocytosis and thrombocytopenia and confirmed to have
AML
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20931020.001).
[ISSN]
0975-2129
[Journal-full-title]
Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
[ISO-abbreviation]
Indian J Med Paediatr Oncol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
India
[Other-IDs]
NLM/ PMC2941602
[Keywords]
NOTNLM ; Acute myeloid leukemia / chemotherapy / osteosarcoma / secondary malignancy
50.
Shah A, Stiller CA, Kenward MG, Vincent T, Eden TO, Coleman MP:
Childhood leukaemia: long-term excess mortality and the proportion 'cured'.
Br J Cancer
; 2008 Jul 8;99(1):219-23
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Average time to cure increased from 12 years (95% confidence interval (CI): 11-14) to 19 years (95% CI: 14-26) for lymphoid leukaemia (average annual increase of 0.3 years; P<0.001), but remained at about 5 years for
acute nonlymphoblastic
leukaemia.
The proportion of children cured of leukaemia has risen dramatically, but the period of excess mortality associated with lymphoid leukaemia has also increased, possibly because of late relapse,
secondary
malignancy and toxicity from treatment.
MedlinePlus Health Information.
consumer health - Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Blood. 1998 Oct 1;92(7):2334-7
[
9746771.001
]
[Cites]
J Natl Cancer Inst. 1996 Mar 6;88(5):270-8
[
8614005.001
]
[Cites]
Br J Cancer. 2004 Nov 29;91(11):1905-10
[
15534607.001
]
[Cites]
Br J Haematol. 2005 Jul;130(1):67-75
[
15982346.001
]
[Cites]
J Clin Oncol. 2005 Nov 1;23(31):7936-41
[
16258093.001
]
[Cites]
Leukemia. 2005 Dec;19(12):2130-8
[
16304572.001
]
[Cites]
N Engl J Med. 2006 Oct 12;355(15):1572-82
[
17035650.001
]
[Cites]
Br J Cancer. 2007 Apr 10;96(7):1147-52
[
17342086.001
]
[Cites]
Br J Haematol. 2000 Mar;108(3):531-43
[
10759711.001
]
[Cites]
Blood. 2000 May 1;95(9):2770-5
[
10779419.001
]
[Cites]
Leukemia. 2000 Dec;14(12):2307-20
[
11187922.001
]
[Cites]
J Clin Oncol. 2001 Jul 1;19(13):3163-72
[
11432882.001
]
[Cites]
J Clin Oncol. 2001 Jul 1;19(13):3173-81
[
11432883.001
]
[Cites]
Blood. 2002 Jun 15;99(12):4257-64
[
12036851.001
]
[Cites]
Br J Haematol. 2003 Aug;122(3):345-59
[
12877662.001
]
[Cites]
N Engl J Med. 2003 Aug 14;349(7):640-9
[
12917300.001
]
[Cites]
Br J Haematol. 2004 Jan;124(1):33-46
[
14675406.001
]
[Cites]
Pediatr Blood Cancer. 2004 Jun;42(7):563-73
[
15127410.001
]
[Cites]
Lancet. 1986 Feb 22;1(8478):408-11
[
2868339.001
]
[Cites]
Arch Dis Child. 1989 Jun;64(6):798-807
[
2774614.001
]
[Cites]
J Clin Epidemiol. 1997 Feb;50(2):211-6
[
9120515.001
]
[Cites]
Int J Cancer. 1998 Jul 29;77(3):322-9
[
9663589.001
]
[Cites]
J Clin Oncol. 1998 Aug;16(8):2848-53
[
9704738.001
]
[Cites]
N Engl J Med. 1991 Nov 7;325(19):1330-6
[
1922234.001
]
[Cites]
BMJ. 1994 Jul 16;309(6948):162-6
[
8044095.001
]
[Cites]
IARC Sci Publ. 1994;(128):1-302
[
7698823.001
]
[Cites]
Stat Med. 1999 Feb 28;18(4):441-54
[
10070685.001
]
(PMID = 18594545.001).
[ISSN]
1532-1827
[Journal-full-title]
British journal of cancer
[ISO-abbreviation]
Br. J. Cancer
[Language]
ENG
[Grant]
United Kingdom / Department of Health / /
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Other-IDs]
NLM/ PMC2453011
51.
Lichtman MA:
Is there an entity of chemically induced BCR-ABL-positive chronic myelogenous leukemia?
Oncologist
; 2008 Jun;13(6):645-54
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Is there an entity of chemically induced BCR-ABL-positive chronic
myelogenous
leukemia
?
Advances in the therapy of malignancy have been accompanied by an increased frequency of cases of
secondary acute
myelogenous
leukemia
and related clonal cytopenias and oligoblastic (subacute)
myelogenous
leukemia
(myelodysplastic syndromes).
The
acute
myelogenous
leukemia
incidence can be increased by high-dose
acute
ionizing radiation exposure, alkylating agents, topoisomerase II inhibitors, possibly other DNA-damaging therapeutic agents, heavy, prolonged cigarette smoking, and high dose-time exposure to benzene, the latter less frequently seen in industrialized countries with worksite regulations.
Acute
myelogenous
leukemia
and myelodysplastic syndromes may result from innumerable primary types of chromosome damage.
In the case of chronic
myelogenous
leukemia
, a specific break in chromosome bands 9q34 and 22q11 must occur to result in the causal fusion oncogene (BCR-ABL).
A review of 11 studies of the chromosomal abnormalities found in presumptive cases of cytotoxic therapy-induced
leukemia
and of 40 studies of the subtypes of
leukemia
that occur following cytotoxic therapy for other cancers has not provided evidence of an increased risk for chemically induced BCR-ABL-positive chronic
myelogenous
leukemia
.
Studies of the effects of alkylating agents, topoisomerase inhibitors, and benzene on chromosomes of hematopoietic cells in vitro, coupled with the aforementioned epidemiological studies of
secondary leukemia
after cytotoxic therapy or of persons exposed to high dose-time concentrations of benzene in the workplace, do not indicate a relationship among chemical exposure, injury to chromosome bands 9q34 and 22q11, and an increased risk for BCR-ABL-positive chronic
myelogenous
leukemia
.
[MeSH-major]
Antineoplastic Agents / adverse effects. Chromosome Aberrations.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / chemically induced
MedlinePlus Health Information.
consumer health - Chronic Myeloid Leukemia
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18586919.001).
[ISSN]
1083-7159
[Journal-full-title]
The oncologist
[ISO-abbreviation]
Oncologist
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents
[Number-of-references]
113
52.
Kuendgen A, Schmid M, Schlenk R, Knipp S, Hildebrandt B, Steidl C, Germing U, Haas R, Dohner H, Gattermann N:
The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia.
Cancer
; 2006 Jan 1;106(1):112-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with
acute
myeloid
leukemia
.
BACKGROUND: Valproic acid (VPA) inhibits histone deacetylase activity and, synergizing with all-trans retinoic acid (ATRA), achieves differentiation induction of
myeloid
blast cells in vitro.
METHODS: We used VPA in 58 patients with
acute
myeloid
leukemia
(
AML
) who were too old and/or medically unfit to receive intensive chemotherapy (32
AML
secondary
to myelodysplastic syndrome [MDS], 22 de novo
AML
, 4
AML
secondary
to myeloproliferative syndrome).
RESULTS: The response rate was only 5% according to International Working Group (IWG) criteria for
AML
but was 16% when IWG response criteria for MDS were used, which capture hematologic improvement and stabilization of the disease.
[MeSH-major]
Antineoplastic Agents / therapeutic use. Histone Deacetylase Inhibitors.
Leukemia
,
Myeloid
/ drug therapy. Tretinoin / therapeutic use. Valproic Acid / therapeutic use
[MeSH-minor]
Acute
Disease. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Treatment Outcome
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
Hazardous Substances Data Bank.
ALL-TRANS-RETINOIC ACID
.
Hazardous Substances Data Bank.
VALPROIC ACID
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2005 American Cancer Society.
(PMID = 16323176.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Histone Deacetylase Inhibitors; 5688UTC01R / Tretinoin; 614OI1Z5WI / Valproic Acid
53.
Pyatt DW, Hays SM, Cushing CA:
Do children have increased susceptibility for developing secondary acute myelogenous leukemia?
Chem Biol Interact
; 2005 May 30;153-154:223-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Do children have increased susceptibility for developing
secondary acute
myelogenous
leukemia
?
This study was undertaken to evaluate the effects of age on a child's susceptibility to developing
leukemia
following exposure to known leukemogenic agents.
The clinical literature describing the risk of developing
acute
myelogenous
leukemia
(
AML
) following treatment with alkylating agents or topoisomerase reactive drugs (known leukemogens) was used as a basis for this investigation.
Although the number of studies and cases was very small, the available scientific and medical literature does not support the hypothesis that children will necessarily have an altered susceptibility or increased risk of developing chemotherapy-induced
AML
.
[MeSH-major]
Antineoplastic Agents, Alkylating / adverse effects.
Leukemia
,
Myeloid
,
Acute
/ epidemiology. Neoplasms, Second Primary / epidemiology
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[ErratumIn]
Chem Biol Interact. 2005 Aug 15;155(3):191
(PMID = 15878160.001).
[ISSN]
0009-2797
[Journal-full-title]
Chemico-biological interactions
[ISO-abbreviation]
Chem. Biol. Interact.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Ireland
[Chemical-registry-number]
0 / Antineoplastic Agents, Alkylating; 0 / Topoisomerase II Inhibitors
54.
Ravoet C, Mineur P, Robin V, Debusscher L, Bosly A, André M, El Housni H, Soree A, Bron D, Martiat P:
Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study.
Ann Hematol
; 2008 Nov;87(11):881-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or
secondary acute
myeloid
leukaemia: a phase II study.
We prospectively studied efficiency and tolerance of lonafarnib, a compound able to inhibit Ras signalling pathway through an inhibition of farnesyl transferase, in patients with MDS or
secondary acute
myeloid
leukaemia (sAML).
Sixteen patients were included: FAB/RAEB (n = 10), RAEB-T (n = 2), sAML (n = 2) and chronic myelomonocytic leukaemia (CMML; n = 2); WHO/RAEB-1 (n = 4), RAEB-2 (n = 5),
AML
(n = 5), CMML (n = 2).
Lonafarnib alone, administered following our schedule, has shown limited activity in patients with MDS or
secondary
AML
.
[MeSH-major]
Farnesyltranstransferase / antagonists & inhibitors.
Leukemia
,
Myeloid
,
Acute
/ drug therapy. Myelodysplastic Syndromes / drug therapy. Piperidines / adverse effects. Pyridines / adverse effects
Genetic Alliance.
consumer health - Myelodysplastic syndromes
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18641985.001).
[ISSN]
1432-0584
[Journal-full-title]
Annals of hematology
[ISO-abbreviation]
Ann. Hematol.
[Language]
eng
[Publication-type]
Clinical Trial, Phase II; Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Piperidines; 0 / Pyridines; 193275-84-2 / lonafarnib; EC 2.5.1.29 / Farnesyltranstransferase
55.
Karp JE, Smith BD, Gojo I, Lancet JE, Greer J, Klein M, Morris L, Levis MJ, Gore SD, Wright JJ, Garrett-Mayer E:
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features.
Clin Cancer Res
; 2008 May 15;14(10):3077-82
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with
acute
myelogenous
leukemia
and poor-risk features.
PURPOSE:
Acute
myelogenous
leukemia
(
AML
) does not have a high cure rate, particularly in patients with poor-risk features.
Tipifarnib is an oral farnesyltransferase inhibitor with activity in
AML
.
We conducted a phase II trial of maintenance tipifarnib monotherapy for 48 adults with poor-risk
AML
in first CR.
Comparison of CR durations for 25 patients who received two-cycle timed sequential therapy followed by tipifarnib maintenance with 23 historically similar patients who did not receive tipifarnib showed that tipifarnib was associated with DFS prolongation for patients with
secondary
AML
and adverse cytogenetics.
CONCLUSIONS: This study suggests that some patients with poor-risk
AML
, including patients with
secondary
AML
and adverse cytogenetics, may benefit from tipifarnib maintenance therapy.
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Oncol. 1999 Dec;17(12):3835-49
[
10577857.001
]
[Cites]
Leukemia. 2007 Sep;21(9):1964-70
[
17581608.001
]
[Cites]
Blood. 2001 Jun 1;97(11):3361-9
[
11369625.001
]
[Cites]
Blood. 2001 Aug 1;98(3):548-53
[
11468148.001
]
[Cites]
Blood. 2001 Sep 1;98(5):1302-11
[
11520775.001
]
[Cites]
Blood. 2001 Sep 1;98(5):1312-20
[
11520776.001
]
[Cites]
Leuk Res. 2003 Apr;27(4):313-21
[
12531222.001
]
[Cites]
Blood. 2003 Mar 1;101(5):1692-7
[
12411300.001
]
[Cites]
Am J Clin Pathol. 2003 May;119(5):672-80
[
12760285.001
]
[Cites]
Blood. 2003 Dec 1;102(12):3880-9
[
12920034.001
]
[Cites]
Blood. 2003 Dec 15;102(13):4527-34
[
12947010.001
]
[Cites]
Blood Rev. 2004 Mar;18(1):39-63
[
14684148.001
]
[Cites]
J Clin Oncol. 2004 Apr 1;22(7):1287-92
[
15051776.001
]
[Cites]
N Engl J Med. 2004 Apr 15;350(16):1605-16
[
15084693.001
]
[Cites]
Blood. 1989 Oct;74(5):1499-506
[
2676014.001
]
[Cites]
Blood. 1992 Apr 15;79(8):1924-30
[
1562720.001
]
[Cites]
Blood. 1997 Oct 15;90(8):2952-61
[
9376575.001
]
[Cites]
J Clin Oncol. 1998 Mar;16(3):872-81
[
9508168.001
]
[Cites]
Leukemia. 1999 Jun;13(6):843-9
[
10360370.001
]
[Cites]
J Clin Oncol. 2005 Mar 20;23(9):1969-78
[
15632409.001
]
[Cites]
Eur J Haematol. 2005 May;74(5):418-23
[
15813916.001
]
[Cites]
J Clin Oncol. 2006 Jun 1;24(16):2480-9
[
16735702.001
]
[Cites]
Blood. 2006 Sep 1;108(5):1677-83
[
16670265.001
]
[Cites]
Blood. 2007 Jan 15;109(2):431-48
[
16960150.001
]
[Cites]
Blood. 2007 Feb 15;109(4):1387-94
[
17082323.001
]
[Cites]
Blood. 2007 May 15;109(10):4158-63
[
17264294.001
]
[Cites]
J Clin Oncol. 2007 May 10;25(14):1908-15
[
17488990.001
]
[Cites]
Hematol Oncol Clin North Am. 2000 Feb;14(1):251-67
[
10680081.001
]
(PMID = 18483374.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA 69854; United States / NCI NIH HHS / CA / U01 CA069854-07; United States / NCI NIH HHS / CA / U01 CA069854; United States / NCI NIH HHS / CA / U01 CA70095; United States / NCI NIH HHS / CA / U01 CA070095
[Publication-type]
Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Quinolones; 192185-72-1 / tipifarnib
[Other-IDs]
NLM/ NIHMS281726; NLM/ PMC3074480
56.
Figueroa ME, Skrabanek L, Li Y, Jiemjit A, Fandy TE, Paietta E, Fernandez H, Tallman MS, Greally JM, Carraway H, Licht JD, Gore SD, Melnick A:
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation.
Blood
; 2009 Oct 15;114(16):3448-58
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
MDS and
secondary
AML
display unique patterns and abundance of aberrant DNA methylation.
Increasing evidence shows aberrant hypermethylation of genes occurring in and potentially contributing to pathogenesis of
myeloid
malignancies.
To determine the extent of promoter hypermethylation in such tumors, we compared the distribution of DNA methylation of 14 000 promoters in MDS and
secondary acute
myeloid
leukemia
(
AML
) patients enrolled in a phase 1 trial of 5-azacytidine and the histone deacetylase inhibitor entinostat against de novo
AML
patients and normal CD34(+) bone marrow cells.
The MDS and
secondary
AML
patients displayed more extensive aberrant DNA methylation involving thousands of genes than did the normal CD34(+) bone marrow cells or de novo
AML
blasts.
Aberrant methylation in MDS and
secondary
AML
tended to affect particular chromosomal regions, occurred more frequently in Alu-poor genes, and included prominent involvement of genes involved in the WNT and MAPK signaling pathways.
[MeSH-major]
Azacitidine / administration & dosage. DNA Methylation / drug effects. DNA, Neoplasm / metabolism. Enzyme Inhibitors / administration & dosage.
Leukemia
,
Myeloid
,
Acute
. Myelodysplastic Syndromes. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / metabolism
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
Hazardous Substances Data Bank.
AZACITIDINE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Mol Pharmacol. 2001 Apr;59(4):751-7
[
11259619.001
]
[Cites]
Lancet Oncol. 2009 Mar;10(3):223-32
[
19230772.001
]
[Cites]
Blood. 2009 Feb 5;113(6):1315-25
[
18832655.001
]
[Cites]
Blood. 2009 Sep 24;114(13):2764-73
[
19546476.001
]
[Cites]
Nucleic Acids Res. 2002 Jan 1;30(1):207-10
[
11752295.001
]
[Cites]
J Clin Oncol. 2002 May 15;20(10):2429-40
[
12011120.001
]
[Cites]
Nat Rev Genet. 2002 Jun;3(6):415-28
[
12042769.001
]
[Cites]
Hum Mol Genet. 2002 Oct 1;11(20):2479-88
[
12351584.001
]
[Cites]
Leukemia. 2003 May;17(5):910-8
[
12750705.001
]
[Cites]
Leukemia. 2003 Sep;17(9):1813-9
[
12970781.001
]
[Cites]
N Engl J Med. 2003 Nov 20;349(21):2042-54
[
14627790.001
]
[Cites]
J Biol Chem. 2004 Apr 9;279(15):15161-6
[
14722112.001
]
[Cites]
Nat Med. 2004 May;10(5):481-3
[
15048110.001
]
[Cites]
Genome Biol. 2004;5(10):R80
[
15461798.001
]
[Cites]
Nat Genet. 1999 Jan;21(1):103-7
[
9916800.001
]
[Cites]
Bioinformatics. 2005 Jun 1;21(11):2789-90
[
15797915.001
]
[Cites]
Br J Haematol. 2005 Jul;130(2):209-17
[
16029449.001
]
[Cites]
Cancer Res. 2005 Aug 15;65(16):7086-90
[
16103056.001
]
[Cites]
Genes Chromosomes Cancer. 2005 Nov;44(3):305-19
[
16075461.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15785-90
[
16243968.001
]
[Cites]
Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S36-44
[
16341239.001
]
[Cites]
Eur J Haematol. 2006 Jan;76(1):23-32
[
16343268.001
]
[Cites]
Cancer Res. 2006 Jun 15;66(12):6361-9
[
16778214.001
]
[Cites]
BMC Genomics. 2006;7:133
[
16740159.001
]
[Cites]
Genome Res. 2006 Aug;16(8):1046-55
[
16809668.001
]
[Cites]
J Clin Oncol. 2006 Aug 20;24(24):3895-903
[
16921040.001
]
[Cites]
Blood. 2007 Jan 1;109(1):52-7
[
16882708.001
]
[Cites]
Leukemia. 2007 Sep;21(9):1937-44
[
17611569.001
]
[Cites]
Cancer Res. 2007 Sep 1;67(17):8248-54
[
17804739.001
]
[Cites]
Mol Cell. 2007 Oct 26;28(2):337-50
[
17964271.001
]
[Cites]
Mol Cell Biol. 2008 Jan;28(2):752-71
[
17991895.001
]
[Cites]
Semin Hematol. 2008 Jan;45(1):23-30
[
18179966.001
]
[Cites]
Nucleic Acids Res. 2008 Jan;36(Database issue):D773-9
[
18086701.001
]
[Cites]
PLoS One. 2008;3(3):e1882
[
18365023.001
]
[Cites]
Bioinformatics. 2008 May 1;24(9):1161-7
[
18353789.001
]
[Cites]
Mol Cancer Ther. 2008 Sep;7(9):2998-3005
[
18790780.001
]
[CommentIn]
Blood. 2009 Oct 15;114(16):3363-4
[
19833849.001
]
(PMID = 19652201.001).
[ISSN]
1528-0020
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
eng
[Databank-accession-numbers]
ClinicalTrials.gov/ NCT00101179
[Grant]
United States / NCI NIH HHS / CA / R21 CA110507; United States / NCI NIH HHS / CA / U10 CA021115; United States / NCI NIH HHS / CA / U54 CA143876-01; United States / NCI NIH HHS / CA / K24 CA111717; United States / NCI NIH HHS / CA / R01 CA125635; United States / NCI NIH HHS / CA / U01 CA070095; United States / NCI NIH HHS / CA / U54 CA143876; United States / NICHD NIH HHS / HD / R01 HD044078; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / U24 CA114737; United States / NCI NIH HHS / CA / R01 CA104348; United States / NCI NIH HHS / CA / U01CA70095
[Publication-type]
Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD34; 0 / DNA, Neoplasm; 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Wnt Proteins; EC 3.5.1.98 / Histone Deacetylases; M801H13NRU / Azacitidine
[Other-IDs]
NLM/ PMC2765680
57.
de Witte T, Hagemeijer A, Suciu S, Belhabri A, Delforge M, Kobbe G, Selleslag D, Schouten HC, Ferrant A, Biersack H, Amadori S, Muus P, Jansen JH, Hellström-Lindberg E, Kovacsovics T, Wijermans P, Ossenkoppele G, Gratwohl A, Marie JP, Willemze R:
Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial.
Haematologica
; 2010 Oct;95(10):1754-61
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and
secondary acute
myeloid
leukemia
. Final results of a prospective randomized European Intergroup Trial.
[MeSH-major]
Hematopoietic Stem Cell Transplantation / methods.
Leukemia
,
Myeloid
,
Acute
/ therapy. Myelodysplastic Syndromes / therapy
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
Genetic Alliance.
consumer health - Myelodysplastic syndromes
.
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Mod Pathol. 2000 Feb;13(2):193-207
[
10697278.001
]
[Cites]
Br J Haematol. 2000 Sep;110(3):620-30
[
10997974.001
]
[Cites]
Blood. 2001 Oct 15;98(8):2326-31
[
11588026.001
]
[Cites]
Br J Haematol. 2002 Aug;118(2):385-400
[
12139722.001
]
[Cites]
Blood. 2002 Aug 15;100(4):1201-7
[
12149198.001
]
[Cites]
Blood. 2002 Sep 15;100(6):1997-2004
[
12200358.001
]
[Cites]
Leukemia. 2002 Sep;16(9):1615-21
[
12200672.001
]
[Cites]
Leukemia. 2003 May;17(5):859-68
[
12750698.001
]
[Cites]
Blood. 2003 Aug 15;102(4):1232-40
[
12714526.001
]
[Cites]
Blood. 2004 Apr 15;103(8):2908-13
[
15070662.001
]
[Cites]
Blood. 2004 Jul 15;104(2):579-85
[
15039286.001
]
[Cites]
Ann Hematol. 2004 Aug;83(8):498-503
[
15156346.001
]
[Cites]
Br J Haematol. 1985 Mar;59(3):425-33
[
3970861.001
]
[Cites]
Br J Haematol. 1991 Apr;77(4):497-501
[
2025575.001
]
[Cites]
Blood. 1995 Nov 15;86(10):3660-7
[
7579331.001
]
[Cites]
Leukemia. 1995 Nov;9(11):1805-11
[
7475266.001
]
[Cites]
Leukemia. 1996 Oct;10(10):1648-52
[
8847900.001
]
[Cites]
Blood. 1997 Mar 15;89(6):2079-88
[
9058730.001
]
[Cites]
Blood. 1997 Nov 15;90(10):3853-7
[
9354651.001
]
[Cites]
Br J Haematol. 1997 Dec;99(4):939-44
[
9432047.001
]
[Cites]
Br J Haematol. 1998 Sep;102(4):1015-24
[
9734653.001
]
[Cites]
Blood. 1998 Oct 1;92(7):2322-33
[
9746770.001
]
[Cites]
Leukemia. 1999 Apr;13(4):524-9
[
10214857.001
]
[Cites]
Ann Oncol. 1999 Jul;10(7):825-9
[
10470430.001
]
[Cites]
Leukemia. 2005 Mar;19(3):396-401
[
15674354.001
]
[Cites]
Bone Marrow Transplant. 2006 Jan;37(2):183-9
[
16299545.001
]
[Cites]
Haematologica. 2006 Mar;91(3):373-6
[
16531261.001
]
[Cites]
Blood. 2007 May 1;109(9):3658-66
[
17213292.001
]
[Cites]
Leukemia. 2007 Sep;21(9):1945-51
[
17611571.001
]
[Cites]
Br J Haematol. 1982 Jun;51(2):189-99
[
6952920.001
]
[CommentIn]
Haematologica. 2010 Oct;95(10):1623-7
[
20884716.001
]
(PMID = 20494931.001).
[ISSN]
1592-8721
[Journal-full-title]
Haematologica
[ISO-abbreviation]
Haematologica
[Language]
eng
[Databank-accession-numbers]
ClinicalTrials.gov/ NCT00002926
[Grant]
United States / NCI NIH HHS / CA / 5U10 CA11488-32; United States / NCI NIH HHS / CA / 5U10 CA11488-27; United States / NCI NIH HHS / CA / 5U10 CA11488-38; United States / NCI NIH HHS / CA / 5U10 CA11488-28; United States / NCI NIH HHS / CA / 5U10 CA11488-35; United States / NCI NIH HHS / CA / 5U10 CA11488-31; United States / NCI NIH HHS / CA / 5U10 CA11488-26; United States / NCI NIH HHS / CA / 5U10 CA11488-37; United States / NCI NIH HHS / CA / U10 CA011488; United States / NCI NIH HHS / CA / 5U10 CA11488-29; United States / NCI NIH HHS / CA / 5U10 CA11488-36; United States / NCI NIH HHS / CA / 5U10 CA11488-33; United States / NCI NIH HHS / CA / 5U10 CA11488-34; United States / NCI NIH HHS / CA / 5U10 CA11488-30
[Publication-type]
Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
Italy
[Other-IDs]
NLM/ PMC2948102
58.
Gupta V, Chun K, Yi QL, Minden M, Schuh A, Wells R, Brandwein J:
Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
Cancer
; 2005 May 15;103(10):2082-90
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with
acute
myeloid
leukemia
treated with uniform intensive therapy.
BACKGROUND: The objectives of the current study were to evaluate the outcome of patients > or = 60 years with
acute
myeloid
leukemia
(
AML
) treated uniformly with high-dose daunorubicin containing induction and modified high-dose cytosine arabinoside containing postremission therapy, and to identify factors predictive of complete disease remission (CR) and survival.
METHODS: Between 1998 and 2002, the authors treated 117 newly diagnosed patients (
acute
promyelocytic
leukemia
excluded) with
AML
> or = 60 years (median, 67 years; range, 60-82 years).
A normal karyotype was seen in 41 patients and 40 (34%) had
secondary
AML
.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Leukemia
,
Myeloid
/ drug therapy
[MeSH-minor]
Acute
Disease. Age Factors. Aged. Aged, 80 and over. Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Disease-Free Survival. Female. Follow-Up Studies. Hematologic Diseases / complications. Humans. Karyotyping. L-Lactate Dehydrogenase / analysis. Leukocyte Count. Male. Middle Aged. Myelodysplastic Syndromes / complications. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
Hazardous Substances Data Bank.
CYTARABINE
.
Hazardous Substances Data Bank.
DAUNORUBICIN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15830348.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; EC 1.1.1.27 / L-Lactate Dehydrogenase; ZS7284E0ZP / Daunorubicin
59.
D'Andrea AD:
Targeting DNA repair pathways in AML.
Best Pract Res Clin Haematol
; 2010 Dec;23(4):469-73
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Targeting DNA repair pathways in
AML
.
DNA repair inhibitors, such as poly-ADP-ribose polymerase (PARP) inhibitors, may be useful in a small subset of
acute
myeloid
leukemia
(
AML
) patients, especially those who have complex karyotypes or those with
secondary
AML
.
[MeSH-major]
Antineoplastic Agents / therapeutic use. DNA Repair / drug effects. Enzyme Inhibitors / therapeutic use.
Leukemia
,
Myeloid
,
Acute
/ drug therapy.
Leukemia
,
Myeloid
,
Acute
/ metabolism
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright © 2010 Elsevier Ltd. All rights reserved.
(PMID = 21130409.001).
[ISSN]
1532-1924
[Journal-full-title]
Best practice & research. Clinical haematology
[ISO-abbreviation]
Best Pract Res Clin Haematol
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Enzyme Inhibitors; 0 / Poly(ADP-ribose) Polymerase Inhibitors; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases
60.
Karp JE, Smith BD, Levis MJ, Gore SD, Greer J, Hattenburg C, Briel J, Jones RJ, Wright JJ, Colevas AD:
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
Clin Cancer Res
; 2007 Aug 1;13(15 Pt 1):4467-73
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk
acute
myelogenous
leukemia
.
In a phase I study of flavopiridol followed by 1-beta-d-arabinofuranosylcytosine (ara-C) and mitoxantrone, overall response rate for adults with relapsed and refractory
acute
myelogenous
leukemias (
AML
) was 31%.
We have now completed a phase II study of sequential flavopiridol, ara-C, and mitoxantrone in 62 adults with poor-risk
AML
.
Complete remissions (CR) were achieved in 12 of 15 (75%) newly diagnosed
secondary
AML
, 18 of 24 (75%) first relapse after short CR (median CR, 9 months, including prior allotransplant), and 2 of 13 (15%) primary refractory but 0 of 10 multiply refractory
AML
.
CONCLUSIONS: Flavopiridol has anti-
AML
activity directly and in combination with ara-C and mitoxantrone.
This timed sequential regimen induces durable CRs in a significant proportion of adults with newly diagnosed
secondary
AML
(including complex cytogenetics) and adults with
AML
in first relapse after short first CR.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Leukemia
,
Myeloid
,
Acute
/ drug therapy
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
CYTARABINE
.
Hazardous Substances Data Bank.
NOVANTRONE
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17671131.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
eng
[Grant]
United States / NCRR NIH HHS / RR / M01-RR0052; United States / NCI NIH HHS / CA / U01 CA70095
[Publication-type]
Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Flavonoids; 0 / Piperidines; 04079A1RDZ / Cytarabine; 45AD6X575G / alvocidib; BZ114NVM5P / Mitoxantrone
61.
Roboz GJ, Giles FJ, List AF, Cortes JE, Carlin R, Kowalski M, Bilic S, Masson E, Rosamilia M, Schuster MW, Laurent D, Feldman EJ:
Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
Leukemia
; 2006 Jun;20(6):952-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of
acute
myeloid
leukemia
and myelodysplastic syndrome.
The objective of this Phase I study was to evaluate the safety, tolerability, biologic activity and pharmacologic profile of PTK/ZK administered orally, twice daily, on a continuous dosing schedule in patients with primary refractory or relapsed
acute
myeloid
leukemia
(
AML
),
secondary
AML
, poor-prognosis de novo
AML
or advanced myelodysplastic syndrome (MDS).
Acute
myeloid
leukemia
patients for whom PTK/ZK monotherapy was ineffective could receive PTK/ZK combined with standard induction chemotherapy.
Complete remission was observed in five of 17
AML
patients treated with PTK/ZK combined with chemotherapy.
The drug is generally well tolerated and can be given in combination with chemotherapy for patients with MDS and
AML
.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Leukemia
,
Myeloid
/ drug therapy. Myelodysplastic Syndromes / drug therapy. Phthalazines / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Pyridines / therapeutic use
[MeSH-minor]
Acute
Disease. Adult. Aged. Aged, 80 and over. Cell Proliferation / drug effects. Cohort Studies. Dose-Response Relationship, Drug. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Receptor Protein-Tyrosine Kinases / antagonists & inhibitors. Treatment Outcome. Vascular Endothelial Growth Factor Receptor-2 / antagonists & inhibitors
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
Genetic Alliance.
consumer health - Myelodysplastic syndromes
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16617323.001).
[ISSN]
0887-6924
[Journal-full-title]
Leukemia
[ISO-abbreviation]
Leukemia
[Language]
eng
[Publication-type]
Clinical Trial, Phase I; Journal Article; Multicenter Study
[Publication-country]
England
[Chemical-registry-number]
0 / Phthalazines; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 5DX9U76296 / vatalanib; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
62.
Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, Romanski A, Kramer OH, Kampfmann M, Hoelzer D, Neubauer A, Ruthardt M, Ottmann OG:
Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.
Cancer
; 2005 Dec 15;104(12):2717-25
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk
acute
myeloid
leukemia
.
BACKGROUND: Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, induced in vitro differentiation of primary
acute
myeloid
leukemia
(
AML
) blasts, an effect enhanced by all-trans retinoic acid (ATRA).
Herein, the authors have described results of a clinical trial with VPA plus ATRA in 26 patients with poor-risk
AML
.
No patient achieved complete remission, one with de novo
AML
had a minor response, and two patients with
secondary
AML
arising from myeloproliferative disorder (MPD) achieved a partial remission and clearance of PB blasts, respectively.
The latter responses were accompanied by profound granulocytosis and erythrocytosis in both patients, reminiscent of the response pattern known from ATRA treatment of
acute
promyelocytic
leukemia
.
CONCLUSIONS: Treatment with VPA/ATRA results in transient disease control in a subset of patients with
AML
that has evolved from a myeloproliferative disorder but not in patients with a primary or MDS-related
AML
.
[MeSH-major]
Leukemia
,
Myeloid
,
Acute
/ diagnosis.
Leukemia
,
Myeloid
,
Acute
/ drug therapy. Tretinoin / administration & dosage. Valproic Acid / administration & dosage
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
Hazardous Substances Data Bank.
ALL-TRANS-RETINOIC ACID
.
Hazardous Substances Data Bank.
VALPROIC ACID
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2005 American Cancer Society.
(PMID = 16294345.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Publication-type]
Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
5688UTC01R / Tretinoin; 614OI1Z5WI / Valproic Acid
63.
Wadehra N, Farag S, Bolwell B, Elder P, Penza S, Kalaycio M, Avalos B, Pohlman B, Marcucci G, Sobecks R, Lin T, Andrèsen S, Copelan E:
Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation.
Biol Blood Marrow Transplant
; 2006 Dec;12(12):1343-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Five patients died between 5.3 and 9.3 years of late complications, including
secondary
myelodysplasia or
acute
myeloid
leukemia
,
secondary
solid malignancies, and pulmonary toxicity.
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
ETOPOSIDE
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
BUSULFAN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Biol Blood Marrow Transplant. 2007 Jun;13(6):746-7
[
17531785.001
]
(PMID = 17162217.001).
[ISSN]
1083-8791
[Journal-full-title]
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
[ISO-abbreviation]
Biol. Blood Marrow Transplant.
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan
64.
Suzuki K, Ohishi K, Sekine T, Masuya M, Katayama N:
Selective blast cell reduction in elderly patients with acute myeloid leukemia secondary to myelodysplastic syndrome treated with methylprednisolone.
Int J Hematol
; 2007 May;85(4):344-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Selective blast cell reduction in elderly patients with
acute
myeloid
leukemia secondary
to myelodysplastic syndrome treated with methylprednisolone.
The management of elderly patients with
acute
myeloid
leukemia
(
AML
) and a poor performance status is challenging.
An 89-year-old man with
AML
secondary
to myelodysplastic syndrome (MDS) and a poor performance status (4) underwent treatment with methylprednisolone (mPSL) (125 mg/body), which resulted in a remarkable reduction of blast cells in the peripheral blood.
On the basis of this experience, we gave the same mPSL dose to other elderly patients with MDS/
AML
(n=5) or
AML
-M4 (n=1) who had a poor performance status (3 or higher) and appeared unable to tolerate standard cytotoxic chemotherapies.
Selective and significant blast cell reduction was observed in 4 of the 5 patients with MDS/
AML
, whereas no effects were seen in the
AML
patient.
Although our experience is limited, these findings may provide a clue to understanding the mechanisms regulating the survival of blast cells of MDS/
AML
and indicate that mPSL may provide a benefit to a subset of these patients.
[MeSH-major]
Blast Crisis / drug therapy. Blast Crisis / etiology.
Leukemia
,
Myeloid
,
Acute
/ drug therapy.
Leukemia
,
Myeloid
,
Acute
/ etiology. Methylprednisolone / administration & dosage. Myelodysplastic Syndromes / complications. Myelodysplastic Syndromes / drug therapy
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
Genetic Alliance.
consumer health - Myelodysplastic syndromes
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
Hazardous Substances Data Bank.
METHYLPREDNISOLONE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Leuk Res. 1999 Jul;23(7):603-13
[
10400181.001
]
[Cites]
Medicine (Baltimore). 1962 Sep;41:163-225
[
13870584.001
]
[Cites]
Leuk Lymphoma. 2001 Aug;42(4):665-74
[
11697496.001
]
[Cites]
N Engl J Med. 1962 Jun 28;266:1354-8
[
13911203.001
]
[Cites]
Blood. 2001 Oct 15;98 (8):2301-7
[
11588023.001
]
[Cites]
Blood. 2006 May 1;107(9):3481-5
[
16455952.001
]
[Cites]
Acta Haematol. 2004;111(1-2):78-99
[
14646347.001
]
[Cites]
Blood. 2006 Feb 1;107(3):1156-65
[
16223780.001
]
[Cites]
Endocr Rev. 1999 Aug;20(4):435-59
[
10453354.001
]
[Cites]
Ann Hematol. 2006 Mar;85(3):139-63
[
16391911.001
]
[Cites]
Am J Med. 1957 Mar;22(3):405-13
[
13402792.001
]
[Cites]
J Am Geriatr Soc. 1956 Jul;4(7):627-41
[
13331730.001
]
[Cites]
Leuk Lymphoma. 1994 Apr;13(3-4):187-201
[
8049644.001
]
[Cites]
CA Cancer J Clin. 2002 Nov-Dec;52(6):363-71
[
12469764.001
]
[Cites]
Haematologica. 2006 Nov;91(11):1513-22
[
17082009.001
]
[Cites]
Leuk Res. 2006 Jan;30(1):60-8
[
15979702.001
]
[Cites]
Leuk Res. 2004 Jan;28(1):25-34
[
14630077.001
]
(PMID = 17483080.001).
[ISSN]
0925-5710
[Journal-full-title]
International journal of hematology
[ISO-abbreviation]
Int. J. Hematol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
X4W7ZR7023 / Methylprednisolone
65.
Infante-Rivard C, Vermunt JK, Weinberg CR:
Excess transmission of the NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T polymorphism in families of children with acute lymphoblastic leukemia.
Am J Epidemiol
; 2007 Jun 1;165(11):1248-54
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Excess transmission of the NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T polymorphism in families of children with
acute
lymphoblastic
leukemia
.
Topoisomerase II is a DNA-processing enzyme, and
secondary acute
myeloid
leukemia
has been associated with exposure to drugs that inhibit its action.
Hence, prenatal exposure to chemicals that inhibit topoisomerase II could plausibly contribute to the incidence of childhood
leukemia
.
To assess its role in the etiology of childhood
acute
lymphoblastic
leukemia
, the authors studied transmission of the variant T allele in the families (parents and grandparents) of 657 affected children in Québec, Canada (1980-2000).
[MeSH-major]
Family Health. Inheritance Patterns. NAD(P)H Dehydrogenase (Quinone) / genetics. Polymorphism, Genetic. Precursor Cell
Lymphoblastic
Leukemia
-Lymphoma / epidemiology. Precursor Cell
Lymphoblastic
Leukemia
-Lymphoma / genetics
Genetic Alliance.
consumer health - Acute Lymphoblastic Leukemia
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
BENZENE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Crit Rev Toxicol. 2002 May;32(3):155-210
[
12071572.001
]
[Cites]
Blood. 2002 Dec 15;100(13):4590-3
[
12393620.001
]
[Cites]
Am J Epidemiol. 2003 Jan 15;157(2):176-82
[
12522025.001
]
[Cites]
Am J Hum Genet. 2003 Feb;72(2):438-47
[
12533786.001
]
[Cites]
J Biol Chem. 2003 Mar 21;278(12):10368-73
[
12529318.001
]
[Cites]
Int J Epidemiol. 2003 Feb;32(1):1-22
[
12689998.001
]
[Cites]
Nat Rev Cancer. 2003 Sep;3(9):639-49
[
12951583.001
]
[Cites]
Methods Enzymol. 2004;382:115-44
[
15047100.001
]
[Cites]
Mutat Res. 2004 Mar;566(2):99-130
[
15164977.001
]
[Cites]
Pediatr Blood Cancer. 2004 Oct;43(5):568-70
[
15382274.001
]
[Cites]
Nature. 1993 May 27;363(6427):358-60
[
8497319.001
]
[Cites]
Am J Hum Genet. 1993 Nov;53(5):1114-26
[
8213835.001
]
[Cites]
Biotechniques. 1998 Feb;24(2):206-8, 210, 212
[
9494715.001
]
[Cites]
Am J Hum Genet. 1998 Apr;62(4):969-78
[
9529360.001
]
[Cites]
Am J Epidemiol. 1998 Nov 1;148(9):893-901
[
9801020.001
]
[Cites]
Annu Rev Genet. 1998;32:495-519
[
9928489.001
]
[Cites]
Am J Hum Genet. 1999 Apr;64(4):1186-93
[
10090904.001
]
[Cites]
Pharmacogenetics. 1999 Feb;9(1):113-21
[
10208650.001
]
[Cites]
Lancet. 1999 May 29;353(9167):1816-7
[
10359403.001
]
[Cites]
Cancer Res. 1999 Aug 15;59(16):4095-9
[
10463613.001
]
[Cites]
Epidemiology. 1999 Sep;10(5):481-7
[
10468419.001
]
[Cites]
Haematologica. 2004 Dec;89(12):1492-7
[
15590400.001
]
[Cites]
Eur J Hum Genet. 2005 Jan;13(1):79-85
[
15470368.001
]
[Cites]
Leukemia. 2005 Feb;19(2):214-6
[
15618957.001
]
[Cites]
Environ Health Perspect. 2005 Jun;113(6):787-92
[
15929905.001
]
[Cites]
Chem Biol Interact. 2005 May 30;153-154:137-46
[
15935810.001
]
[Cites]
Haematologica. 2005 Nov;90(11):1511-5
[
16266898.001
]
[Cites]
J Biol Chem. 2006 Jul 21;281(29):19798-808
[
16682409.001
]
[Cites]
Am J Hum Genet. 2000 Jan;66(1):251-61
[
10631155.001
]
[Cites]
Am J Hum Genet. 2000 Jan;66(1):335-8
[
10631165.001
]
[Cites]
Cancer Causes Control. 2000 Jul;11(6):547-53
[
10880037.001
]
[Cites]
Am J Epidemiol. 2000 Sep 1;152(5):480-6
[
10981463.001
]
[Cites]
Br J Cancer. 2000 Dec;83(11):1559-64
[
11076669.001
]
[Cites]
Epidemiology. 2001 Jan;12(1):13-9
[
11138808.001
]
[Cites]
Cancer Chemother Biol Response Modif. 2001;19:129-47
[
11686011.001
]
[Cites]
Int J Cancer. 2002 Jan 10;97(2):230-6
[
11774269.001
]
[Cites]
BMJ. 2002 Feb 2;324(7332):283-7
[
11823363.001
]
(PMID = 17332311.001).
[ISSN]
0002-9262
[Journal-full-title]
American journal of epidemiology
[ISO-abbreviation]
Am. J. Epidemiol.
[Language]
eng
[Grant]
United States / Intramural NIH HHS / / Z01 ES045005-11
[Publication-type]
Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, human; J64922108F / Benzene
[Other-IDs]
NLM/ NIHMS33454; NLM/ PMC2080583
66.
Gyurkocza B, Storb R, Storer BE, Chauncey TR, Lange T, Shizuru JA, Langston AA, Pulsipher MA, Bredeson CN, Maziarz RT, Bruno B, Petersen FB, Maris MB, Agura E, Yeager A, Bethge W, Sahebi F, Appelbaum FR, Maloney DG, Sandmaier BM:
Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.
J Clin Oncol
; 2010 Jun 10;28(17):2859-67
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with
acute
myeloid
leukemia
.
PURPOSE: Allogeneic hematopoietic cell transplantation (HCT) after high-dose conditioning regimens imposes prohibitively high risks of morbidity and mortality for patients with high-risk
acute
myeloid
leukemia
(
AML
) who are older or have comorbid conditions.
PATIENTS AND METHODS: Two hundred seventy-four patients (median age, 60 years) with de novo or
secondary
AML
underwent allogeneic HCT from related (n = 118) or unrelated donors (n = 156) after conditioning with 2 Gy of total-body irradiation (TBI) with or without fludarabine.
The cumulative incidences of grades 2, 3, and 4
acute
graft-versus-host disease (GVHD) were 38%, 9%, and 5%, respectively.
CONCLUSION: Allogeneic HCT from related or unrelated donors after conditioning with low-dose TBI and fludarabine, relying almost exclusively on graft-versus-
leukemia
effects, can result in long-term remissions in older or medically infirm patients with
AML
.
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Blood. 2009 Mar 26;113(13):3110-8
[
19059878.001
]
[Cites]
J Clin Oncol. 2008 Feb 1;26(4):577-84
[
18086801.001
]
[Cites]
Blood. 2009 Sep 10;114(11):2220-31
[
19587375.001
]
[Cites]
N Engl J Med. 2009 Sep 24;361(13):1235-48
[
19776405.001
]
[Cites]
J Clin Oncol. 2009 Sep 20;27(27):4570-7
[
19652066.001
]
[Cites]
Blood. 2000 Dec 15;96(13):4075-83
[
11110676.001
]
[Cites]
Blood. 2002 Dec 1;100(12):3869-76
[
12393614.001
]
[Cites]
Blood. 2003 Feb 15;101(4):1620-9
[
12393457.001
]
[Cites]
Bone Marrow Transplant. 2003 Jun;31(12):1089-95
[
12796788.001
]
[Cites]
Biol Blood Marrow Transplant. 2003 Aug;9(8):489-95
[
12931117.001
]
[Cites]
Blood. 2003 Sep 15;102(6):2021-30
[
12791654.001
]
[Cites]
Blood. 2003 Nov 1;102(9):3447-54
[
12855572.001
]
[Cites]
J Clin Oncol. 2003 Dec 15;21(24):4642-9
[
14673054.001
]
[Cites]
Blood. 2004 Aug 1;104(3):865-72
[
15090449.001
]
[Cites]
Blood. 1988 Oct;72(4):1300-4
[
3048439.001
]
[Cites]
Blood. 1991 Apr 15;77(8):1666-74
[
2015395.001
]
[Cites]
N Engl J Med. 1994 Oct 6;331(14):896-903
[
8078551.001
]
[Cites]
Blood. 1994 Nov 15;84(10):3558-66
[
7524741.001
]
[Cites]
Blood. 1995 Dec 1;86(11):4376-81
[
7492799.001
]
[Cites]
Bone Marrow Transplant. 1995 Jun;15(6):825-8
[
7581076.001
]
[Cites]
Leukemia. 1996 Jan;10(1):13-9
[
8558917.001
]
[Cites]
Blood. 1996 Mar 1;87(5):1710-7
[
8634416.001
]
[Cites]
Blood. 1997 Apr 15;89(8):3048-54
[
9108426.001
]
[Cites]
Blood. 1998 May 15;91(10):3607-15
[
9572995.001
]
[Cites]
Blood. 1998 Nov 15;92(10):3515-20
[
9808542.001
]
[Cites]
J Clin Oncol. 2005 Mar 20;23(9):1969-78
[
15632409.001
]
[Cites]
Biol Blood Marrow Transplant. 2005 Apr;11(4):272-9
[
15812392.001
]
[Cites]
J Clin Oncol. 2005 May 20;23(15):3439-46
[
15824415.001
]
[Cites]
Leukemia. 2005 Jun;19(6):990-7
[
15800667.001
]
[Cites]
Leukemia. 2005 Jun;19(6):916-20
[
15843817.001
]
[Cites]
J Clin Oncol. 2005 Aug 20;23(24):5728-38
[
16009946.001
]
[Cites]
Blood. 2005 Oct 15;106(8):2912-9
[
15994282.001
]
[Cites]
Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56
[
16338616.001
]
[Cites]
J Clin Oncol. 2005 Dec 20;23(36):9387-93
[
16314618.001
]
[Cites]
J Clin Oncol. 2006 Jan 20;24(3):444-53
[
16344316.001
]
[Cites]
Leukemia. 2006 Feb;20(2):322-8
[
16307018.001
]
[Cites]
J Clin Oncol. 2006 Aug 20;24(24):3959-66
[
16880451.001
]
[Cites]
Biol Blood Marrow Transplant. 2006 Oct;12(10):1047-55
[
17067911.001
]
[Cites]
Blood. 2007 Oct 1;110(7):2744-8
[
17595333.001
]
[Cites]
Br J Haematol. 2009 Jun;145(5):598-605
[
19344426.001
]
(PMID = 20439626.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA18029; United States / NHLBI NIH HHS / HL / HL36444; United States / NCI NIH HHS / CA / P01 CA018029; United States / NCI NIH HHS / CA / P30 CA015704; United States / NCI NIH HHS / CA / CA78902; United States / NCI NIH HHS / CA / R21 CA106177; United States / NCI NIH HHS / CA / CA15704; United States / NHLBI NIH HHS / HL / P01 HL036444; United States / NCI NIH HHS / CA / CA106177; United States / NCI NIH HHS / CA / P01 CA078902
[Publication-type]
Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Other-IDs]
NLM/ PMC2903320
67.
Larson RA:
Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?
Best Pract Res Clin Haematol
; 2007 Mar;20(1):29-37
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Is
secondary leukemia
an independent poor prognostic factor in
acute
myeloid
leukemia
?
Secondary leukemia
is a poorly defined term that often refers to the development of
acute
myeloid
leukemia
(
AML
) following the history of a previous disease, such as a myelodysplastic syndrome or a chronic myeloproliferative disorder.
Secondary leukemia
can also be a consequence of treatment with chemotherapy, including alkylating agents and topoisomerase II inhibitors, and/or radiotherapy, or due to exposure to environmental carcinogens.
Outcomes for this large and variable group of patients with
secondary
AML
have been poor compared to people who develop
AML
de novo.
The question arises whether a diagnosis of
secondary leukemia
per se indicates a poor prognosis or whether their bad outcomes result from an association with certain morphologic and biologic characteristics.
Morphologic dysplasia in de novo
AML
is related to unfavorable cytogenetics, but has no independent prognostic relevance under the conditions of intensive chemotherapy.
While there is no significant correlation between cytogenetic risk groups and dysplasia, cytogenetic features do have an impact on outcome among both de novo and
secondary
AML
patients.
In various subgroups of
secondary
AML
, the spectrum of cytogenetic abnormalities is similar to de novo
AML
, but the frequency of abnormalities associated with unfavorable and intermediate risk cytogenetics, such as a complex karyotype, trisomy 8, monosomy 7, and others, is higher in
secondary
AML
.
The survival of patients with therapy-related
myeloid
leukemia
(t-
AML
) is generally shorter than for those with de novo
AML
within the same cytogenetic risk group.
Across the population of t-
AML
, however, survival varies according to cytogenetic risk group, with longer survival in patients with favorable-risk karyotypes.
The term
secondary
AML
is too broad and imprecise to be of importance and should not be used.
These
AML
patients should be enrolled on front-line chemotherapy trials and should be stratified by pretreatment disease status and exposure history, if necessary.
[MeSH-major]
Chromosome Aberrations.
Leukemia
,
Myeloid
/ drug therapy.
Leukemia
,
Myeloid
/ genetics
[MeSH-minor]
Acute
Disease. Humans. Myelodysplastic Syndromes. Myeloproliferative Disorders. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / genetics. Prognosis. Survival Analysis
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17336252.001).
[ISSN]
1521-6926
[Journal-full-title]
Best practice & research. Clinical haematology
[ISO-abbreviation]
Best Pract Res Clin Haematol
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Number-of-references]
23
68.
Gombos DS, Hungerford J, Abramson DH, Kingston J, Chantada G, Dunkel IJ, Antoneli CB, Greenwald M, Haik BG, Leal CA, Medina-Sanson A, Schefler AC, Veerakul G, Wieland R, Bornfeld N, Wilson MW, Yu CB:
Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor?
Ophthalmology
; 2007 Jul;114(7):1378-83
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Secondary acute
myelogenous
leukemia
in patients with retinoblastoma: is chemotherapy a factor?
PURPOSE: To describe a series of patients with
secondary acute
myelogenous
leukemia
(sAML) and retinoblastoma (RB).
MAIN OUTCOME MEASURES: History of RB and development of sAML, management of RB (surgery, radiotherapy, chemotherapy), age at diagnosis of RB and
leukemia
, French-American-British (FAB) subtype, and current status of patient (alive or dead).
Mean latent period from RB to
AML
diagnosis was 9.8 years (median, 42 months).
Ten children died of their
leukemia
.
CONCLUSIONS:
Acute
myelogenous
leukemia
is a rare
secondary
malignancy among retinoblastoma patients, many of whom were treated with primary or adjuvant chemotherapy.
[MeSH-major]
Antineoplastic Agents, Phytogenic / adverse effects. Enzyme Inhibitors / adverse effects.
Leukemia
,
Myeloid
,
Acute
/ chemically induced. Neoplasms, Second Primary / chemically induced. Podophyllotoxin / adverse effects. Retinal Neoplasms / drug therapy. Retinoblastoma / drug therapy. Topoisomerase II Inhibitors
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
Genetic Alliance.
consumer health - Retinoblastoma
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
PODOFILOX
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
SciCrunch.
Clinical Genomic Database: Data: Gene Annotation
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17613328.001).
[ISSN]
1549-4713
[Journal-full-title]
Ophthalmology
[ISO-abbreviation]
Ophthalmology
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents, Phytogenic; 0 / Enzyme Inhibitors; 0 / Topoisomerase II Inhibitors; L36H50F353 / Podophyllotoxin
[Number-of-references]
42
69.
Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, An J, Lamperti ED, Koh KP, Ganetzky R, Liu XS, Aravind L, Agarwal S, Maciejewski JP, Rao A:
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.
Nature
; 2010 Dec 9;468(7325):839-43
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Impaired hydroxylation of 5-methylcytosine in
myeloid
cancers with mutant TET2.
The gene encoding TET2 resides at chromosome 4q24, in a region showing recurrent microdeletions and copy-neutral loss of heterozygosity (CN-LOH) in patients with diverse
myeloid
malignancies.
Somatic TET2 mutations are frequently observed in myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), MDS/MPN overlap syndromes including chronic myelomonocytic leukaemia (CMML),
acute
myeloid
leukaemias (
AML
) and
secondary
AML
(sAML).
We show here that TET2 mutations associated with
myeloid
malignancies compromise catalytic activity.
Our results demonstrate that Tet2 is important for normal myelopoiesis, and suggest that disruption of TET2 enzymatic activity favours
myeloid
tumorigenesis.
Measurement of 5hmC levels in
myeloid
malignancies may prove valuable as a diagnostic and prognostic tool, to tailor therapies and assess responses to anticancer drugs.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
COS Scholar Universe.
author profiles
.
Gene Ontology.
gene/protein/disease-specific - Gene Ontology annotations from this paper
.
Addgene Non-profit plasmid repository.
clones/clone libraries - Get Article's Plasmids - Addgene
(subscription/membership/fee required).
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
SciCrunch.
OMIM: Data: Gene Annotation
.
SciCrunch.
The Antibody Registry: Reagent: Antibodies
.
SciCrunch.
ArrayExpress: Data: Microarray
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Biochemistry. 1979 Feb 20;18(4):632-7
[
420806.001
]
[Cites]
Science. 2003 Apr 18;300(5618):489-92
[
12702876.001
]
[Cites]
Leukemia. 2005 Aug;19(8):1411-5
[
15920487.001
]
[Cites]
Trends Genet. 2007 Sep;23(9):449-56
[
17681396.001
]
[Cites]
Annu Rev Med. 2008;59:267-80
[
17937590.001
]
[Cites]
N Engl J Med. 2008 Mar 13;358(11):1148-59
[
18337604.001
]
[Cites]
Leuk Lymphoma. 2008 Dec;49(12):2231-2
[
19052966.001
]
[Cites]
Blood. 2009 Feb 5;113(6):1315-25
[
18832655.001
]
[Cites]
Leukemia. 2009 May;23(5):900-4
[
19262599.001
]
[Cites]
Leukemia. 2009 May;23(5):905-11
[
19262601.001
]
[Cites]
Science. 2009 May 15;324(5929):930-5
[
19372391.001
]
[Cites]
Cell Cycle. 2009 Jun 1;8(11):1698-710
[
19411852.001
]
[Cites]
N Engl J Med. 2009 May 28;360(22):2289-301
[
19474426.001
]
[Cites]
N Engl J Med. 2009 May 28;360(22):2355-7
[
19474434.001
]
[Cites]
Blood. 2009 Jun 18;113(25):6403-10
[
19372255.001
]
[Cites]
Nat Genet. 2009 Jul;41(7):838-42
[
19483684.001
]
[Cites]
Nat Genet. 2009 Jul;41(7):766-7
[
19557078.001
]
[Cites]
Blood. 2009 Jul 2;114(1):144-7
[
19420352.001
]
[Cites]
Leukemia. 2009 Jul;23(7):1343-5
[
19295549.001
]
[Cites]
Nat Genet. 2009 Nov;41(11):1207-15
[
19801979.001
]
[Cites]
Nature. 2009 Nov 19;462(7271):315-22
[
19829295.001
]
[Cites]
PLoS One. 2010;5(1):e8888
[
20126651.001
]
[Cites]
Nature. 2010 Aug 26;466(7310):1129-33
[
20639862.001
]
[Cites]
Epigenomics. 2009 Dec;1(2):239-59
[
20495664.001
]
[Cites]
Science. 2003 Apr 18;300(5618):442-3
[
12702865.001
]
[Cites]
Nat Genet. 1998 Oct;20(2):116-7
[
9771701.001
]
(PMID = 21057493.001).
[ISSN]
1476-4687
[Journal-full-title]
Nature
[ISO-abbreviation]
Nature
[Language]
ENG
[Databank-accession-numbers]
GEO/ GSE25706
[Grant]
United States / NCI NIH HHS / CA / R37 CA042471-20; United States / NCRR NIH HHS / RR / 1 UL1 RR 025758-02; United States / NHLBI NIH HHS / HL / K08 HL089150; United States / NCI NIH HHS / CA / R37 CA042471-21; United States / NIAID NIH HHS / AI / AI044432-13; United States / NIDA NIH HHS / DA / RC1 DA028422-02; United States / NIAID NIH HHS / AI / R01 AI044432; United States / NICHD NIH HHS / HD / R01 HD065812; United States / NHLBI NIH HHS / HL / K24 HL077522; United States / CCR NIH HHS / RC / DA028422-02; United States / NCI NIH HHS / CA / CA042471-20; United States / NHLBI NIH HHS / HL / R01 HL098522; United States / NHGRI NIH HHS / HG / R01 HG004069; United States / NIAID NIH HHS / AI / R01 AI044432-13; United States / NCI NIH HHS / CA / R37 CA042471; United States / CCR NIH HHS / RC / DA028422-01; United States / NCRR NIH HHS / RR / UL1 RR025758; United States / NCI NIH HHS / CA / CA042471-21; United States / NIAID NIH HHS / AI / R01 AI44432; United States / NIDA NIH HHS / DA / RC1 DA028422; United States / NHGRI NIH HHS / HG / R01 HG4069; United States / NIAID NIH HHS / AI / AI044432-12; United States / NIDA NIH HHS / DA / RC1 DA028422-01; United States / NIAID NIH HHS / AI / R01 AI044432-12
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / Mutant Proteins; 0 / Proto-Oncogene Proteins; 0 / TET2 protein, human; 0 / Tet2 protein, mouse; 6R795CQT4H / 5-Methylcytosine
[Other-IDs]
NLM/ NIHMS247005; NLM/ PMC3003755
70.
Al-Ali HK, Brand R, van Biezen A, Finke J, Boogaerts M, Fauser AA, Egeler M, Cahn JY, Arnold R, Biersack H, Niederwieser D, de Witte T:
A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
Leukemia
; 2007 Sep;21(9):1945-51
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and
secondary acute
myeloid
leukemia
: a report on behalf of the Chronic
Leukemia
Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
Hematopoietic cell transplantation (HCT) is an effective treatment for myelodysplasia (MDS) and
secondary acute
myeloid
leukemia
(sAML).
[MeSH-major]
Hematopoietic Stem Cell Transplantation / mortality.
Leukemia
,
Myeloid
/ mortality.
Leukemia
,
Myeloid
/ therapy. Myelodysplastic Syndromes / mortality. Myelodysplastic Syndromes / therapy
[MeSH-minor]
Acute
Disease. Adolescent. Adult. Age Distribution. Aged. Disease-Free Survival. Female. Humans. Incidence. Male. Middle Aged. Recurrence. Retrospective Studies. Survival Analysis. Tissue Donors. Transplantation, Autologous. Transplantation, Homologous. Treatment Outcome
Genetic Alliance.
consumer health - Chronic Myeloid Leukemia
.
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
Genetic Alliance.
consumer health - Myelodysplastic syndromes
.
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17611571.001).
[ISSN]
0887-6924
[Journal-full-title]
Leukemia
[ISO-abbreviation]
Leukemia
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
England
71.
Preudhomme C, Renneville A, Bourdon V, Philippe N, Roche-Lestienne C, Boissel N, Dhedin N, André JM, Cornillet-Lefebvre P, Baruchel A, Mozziconacci MJ, Sobol H:
High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder.
Blood
; 2009 May 28;113(22):5583-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
High frequency of RUNX1 biallelic alteration in
acute
myeloid
leukemia secondary
to familial platelet disorder.
Familial platelet disorder (FPD), a rare autosomal dominant disorder characterized by quantitative and qualitative platelet abnormalities, is considered as a model of genetic predisposition to
acute
myeloid
leukemia
(
AML
).
So far, monoallelic RUNX1 germline mutations have been found in 19 of 20 families with reported FPD, and the analysis of blast cells from only 5 patients at
acute leukemia
(AL) stage has shown no additional RUNX1 abnormality.
In addition to the germline RUNX1 mutation, we identified a second RUNX1 alteration in 6
AML
cases (acquired point mutations in 4 cases and duplication of the altered RUNX1 allele associated with acquired trisomy 21 in 2 other cases).
Although haploinsufficiency of RUNX1 causes FPD, our findings suggest that a second genetic event involving RUNX1 is often associated with progression to
AML
.
[MeSH-major]
Blood Platelet Disorders / genetics. Core Binding Factor Alpha 2 Subunit / genetics.
Leukemia
,
Myeloid
,
Acute
/ genetics
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Platelet Disorders
.
SciCrunch.
OMIM: Data: Gene Annotation
.
SciCrunch.
Clinical Genomic Database: Data: Gene Annotation
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19357396.001).
[ISSN]
1528-0020
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Core Binding Factor Alpha 2 Subunit; 0 / RUNX1 protein, human
72.
Pulsoni A, Pagano L:
Treatment of secondary acute myeloid leukemia.
J Clin Oncol
; 2005 Feb 1;23(4):926-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Treatment of
secondary acute
myeloid
leukemia
.
[MeSH-major]
Leukemia
,
Myeloid
,
Acute
/ therapy. Neoplasms, Second Primary / therapy
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentOn]
J Clin Oncol. 2004 Jun 15;22(12):2510-1
[
15197216.001
]
(PMID = 15681547.001).
[ISSN]
0732-183X
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Publication-type]
Comment; Letter
[Publication-country]
United States
73.
Marcucci G, Mrózek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, Mayer RJ, Pettenati MJ, Powell BL, Edwards CG, Sterling LJ, Vardiman JW, Schiffer CA, Carroll AJ, Larson RA, Bloomfield CD:
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
J Clin Oncol
; 2005 Aug 20;23(24):5705-17
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prognostic factors and outcome of core binding factor
acute
myeloid
leukemia
patients with t(8;21) differ from those of patients with inv(16): a Cancer and
Leukemia
Group B study.
PURPOSE: Because both t(8;21) and inv(16) disrupt core binding factor (CBF) in
acute
myeloid
leukemia
(
AML
) and confer relatively favorable prognoses, these cytogenetic groups are often treated similarly.
PATIENTS AND METHODS: We analyzed 144 consecutive adults with t(8;21) and 168 with inv(16) treated on Cancer and
Leukemia
Group B front-line studies.
RESULTS: With a median follow-up of 6.4 years, for CBF
AML
as a whole, the CR rate was 88%, 5-year OS was 50% and CIR was 53%.
Unexpectedly, race was an important predictor for t(8;21)
AML
, in that nonwhites failed induction more often (odds ratio = 5.7; P = .006) and had shorter OS than whites when certain
secondary
cytogenetic abnormalities were present.
For inv(16)
AML
,
secondary
cytogenetic abnormalities (especially +22) and male sex predicted better outcome.
CONCLUSION: When the prognostic impact of race,
secondary
cytogenetic abnormalities, sex, and response to salvage treatment is considered, t(8;21) and inv(16) AMLs seem to be distinct clinical entities and should be stratified and reported separately.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosome Aberrations.
Leukemia
,
Myeloid
/ drug therapy.
Leukemia
,
Myeloid
/ genetics
[MeSH-minor]
Acute
Disease. Aged. Aziridines / administration & dosage. Benzoquinones / administration & dosage. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Prognosis. Proportional Hazards Models. Prospective Studies. Remission Induction. Statistics, Nonparametric. Survival Analysis
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
CYTARABINE
.
Hazardous Substances Data Bank.
DAUNORUBICIN
.
Hazardous Substances Data Bank.
ETOPOSIDE
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
NOVANTRONE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16110030.001).
[ISSN]
0732-183X
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA101140; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA77658; United States / NCI NIH HHS / CA / K08-CA90469; United States / NCI NIH HHS / CA / P30-CA16058
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / Aziridines; 0 / Benzoquinones; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; FQL5EUP13W / diaziquone; ZS7284E0ZP / Daunorubicin
74.
Sun XF, Han B, Feng J, Zhou DB, Wang SJ, Xu Y, Chen JL, Jiao L, Zhang W, Li J, Duan MH, Zhu TN, Zou N, Hua BL, Cai HC, Zhao YQ:
[Clinical features of invasive pulmonary fungal infection secondary to malignant blood diseases].
Zhongguo Yi Xue Ke Xue Yuan Xue Bao
; 2009 Oct;31(5):575-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Clinical features of invasive pulmonary fungal infection
secondary
to malignant blood diseases].
OBJECTIVE: To summarize the clinical features of invasive pulmonary fungal infection (IPFI)
secondary
to malignant blood diseases (MBD).
METHODS: We retrospectively analyzed the clinical data of 52 patients with IPFI
secondary
to MBD admitted to Peking Union Medical College Hospital from January 1995 to December 2008.
RESULTS: The incidences of IPFI
secondary
to
acute
myeloid
leukemia
(
AML
),
acute
lymphoblastic
leukemia
(ALL),
non
-Hodgkin's lymphoma (NHL), and aplastic anemia (AA) were 4.6%, 3.2%, 2.8%, and 2.5%, respectively.
In patients with IPFI
secondary
to
AML
, 88.5% (23/26) of the patients suffered from the infections during the
non
-remission (NR) period (including relapse), and 11.5% (3/26) in the complete-remission (CR) period.
In all the patients with IPFI
secondary
to malignant blood diseases, 86.5% (45/52) of MBD were neutropenic or agranulocytic, and 67.3% (35/52) had been treated with broad-spectrum antibiotics for more than 96 hours before anti-fungal therapy.
CONCLUSIONS: IPFI
secondary
to MBD is most common in
AML
patients.
Patients with NR of
AML
, neutropenia or agranulocytosis, and long-term broad-spectrum antibiotics usage are susceptible to IPFI.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19968074.001).
[ISSN]
1000-503X
[Journal-full-title]
Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
[ISO-abbreviation]
Zhongguo Yi Xue Ke Xue Yuan Xue Bao
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
75.
Kornblau SM, Minden MD, Rosen DB, Putta S, Cohen A, Covey T, Spellmeyer DC, Fantl WJ, Gayko U, Cesano A:
Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy.
Clin Cancer Res
; 2010 Jul 15;16(14):3721-33
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Dynamic single-cell network profiles in
acute
myelogenous
leukemia
are associated with patient response to standard induction therapy.
PURPOSE: Complete response to induction chemotherapy is observed in approximately 60% of patients with newly diagnosed
non
-M3
acute
myelogenous
leukemia
(
AML
).
However, no methods exist to predict with high accuracy at the individual patient level the response to standard
AML
induction therapy.
EXPERIMENTAL DESIGN: We applied single-cell network profiling (SCNP) using flow cytometry, a tool that allows a comprehensive functional assessment of intracellular signaling pathways in heterogeneous tissues, to two training cohorts of
AML
samples (n = 34 and 88) to predict the likelihood of response to induction chemotherapy.
Results were independent of cytogenetics, FLT3 mutational status, and diagnosis of
secondary
AML
.
SCNP provides information distinct from other known prognostic factors such as age,
secondary
AML
, cytogenetics, and molecular alterations and is potentially combinable with the latter to improve clinical decision making.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Leukemia
,
Myeloid
,
Acute
/ drug therapy.
Leukemia
,
Myeloid
,
Acute
/ metabolism
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2010 AACR.
[Cites]
Blood. 1998 Feb 15;91(4):1101-34
[
9454740.001
]
[Cites]
J Clin Oncol. 2010 Feb 1;28(4):596-604
[
20026798.001
]
[Cites]
Cancer Res. 1998 Sep 15;58(18):4173-9
[
9751631.001
]
[Cites]
Cytokines Cell Mol Ther. 1998 Sep;4(3):187-98
[
9825844.001
]
[Cites]
N Engl J Med. 1999 Sep 30;341(14):1051-62
[
10502596.001
]
[Cites]
Crit Care. 2004 Dec;8(6):508-12
[
15566624.001
]
[Cites]
Curr Opin Hematol. 2005 Jan;12(1):68-75
[
15604894.001
]
[Cites]
Science. 2005 Apr 22;308(5721):523-9
[
15845847.001
]
[Cites]
Crit Rev Oncol Hematol. 2005 Nov;56(2):195-221
[
16236521.001
]
[Cites]
Blood. 2005 Dec 1;106(12):3740-6
[
16051734.001
]
[Cites]
Blood. 2005 Dec 1;106(12):3733-9
[
16076867.001
]
[Cites]
Nat Rev Cancer. 2006 Feb;6(2):146-55
[
16491074.001
]
[Cites]
Blood. 2006 May 1;107(9):3481-5
[
16455952.001
]
[Cites]
Nat Methods. 2006 May;3(5):361-8
[
16628206.001
]
[Cites]
Leukemia. 2006 Jun;20(6):965-70
[
16598313.001
]
[Cites]
Blood. 2006 Oct 1;108(7):2358-65
[
16763210.001
]
[Cites]
Br J Haematol. 2006 Nov;135(4):438-49
[
16965385.001
]
[Cites]
Blood. 2006 Dec 1;108(12):3898-905
[
16912223.001
]
[Cites]
Front Biosci. 2007;12:800-15
[
17127321.001
]
[Cites]
Crit Rev Oncol Hematol. 2007 Jun;62(3):214-26
[
17368038.001
]
[Cites]
J Clin Oncol. 2007 Aug 1;25(22):3337-43
[
17577018.001
]
[Cites]
Blood. 2008 Feb 15;111(4):1903-12
[
18042804.001
]
[Cites]
Leuk Res. 2008 Jun;32(6):913-8
[
17928050.001
]
[Cites]
Leuk Res. 2008 Jun;32(6):944-53
[
18206229.001
]
[Cites]
Blood. 2008 May 1;111(9):4490-5
[
18309032.001
]
[Cites]
N Engl J Med. 2008 May 1;358(18):1909-18
[
18450602.001
]
[Cites]
N Engl J Med. 2008 May 1;358(18):1919-28
[
18450603.001
]
[Cites]
Blood. 2008 May 15;111(10):5078-85
[
18337557.001
]
[Cites]
J Immunol. 2008 Jun 1;180(11):7358-67
[
18490735.001
]
[Cites]
Blood. 2008 Jun 1;111(11):5371-9
[
18378853.001
]
[Cites]
Front Biosci. 2008;13:4605-16
[
18508532.001
]
[Cites]
J Clin Oncol. 2008 Oct 1;26(28):4595-602
[
18559874.001
]
[Cites]
J Clin Oncol. 2008 Nov 20;26(33):5429-35
[
18591546.001
]
[Cites]
Blood. 2009 Jan 1;113(1):28-36
[
18827183.001
]
[Cites]
Blood. 2009 Jan 1;113(1):154-64
[
18840713.001
]
[Cites]
Blood. 2009 Mar 26;113(13):3088-91
[
19171880.001
]
[Cites]
Br J Haematol. 2009 Jun;145(5):555-68
[
19344393.001
]
[Cites]
J Clin Oncol. 2009 Jul 1;27(19):3198-204
[
19451432.001
]
[Cites]
Hematology. 2009 Aug;14(4):204-12
[
19635183.001
]
[Cites]
Cancer Res. 2001 Oct 1;61(19):7233-9
[
11585760.001
]
[Cites]
Nat Immunol. 2002 Dec;3(12):1129-34
[
12447370.001
]
[Cites]
Semin Hematol. 2002 Oct;39(4 Suppl 3):6-11
[
12447846.001
]
[Cites]
Blood. 2002 Dec 15;100(13):4325-36
[
12393746.001
]
[Cites]
Blood. 2003 Feb 1;101(3):837-45
[
12393383.001
]
[Cites]
Blood. 2003 Sep 1;102(5):1613-8
[
12750167.001
]
[Cites]
J Clin Oncol. 2003 Dec 15;21(24):4642-9
[
14673054.001
]
[Cites]
J Clin Oncol. 2004 Feb 15;22(4):624-33
[
14726504.001
]
[Cites]
Cell. 2004 Jul 23;118(2):217-28
[
15260991.001
]
[Cites]
Radiology. 1982 Apr;143(1):29-36
[
7063747.001
]
[Cites]
Radiology. 1983 Sep;148(3):839-43
[
6878708.001
]
[Cites]
Blood. 1998 Oct 1;92(7):2322-33
[
9746770.001
]
(PMID = 20525753.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / P01 CA108631
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
[Other-IDs]
NLM/ NIHMS378349; NLM/ PMC3385931
76.
Monreal MB, Pardo ML, Pavlovsky MA, Fernandez I, Corrado CS, Giere I, Sapia S, Pavlovsky S:
Increased immature hematopoietic progenitor cells CD34+/CD38dim in myelodysplasia.
Cytometry B Clin Cytom
; 2006 Mar;70(2):63-70
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHODS: We analyzed the expression of CD38 and HLA-DR on CD34+ cells by flow cytometry in 36 patients with MDS, as well as in healthy donors (n = 12) and patients with other hematological disorders:
non
-Hodgkin lymphomas and multiple myeloma, both in complete remission (CR) (n = 32);
acute
lymphoblastic
leukemia
in CR (n = 17); de novo
acute
myeloblastic
leukemia
(
AML
) at diagnosis (n = 22) and in CR (n = 37); and
AML
secondary
to MDS at diagnosis (n = 19).
RESULTS: Compared to normal BM, the fraction of immature HPC, characterized as CD34+bright, intermediate FSC/SSC, and CD38dim, was significantly increased in high risk MDS and
secondary
AML
, but not in low risk MDS, (P < or = 0.001, P = 0.03, and P = 0.7).
De novo
AML
showed decreased immature HPC.
Increased immature HPC in high risk MDS and
secondary
AML
may reflect blocked differentiation of CD34+ cells in these diseases.
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Cell Differentiation. Disease Progression. Female. Flow Cytometry. HLA-DR Antigens / immunology. Humans.
Leukemia
,
Myeloid
,
Acute
/ diagnosis.
Leukemia
,
Myeloid
,
Acute
/ immunology. Lymphoma,
Non
-Hodgkin / diagnosis. Lymphoma,
Non
-Hodgkin / immunology. Male. Middle Aged. Multiple Myeloma / diagnosis. Multiple Myeloma / immunology. Observer Variation. Phenotype. Precursor Cell
Lymphoblastic
Leukemia
-Lymphoma / diagnosis. Precursor Cell
Lymphoblastic
Leukemia
-Lymphoma / immunology. Prognosis. Reproducibility of Results. Risk Factors
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
MedlinePlus Health Information.
consumer health - Stem Cells
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2005 International Society for Analytical Cytology.
(PMID = 16470534.001).
[ISSN]
1552-4949
[Journal-full-title]
Cytometry. Part B, Clinical cytometry
[ISO-abbreviation]
Cytometry B Clin Cytom
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD34; 0 / HLA-DR Antigens; EC 3.2.2.5 / Antigens, CD38
77.
Mihailov G, Ganeva P, Vassileva N, Guenova M, Balacenko G, Toshkov S, Hodjadjik D:
Secondary acute myeloid leukemia early after therapy for Hodgkin's disease--a case report.
J BUON
; 2007 Jul-Sep;12(3):403-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Secondary acute
myeloid
leukemia
early after therapy for Hodgkin's disease--a case report.
A case of
acute
myeloid
leukemia
(
AML
) after successful therapy for Hodgkin's disease (HD) is reported.
Seven months after the CR was obtained the patient developed
AML
.
Knowing that the prognosis of patients with
secondary
AML
(sAML) after primary HD is poor we decided to perform autologous peripheral stem cells' transplantation.
[MeSH-major]
Hematopoietic Stem Cell Transplantation.
Leukemia
,
Myeloid
,
Acute
/ diagnosis.
Leukemia
,
Myeloid
,
Acute
/ surgery. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / surgery
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17918297.001).
[ISSN]
1107-0625
[Journal-full-title]
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
[ISO-abbreviation]
J BUON
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Greece
78.
Mead AJ, Linch DC, Hills RK, Wheatley K, Burnett AK, Gale RE:
FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia.
Blood
; 2007 Aug 15;110(4):1262-70
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with
acute
myeloid
leukemia
.
The prognostic impact of tyrosine kinase domain (TKD) mutations of the fms-like tyrosine kinase-3 (FLT3) gene in
acute
myeloid
leukemia
(
AML
) is currently uncertain.
To resolve this issue we screened 1107 young adult nonacute promyelocytic
leukemia
AML
patients with known FLT3 internal tandem duplication (ITD) status for FLT3/TKDs; they were detected in 127 (11%) cases.
Mutations were associated with a high white cell count (P =.006) and patients with inv(16) (P = .005) but were infrequent in patients with adverse cytogenetics and
secondary
AML
.
The novel finding that biologically distinct activating mutations of the same gene can be associated with markedly different clinical outcomes has implications for risk stratification and therapy and is significant to the understanding of chemoresistance in
AML
.
[MeSH-major]
Gene Duplication.
Leukemia
,
Myeloid
/ genetics. Mutation / genetics. Tandem Repeat Sequences / genetics. fms-Like Tyrosine Kinase 3 / genetics
[MeSH-minor]
Acute
Disease. Adolescent. Adult. Alleles. Amino Acid Substitution. Antimetabolites, Antineoplastic / therapeutic use. Cytarabine / therapeutic use. DNA Mutational Analysis. Female. Follow-Up Studies. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Prognosis. Survival Rate. Treatment Outcome
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
COS Scholar Universe.
author profiles
.
Guide to Pharmacology.
gene/protein/disease-specific - fms related tyrosine kinase 3 - data and references
.
Hazardous Substances Data Bank.
CYTARABINE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17456725.001).
[ISSN]
0006-4971
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
eng
[Grant]
United Kingdom / Medical Research Council / / G0300133; United Kingdom / Medical Research Council / / G84/6443
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
79.
Bakanay ŞM, Topçuoğlu P, Uğur Bilgin A, Yararbaş K, Berker Karaüzüm S, Özcan M, Arat M, Ündar L, Ilhan O:
Clonal evolution of monosomy 7 in acquired severe aplastic anemia: Two cases treated with allogeneic hematopoietic stem cell transplantation.
Turk J Haematol
; 2008 Jun 5;25(2):94-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Aplastic anemia (AA) may evolve into clonal diseases like myelodysplastic syndrome (MDS) and
acute
myeloblastic
leuke¬mia (
AML
).
Monosomy 7 is a poor prognostic chromosomal abnormality commonly associated with therapy related MDS and
secondary
AML
.
Both patients had received immunosuppressive therapy (IST) as first line treatment and had monosomy 7 positive clone at transformation to MDS with refractory anemia and excess of blast (RAEB-II) and
AML
, respectively.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 27264447.001).
[ISSN]
1300-7777
[Journal-full-title]
Turkish journal of haematology : official journal of Turkish Society of Haematology
[ISO-abbreviation]
Turk J Haematol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Turkey
80.
Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C, Heguy A, Bueso-Ramos C, Kantarjian H, Levine RL, Verstovsek S:
Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
Cancer Res
; 2010 Jan 15;70(2):447-52
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The oncogenetic events that transform chronic myeloproliferative neoplasms (MPN) to
acute
myeloid
leukemias (
AML
) are not well characterized.
We investigated the role of several genes implicated in leukemic transformation by mutational analysis of 63 patients with
AML
secondary
to a preexisting MPN (sAML).
In contrast, ASXL1 mutations were almost always detected in both the MPN and
AML
clones from individual patients.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Leukemia. 1994 Apr;8 Suppl 1:S27-9
[
8152300.001
]
[Cites]
Cancer Res. 2010 Jul 15;70(14):5901-11
[
20570890.001
]
[Cites]
Blood. 2005 Feb 1;105(3):973-7
[
15388582.001
]
[Cites]
Lancet. 2005 Mar 19-25;365(9464):1054-61
[
15781101.001
]
[Cites]
Cancer Cell. 2005 Apr;7(4):387-97
[
15837627.001
]
[Cites]
N Engl J Med. 2005 Apr 28;352(17):1779-90
[
15858187.001
]
[Cites]
Nature. 2005 Apr 28;434(7037):1144-8
[
15793561.001
]
[Cites]
Blood. 2006 May 15;107(10):4139-41
[
16434490.001
]
[Cites]
Nat Med. 2006 Jul;12(7):852-5
[
16799556.001
]
[Cites]
Blood. 2006 Nov 15;108(10):3548-55
[
16873677.001
]
[Cites]
N Engl J Med. 2006 Dec 7;355(23):2452-66
[
17151367.001
]
[Cites]
Blood. 2007 Jul 1;110(1):375-9
[
17363731.001
]
[Cites]
N Engl J Med. 2009 Feb 19;360(8):765-73
[
19228619.001
]
[Cites]
N Engl J Med. 2009 May 28;360(22):2289-301
[
19474426.001
]
[Cites]
Blood. 2009 Jul 2;114(1):144-7
[
19420352.001
]
[Cites]
N Engl J Med. 2009 Sep 10;361(11):1058-66
[
19657110.001
]
[Cites]
Leukemia. 2009 Nov;23(11):2183-6
[
19609284.001
]
[Cites]
Semin Hematol. 1997 Jan;34(1):6-16
[
9025157.001
]
(PMID = 20068184.001).
[ISSN]
1538-7445
[Journal-full-title]
Cancer research
[ISO-abbreviation]
Cancer Res.
[Language]
ENG
[Grant]
United States / NHLBI NIH HHS / HL / K08 HL082677; United States / NCI NIH HHS / CA / P30 CA008748; United States / NHLBI NIH HHS / HL / K08 HL082677-01A1; United States / Howard Hughes Medical Institute / / ; United States / NCI NIH HHS / CA / R01 CA151949; United States / NHLBI NIH HHS / HL / HL082677-01A1
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / ASXL1 protein, human; 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins; 0 / Repressor Proteins; 0 / TET2 protein, human; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.42. / IDH1 protein, human; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
[Other-IDs]
NLM/ NIHMS162374; NLM/ PMC2947340
81.
Xu LP, Huang XJ, Liu KY, Chen H, Liu DH, Han W, Chen YH, Gao ZY, Lu J, Wang JZ, Lu DP:
[Allogenic stem cell transplantation from genotypically HLA-identical siblings for 30 patients with myelodysplastic syndromes].
Zhonghua Xue Ye Xue Za Zhi
; 2006 Aug;27(8):518-21
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
On HSCT, 4 patients had refractory anemia (RA) , 2 RA with ringed sideroblasts (RARS) , 7 RA with excess blasts(RAEB) , 14 RAEB in transformation (RAEB-t) , 3 already progressed to
secondary
AML
.
RESULTS: The 3-year expected overall survival (OS) was 63.61%, 3-year expected disease-free survival ( DFS) 61.41%, and relapse rate 5.26%; OS for RA/ RAS, RAEB and RAEB-t/
AML
subgroup was 83.33%, 34.29% and 66.67% , respectively, and all had no statistic difference among them.
Genetic Alliance.
consumer health - Myelodysplastic syndromes
.
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17172123.001).
[ISSN]
0253-2727
[Journal-full-title]
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
[ISO-abbreviation]
Zhonghua Xue Ye Xue Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
82.
Burcu M, O'Loughlin KL, Ford LA, Baer MR:
Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia.
Leukemia
; 2008 Nov;22(11):2110-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Amonafide L-malate is not a substrate for multidrug resistance proteins in
secondary acute
myeloid
leukemia
.
[MeSH-major]
ATP-Binding Cassette Transporters / metabolism. ATP-Binding Cassette, Sub-Family B, Member 1 / metabolism. Antineoplastic Agents / pharmacokinetics. Drug Resistance, Multiple.
Leukemia
,
Myeloid
,
Acute
/ metabolism. Naphthalimides / pharmacokinetics. Neoplasm Proteins / metabolism
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18418409.001).
[ISSN]
1476-5551
[Journal-full-title]
Leukemia
[ISO-abbreviation]
Leukemia
[Language]
eng
[Publication-type]
Letter
[Publication-country]
England
[Chemical-registry-number]
0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / ATP-Binding Cassette, Sub-Family B, Member 1; 0 / Antineoplastic Agents; 0 / Cyclosporins; 0 / Enzyme Inhibitors; 0 / Naphthalimides; 0 / Neoplasm Proteins; 0 / Topoisomerase II Inhibitors; LI06Q37TEG / xanafide; Q7ZP55KF3X / valspodar
83.
Soares EM, Santos N, de Araújo Silva Amaral B, Silva ML, Leite EP, Silva MO, Muniz MT, Ribeiro RC, de Morais VL, de Jesus Marques Salles T:
Secondary acute myeloid leukemia with a t(1;11)(q23;p15) in an adolescent treated for testicular sarcoma.
Cancer Genet Cytogenet
; 2006 Aug;169(1):83-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Secondary acute
myeloid
leukemia
with a t(1;11)(q23;p15) in an adolescent treated for testicular sarcoma.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / adverse effects. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 11.
Leukemia
,
Myeloid
/ genetics. Sarcoma / genetics. Testicular Neoplasms / drug therapy. Testicular Neoplasms / genetics
[MeSH-minor]
Acute
Disease. Adolescent. Humans. Karyotyping. Male
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
Genetic Alliance.
consumer health - Myeloid sarcoma
.
MedlinePlus Health Information.
consumer health - Soft Tissue Sarcoma
.
MedlinePlus Health Information.
consumer health - Testicular Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16875945.001).
[ISSN]
0165-4608
[Journal-full-title]
Cancer genetics and cytogenetics
[ISO-abbreviation]
Cancer Genet. Cytogenet.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA 21765
[Publication-type]
Case Reports; Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
84.
Sonneck K, Mannhalter C, Krauth MT, Sperr WR, Schwarzinger I, Fonatsch C, Haas O, Geissler K, Valent P:
An unusual case of myelodysplastic syndrome with prolonged clonal stability, indolent clinical course over a decade, and spontaneous regression of AML in the terminal phase.
Eur J Haematol
; 2005 Jul;75(1):73-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
An unusual case of myelodysplastic syndrome with prolonged clonal stability, indolent clinical course over a decade, and spontaneous regression of
AML
in the terminal phase.
An unusual case of
secondary acute
myeloid
leukemia
(
AML
) with indolent clinical course is described.
In 2001, transformation to
secondary
AML
with an increase in bone marrow blasts (>20%) and thrombocytopenia, was found.
However, the bone marrow still showed
AML
with >20% blasts.
[MeSH-major]
Leukemia
,
Myeloid
,
Acute
/ physiopathology. Myelodysplastic Syndromes / complications
Genetic Alliance.
consumer health - Myelodysplastic syndromes
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) Blackwell Munksgaard 2005.
(PMID = 15946315.001).
[ISSN]
0902-4441
[Journal-full-title]
European journal of haematology
[ISO-abbreviation]
Eur. J. Haematol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Denmark
[Chemical-registry-number]
0 / Receptors, Androgen
85.
Takei N, Suzukawa K, Mukai HY, Itoh T, Okoshi Y, Yoda Y, Nagasawa T:
Therapy-related acute myeloid leukemia 6 years after clonal detection of inv(11)(q21q23) and MLL gene rearrangement.
Int J Hematol
; 2006 Apr;83(3):247-51
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Therapy-related
acute
myeloid
leukemia
6 years after clonal detection of inv(11)(q21q23) and MLL gene rearrangement.
Results of recent studies with animal models suggest that expression of MLL fusion proteins promotes
acute
leukemogenesis.
However, the most potent MLL fusion proteins are not sufficient for the development of
acute
myeloid
leukemia
(
AML
).
The clinical data on the pathogenesis of this type of
leukemia
are limited.
We analyzed the case of a patient with therapy-related
AML
with MLL rearrangement.
The patient initially developed
AML
with t(8;21).
After 6-year persistence of a clone with the inversion 11 karyotype in the bone marrow,
secondary
AML
developed.
One was that MLL rearrangement was not sufficient for the development of
leukemia
.
[MeSH-major]
Chromosome Inversion / genetics. Chromosomes, Human, Pair 11 / genetics.
Leukemia
,
Myeloid
,
Acute
/ genetics. Neoplasms, Second Primary / genetics
[MeSH-minor]
Antigens, CD13 / biosynthesis. Antigens, CD34 / biosynthesis. Bone Marrow Cells / metabolism. Bone Marrow Cells / pathology. Female. Humans. Middle Aged.
Myeloid
-Lymphoid
Leukemia
Protein / genetics
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Semin Hematol. 2003 Oct;40(4):268-73
[
14582077.001
]
[Cites]
Hematol Oncol Clin North Am. 1997 Oct;11(5):963-73
[
9336725.001
]
[Cites]
Cancer. 1993 Jun 15;71(12):3888-95
[
8508355.001
]
[Cites]
Genes Dev. 2004 May 1;18(9):965-74
[
15132992.001
]
[Cites]
Med Pediatr Oncol. 2001 May;36(5):525-35
[
11340607.001
]
[Cites]
J Clin Oncol. 1991 Jan;9(1):25-38
[
1702144.001
]
[Cites]
Leukemia. 1999 Dec;13(12):2116-8
[
10602439.001
]
[Cites]
Blood. 2005 May 15;105(10):4151-2
[
15867425.001
]
[Cites]
Blood. 1992 Jul 1;80(1):217-24
[
1611087.001
]
[Cites]
Best Pract Res Clin Haematol. 2001 Mar;14(1):119-37
[
11355927.001
]
[Cites]
Leukemia. 1991 Oct;5(10):908-11
[
1961025.001
]
[Cites]
Med Pediatr Oncol. 1994;23(2):86-98
[
8202047.001
]
[Cites]
Int J Hematol. 2000 Apr;71(3):238-44
[
10846828.001
]
[Cites]
Blood. 1998 Oct 15;92(8):2886-92
[
9763574.001
]
[Cites]
Oncogene. 2001 Sep 10;20(40):5695-707
[
11607819.001
]
[Cites]
Leukemia. 1998 May;12(5):811-22
[
9593286.001
]
[Cites]
Blood. 1997 Jul 15;90(2):535-41
[
9226152.001
]
[Cites]
FASEB J. 2004 Jan;18(1):173-5
[
14630694.001
]
[Cites]
Leuk Lymphoma. 2001 Apr;41(3-4):255-76
[
11378539.001
]
[Cites]
Semin Cancer Biol. 2005 Jun;15(3):175-88
[
15826832.001
]
[Cites]
Genes Dev. 2003 Dec 15;17(24):3029-35
[
14701873.001
]
[Cites]
Blood. 2005 Mar 1;105(5):2124-31
[
15528316.001
]
(PMID = 16720556.001).
[ISSN]
0925-5710
[Journal-full-title]
International journal of hematology
[ISO-abbreviation]
Int. J. Hematol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
0 / Antigens, CD34; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 3.4.11.2 / Antigens, CD13
86.
Ooi J:
The efficacy of unrelated cord blood transplantation for adult myelodysplastic syndrome.
Leuk Lymphoma
; 2006 Apr;47(4):599-602
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Diagnosis at transplantation included refractory anemia (RA) (n = 3), refractory anemia with excess blasts (RAEB) (n = 2), RAEB-t (n = 2), and MDS-related
secondary acute
myeloid
leukemia
(
AML
) (n = 15).
Twenty one patients had
myeloid
reconstitution and the median time to more than 0.5 x 10(9)/l absolute neutrophil count was 22.5 days.
Acute
GVHD above grade II occurred in seven of 21 evaluable patients and chronic GVHD in 16 of 19 evaluable patients.
Genetic Alliance.
consumer health - Myelodysplastic syndromes
.
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Leuk Lymphoma. 2006 Apr;47(4):569-70
[
16690515.001
]
(PMID = 16690517.001).
[ISSN]
1042-8194
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
87.
Hallemeier CL, Girgis MD, Blum WG, Brown RA, Khoury HJ, Devine SM, Vij R, Lin HS, DiPersio JF, Adkins DR:
Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide.
Biol Blood Marrow Transplant
; 2006 Jul;12(7):749-57
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Long-term remissions in patients with myelodysplastic syndrome and
secondary acute
myelogenous
leukemia
undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide.
We analyzed outcomes of patients with myelodysplastic syndrome (MDS) or
secondary acute
myelogenous
leukemia
(sAML) that were treated at our institution with a reduced intensity conditioning (RIC) regimen of 550-cGy total body irradiation and cyclophosphamide followed by related donor (RD) or unrelated donor (URD) transplantation.
[MeSH-major]
Bone Marrow Transplantation / methods.
Leukemia
,
Myeloid
,
Acute
/ therapy. Myelodysplastic Syndromes / therapy. Neoplasms, Second Primary / therapy. Peripheral Blood Stem Cell Transplantation / methods. Transplantation Conditioning / methods
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
Genetic Alliance.
consumer health - Myelodysplastic syndromes
.
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Bone Marrow Transplantation
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16785064.001).
[ISSN]
1083-8791
[Journal-full-title]
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
[ISO-abbreviation]
Biol. Blood Marrow Transplant.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Myeloablative Agonists; 8N3DW7272P / Cyclophosphamide
88.
Balgobind BV, Lugthart S, Hollink IH, Arentsen-Peters ST, van Wering ER, de Graaf SS, Reinhardt D, Creutzig U, Kaspers GJ, de Bont ES, Stary J, Trka J, Zimmermann M, Beverloo HB, Pieters R, Delwel R, Zwaan CM, van den Heuvel-Eibrink MM:
EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia.
Leukemia
; 2010 May;24(5):942-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
EVI1 overexpression in distinct subtypes of pediatric
acute
myeloid
leukemia
.
Overexpression of the ecotropic virus integration-1 (EVI1) gene (EVI1+), localized at chromosome 3q26, is associated with adverse outcome in adult
acute
myeloid
leukemia
(
AML
).
In pediatric
AML
, 3q26 abnormalities are rare, and the role of EVI1 is unknown.
We studied 228 pediatric
AML
samples for EVI1+ using gene expression profiling and RQ-PCR.
EVI1+ was found in 20/213 (9%) of children with de novo
AML
, and in 4/8 with
secondary
AML
.
It was predominantly found in MLL-rearranged
AML
(13/47), monosomy 7 (2/3), or FAB M6/7 (6/10), and mutually exclusive with core-binding factor
AML
, t(15;17), and NPM1 mutations.
Although significant differences in 4 years pEFS for EVI1+ and EVI1- pediatric
AML
were observed (28%+/-11 vs 44%+/-4, P=0.04), multivariate analysis did not identify EVI1+ as an independent prognostic factor.
We conclude that EVI1+ can be found in approximately 10% of pediatric
AML
.
Although EVI1+ was not an independent prognostic factor, it was predominantly found in subtypes of pediatric
AML
that are related with an intermediate to unfavorable prognosis.
Remarkably, no 3q26 abnormalities were identified in EVI1+ pediatric
AML
.
[MeSH-major]
Biomarkers, Tumor / genetics. Chromosomes, Human, Pair 3 / genetics. DNA-Binding Proteins / genetics. Gene Expression Regulation, Leukemic.
Leukemia
,
Myeloid
,
Acute
/ genetics. Proto-Oncogenes / genetics. Transcription Factors / genetics
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20357826.001).
[ISSN]
1476-5551
[Journal-full-title]
Leukemia
[ISO-abbreviation]
Leukemia
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / MECOM protein, human; 0 / RNA, Messenger; 0 / Transcription Factors
89.
Cilloni D, Messa E, Messa F, Carturan S, Defilippi I, Arruga F, Rosso V, Catalano R, Bracco E, Nicoli P, Saglio G:
Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes.
Ann N Y Acad Sci
; 2006 Nov;1089:411-23
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Recent advances in molecular genetics have increased knowledge regarding the mechanisms leading to myelodysplastic syndrome (MDS),
secondary acute
myeloid
leukemia
(
AML
), and therapy-induced MDS.
Many genetic defects underlying MDS and
AML
have been identified thereby allowing the development of new molecular-targeted therapies.
These agents have been tested in patients with solid tumors and hematologic malignancies such as
AML
and MDS.
Genetic Alliance.
consumer health - Myelodysplastic syndromes
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17261784.001).
[ISSN]
0077-8923
[Journal-full-title]
Annals of the New York Academy of Sciences
[ISO-abbreviation]
Ann. N. Y. Acad. Sci.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / DNA-Binding Proteins; 0 / Enzyme Inhibitors; 0 / MECOM protein, human; 0 / Transcription Factors; 0 / WT1 Proteins; EC 2.5.1.29 / Farnesyltranstransferase; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
[Number-of-references]
76
90.
Nemoto N, Suzukawa K, Shimizu S, Shinagawa A, Takei N, Taki T, Hayashi Y, Kojima H, Kawakami Y, Nagasawa T:
Identification of a novel fusion gene MLL-MAML2 in secondary acute myelogenous leukemia and myelodysplastic syndrome with inv(11)(q21q23).
Genes Chromosomes Cancer
; 2007 Sep;46(9):813-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Identification of a novel fusion gene MLL-MAML2 in
secondary acute
myelogenous
leukemia
and myelodysplastic syndrome with inv(11)(q21q23).
We have identified a novel fusion partner of MLL, namely the mastermind like 2 (MAML2 gene), in
secondary acute
myeloid
leukemia
(
AML
) and myelodysplastic syndrome (MDS) with inv(11)(q21q23).
RT-PCR and sequencing revealed that exon 7 of MLL was fused to exon 2 of MAML2 in the
AML
and MDS cells.
MLL-MAML2 in
secondary
AML
/MDS and MECT1-MAML2 in mucoepithelioid carcinoma, benign Wartin's tumor, and clear cell hidradenoma consist of the same COOH-terminal part of MAML2.
[MeSH-major]
Chromosomes, Human, Pair 11 / genetics. DNA-Binding Proteins / genetics.
Leukemia
,
Myeloid
,
Acute
/ genetics. Myelodysplastic Syndromes / genetics.
Myeloid
-Lymphoid
Leukemia
Protein / genetics. Nuclear Proteins / genetics. Oncogene Proteins, Fusion / genetics. Transcription Factors / genetics
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
Genetic Alliance.
consumer health - Myelodysplastic syndromes
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
SciCrunch.
OMIM: Data: Gene Annotation
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2007 Wiley-Liss, Inc.
(PMID = 17551948.001).
[ISSN]
1045-2257
[Journal-full-title]
Genes, chromosomes & cancer
[ISO-abbreviation]
Genes Chromosomes Cancer
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / DNA-Binding Proteins; 0 / MAML2 protein, human; 0 / MLL protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / Transcription Factors; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
91.
Natelson EA:
Benzene-induced acute myeloid leukemia: a clinician's perspective.
Am J Hematol
; 2007 Sep;82(9):826-30
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Benzene-induced
acute
myeloid
leukemia
: a clinician's perspective.
Benzene-induced
acute
myeloid
leukemia
(
AML
) is considered a
secondary
form of
AML
, based both in theory and on limited cohort observations.
Its latency, cytogenetic aberrations, and clinical features are thought similar to, or identical with,
AML
resulting from the use of modern day cytotoxic agents for chemotherapy and immunotherapy.
Although distinction between
secondary
AML
and the far more common de novo
AML
is difficult to establish with certainty in any given case, latency from toxic therapeutic and environmental exposure and certain clinical and pathological features generally separate these two entities.
AML
is the only human neoplasm proven to be potentially caused by benzene, which actually is an obsolete form of chemotherapy.
A review of benzene-induced
AML
suggests that, in developed countries, this entity should no longer merit serious consideration among workers in the modern petrochemical industry and related fields.
[MeSH-major]
Attitude of Health Personnel. Benzene / adverse effects. Developed Countries. Drug-Related Side Effects and Adverse Reactions.
Leukemia
,
Myeloid
/ etiology
[MeSH-minor]
Acute
Disease. Chromosome Aberrations / chemically induced. Chromosome Inversion. Chromosomes, Human, Pair 15. Chromosomes, Human, Pair 16. Chromosomes, Human, Pair 17. Chromosomes, Human, Pair 21. Chromosomes, Human, Pair 8. Humans. Occupational Diseases / chemically induced. Occupational Diseases / epidemiology. Occupational Exposure / adverse effects. Occupational Exposure / analysis. Petroleum / adverse effects. Translocation, Genetic
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Drug Reactions
.
Hazardous Substances Data Bank.
BENZENE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
2007 Wiley-Liss, Inc
(PMID = 17506065.001).
[ISSN]
0361-8609
[Journal-full-title]
American journal of hematology
[ISO-abbreviation]
Am. J. Hematol.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Petroleum; J64922108F / Benzene
[Number-of-references]
79
92.
Viola A, Falco C, D'Elia R, D'Amico MR, Vicari L, Tambaro FP, Correale P, Laudati D, Palmieri S, Ferrara F:
An antecedent diagnosis of refractory anemia with excess blasts has no influence on mobilization of peripheral blood stem cells and hematopoietic recovery after autologous stem cell transplantation in acute myeloid leukemia.
Eur J Haematol
; 2007 Jan;78(1):41-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
An antecedent diagnosis of refractory anemia with excess blasts has no influence on mobilization of peripheral blood stem cells and hematopoietic recovery after autologous stem cell transplantation in
acute
myeloid
leukemia
.
Several studies have reported data on factors influencing mobilization of peripheral blood stem cells (PBSC) in
non
-
myeloid
malignancies.
On the contrary, data from patients with
acute
myeloid
leukemia
(
AML
) are very limited, in particular, as the impact of an antecedent diagnosis of refractory anemia with excess blasts (RAEB) on mobilization of PBSCs as well as hematopoietic recovery after autologous stem cell transplantation (ASCT) is concerned.
We retrospectively analyzed a cohort of 150 consecutive
AML
patients in first complete remission in order to make a comparison between patients with de novo
AML
and
secondary
AML
(s-
AML
) in terms of CD34 positive (CD34+) cells mobilization and number of leukapheresis needed to collect at least one single stem cell graft.
The successful mobilization rate (>2 x 10(6) CD34+ cells/kg) was comparable between de novo
AML
patients (87%) and those with s-
AML
(76%), P:0.21.
An antecedent diagnosis of RAEB has no impact on mobilization and collection of PBSCs in
AML
as well as on hematopoietic recovery after ASCT.
[MeSH-major]
Anemia, Refractory, with Excess of Blasts / diagnosis. Hematopoiesis. Hematopoietic Stem Cell Mobilization.
Leukemia
,
Myeloid
/ therapy. Peripheral Blood Stem Cell Transplantation
[MeSH-minor]
Acute
Disease. Adolescent. Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Transplantation, Autologous. Treatment Outcome
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
Genetic Alliance.
consumer health - Anemia
.
Genetic Alliance.
consumer health - Transplantation
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17042770.001).
[ISSN]
0902-4441
[Journal-full-title]
European journal of haematology
[ISO-abbreviation]
Eur. J. Haematol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Denmark
93.
Ostgård LS, Kjeldsen E, Holm MS, Brown Pde N, Pedersen BB, Bendix K, Johansen P, Kristensen JS, Nørgaard JM:
Reasons for treating secondary AML as de novo AML.
Eur J Haematol
; 2010 Sep;85(3):217-26
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Reasons for treating
secondary
AML
as de novo
AML
.
In a Danish bi-regional registry-based study, we conducted an analysis of the incidence and clinical importance of
secondary acute
myeloid
leukaemia (
AML
).
In a total of 630 cases of
AML
, we found 157 (25%) cases of
secondary
AML
.
The
secondary
leukaemia arose from MDS (myelodysplastic syndrome) in 77 cases (49%), CMPD (chronic myeloproliferative disorder) in 43 cases (27%) and was therapy-related
AML
(t-
AML
) in 37 cases (24%).
Median age at diagnosis of
AML
was 69 yr in
secondary
cases when compared to 66 yr in de novo cases (P = 0.006).
In univariate analyses,
secondary
AML
was associated with an inferior complete remission (CR) rate (P = 0.008) and poorer overall survival (OS, P = 0.003) whereas in complete remitters, disease-free survival (DFS) of
secondary
cases was equal to that of de novo cases.
Interestingly, in all further analyses of CR-rates, OS and DFS, when correcting for the influence of age, cytogenetic abnormalities, performance status and leucocyte count (WBC), presence of
secondary
AML
completely lost prognostic significance.
We conclude that the presence of
secondary
AML
does not per se convey an unfavourable prognosis and that patients with
secondary
AML
should be offered the chance of benefiting from treatment according to current frontline
AML
protocols.
[MeSH-major]
Leukemia
,
Myeloid
,
Acute
/ complications.
Leukemia
,
Myeloid
,
Acute
/ drug therapy. Myelodysplastic Syndromes / complications
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20456491.001).
[ISSN]
1600-0609
[Journal-full-title]
European journal of haematology
[ISO-abbreviation]
Eur. J. Haematol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
94.
Spanaki A, Perdikogianni C, Linardakis E, Kalmanti M:
Quantitative assessment of PRAME expression in diagnosis of childhood acute leukemia.
Leuk Res
; 2007 May;31(5):639-42
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Quantitative assessment of PRAME expression in diagnosis of childhood
acute leukemia
.
The purpose of this study was to investigate PRAME expression levels in children with
acute leukemia
with real-time PCR analysis.
Seventeen children with newly diagnosed or relapsed
acute leukemia
(11 ALL, 4
AML
, 1
acute
myeloblastic
leukemia secondary
to MDS, 1 ALL at relapse) and a control group of seven children were studied.
Overexpression of PRAME was found in 52.9% (3
AML
, 6 ALL) of the patients studied.
The above findings indicate that PRAME expression in
acute leukemia
does not seem to be of prognostic significance, whereas it might represent a candidate marker for the monitoring of minimal residual disease.
[MeSH-major]
Antigens, Neoplasm / genetics. Biomarkers, Tumor / genetics.
Leukemia
,
Myeloid
/ genetics. Neoplasm, Residual / genetics. Precursor Cell
Lymphoblastic
Leukemia
-Lymphoma / genetics
[MeSH-minor]
Acute
Disease. Adolescent. Child. Child, Preschool. Humans. Prognosis. RNA, Messenger. Reverse Transcriptase Polymerase Chain Reaction
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16860864.001).
[ISSN]
0145-2126
[Journal-full-title]
Leukemia research
[ISO-abbreviation]
Leuk. Res.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / PRAME protein, human; 0 / RNA, Messenger
95.
Hussein K, Bock O, Theophile K, Schulz-Bischof K, Porwit A, Schlue J, Jonigk D, Kreipe H:
MPLW515L mutation in acute megakaryoblastic leukaemia.
Leukemia
; 2009 May;23(5):852-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
MPLW515L mutation in
acute
megakaryoblastic leukaemia.
A series of primary and
secondary acute
myeloid
leukaemias (
AML
) with megakaryoblastic phenotype and myelofibrosis unrelated to PMF (n=12) was analysed for the MPL(W515K/L) mutation by pyrosequencing.
None of the
secondary
AML
cases evolving from pre-existing PMF showed MPL(W515K/L) (n=4).
We conclude that MPL(W515L) occurs in a considerable proportion of
acute
megakaryoblastic leukaemias with myelofibrosis unrelated to PMF.
[MeSH-major]
Leukemia
, Megakaryoblastic,
Acute
/ genetics.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / genetics. Mutation / genetics. Primary Myelofibrosis / genetics. Receptors, Thrombopoietin / genetics
MedlinePlus Health Information.
consumer health - Chronic Myeloid Leukemia
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Leukemia. 2009 Nov;23(11):2159-60
[
19657363.001
]
(PMID = 19194467.001).
[ISSN]
1476-5551
[Journal-full-title]
Leukemia
[ISO-abbreviation]
Leukemia
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Receptors, Thrombopoietin; 143641-95-6 / MPL protein, human; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
96.
Schroeder T, Czibere A, Zohren F, Aivado M, Gattermann N, Germing U, Haas R:
Meningioma 1 gene is differentially expressed in CD34 positive cells from bone marrow of patients with myelodysplastic syndromes with the highest expression in refractory anemia with excess of blasts and secondary acute myeloid leukemia.
Leuk Lymphoma
; 2009 Jun;50(6):1043-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Meningioma 1 gene is differentially expressed in CD34 positive cells from bone marrow of patients with myelodysplastic syndromes with the highest expression in refractory anemia with excess of blasts and
secondary acute
myeloid
leukemia
.
[MeSH-major]
Anemia / genetics. Antigens, CD34 / blood. Bone Marrow Cells / metabolism.
Leukemia
,
Myeloid
/ genetics. Myelodysplastic Syndromes / genetics. Tumor Suppressor Proteins / genetics
[MeSH-minor]
Acute
Disease. Adult. Aged. Aged, 80 and over. Disease Progression. Female. Gene Expression Profiling. Gene Expression Regulation, Leukemic. Humans. Male. Middle Aged. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
Genetic Alliance.
consumer health - Anemia
.
Genetic Alliance.
consumer health - Meningioma
.
Genetic Alliance.
consumer health - Myelodysplastic syndromes
.
MedlinePlus Health Information.
consumer health - Anemia
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19391034.001).
[ISSN]
1029-2403
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Letter
[Publication-country]
England
[Chemical-registry-number]
0 / Antigens, CD34; 0 / MN1 protein, human; 0 / Tumor Suppressor Proteins
97.
Klepin HD, Balducci L:
Acute myelogenous leukemia in older adults.
Oncologist
; 2009 Mar;14(3):222-32
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Acute
myelogenous
leukemia
in older adults.
The incidence of
acute
myelogenous
leukemia
(
AML
) increases with age.
Older
AML
patients, generally defined by age > or = 60 years, have worse treatment outcomes than younger patients.
Older patients are more likely to present with unfavorable cytogenetic abnormalities, multidrug resistance phenotypes, and
secondary
AML
.
Investigations of hypomethylating agents and signal transduction inhibitors hold promise for the treatment of
AML
patients.
[MeSH-major]
Geriatrics / methods.
Leukemia
,
Myeloid
,
Acute
/ pathology.
Leukemia
,
Myeloid
,
Acute
/ therapy
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19282349.001).
[ISSN]
1549-490X
[Journal-full-title]
The oncologist
[ISO-abbreviation]
Oncologist
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
72
98.
Bacher U, Haferlach T, Schoch C:
Gain of 9p due to an unbalanced rearrangement der(9;18): a recurrent clonal abnormality in chronic myeloproliferative disorders.
Cancer Genet Cytogenet
; 2005 Jul 15;160(2):179-83
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Three cases were diagnosed as polycythemia vera; one case presented with
secondary acute
myeloid
leukemia
following idiopathic osteomyelofibrosis.
Genetic Alliance.
consumer health - Chronic Myeloproliferative Disorders
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15993276.001).
[ISSN]
0165-4608
[Journal-full-title]
Cancer genetics and cytogenetics
[ISO-abbreviation]
Cancer Genet. Cytogenet.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States